<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia - Pattanaik, S - 2018 | Cochrane Library</title> <meta content="Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia - Pattanaik, S - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010060.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia - Pattanaik, S - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010060.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010060.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia" name="citation_title"/> <meta content="Smita Pattanaik" name="citation_author"/> <meta content="Post Graduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Ravimohan S Mavuduru" name="citation_author"/> <meta content="Post Graduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="ravismi2003@yahoo.com" name="citation_author_email"/> <meta content="Arabind Panda" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Joseph L Mathew" name="citation_author"/> <meta content="Post Graduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Mayank M Agarwal" name="citation_author"/> <meta content="Post Graduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Eu Chang Hwang" name="citation_author"/> <meta content="Chonnam National University Medical School, Chonnam National University Hwasun Hospital" name="citation_author_institution"/> <meta content="Jennifer A Lyon" name="citation_author"/> <meta content="Children's Mercy Hospital" name="citation_author_institution"/> <meta content="Shrawan K Singh" name="citation_author"/> <meta content="Post Graduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Arup K Mandal" name="citation_author"/> <meta content="Post Graduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD010060.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/11/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010060.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010060.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010060.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic alpha‐Antagonists [therapeutic use]; Drug Therapy, Combination; Lower Urinary Tract Symptoms [*drug therapy, etiology]; Phosphodiesterase Inhibitors [adverse effects, *therapeutic use]; Prostatic Hyperplasia [*complications]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010060.pub2&amp;doi=10.1002/14651858.CD010060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010060\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010060\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","fr","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010060.pub2",title:"Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia",firstPublishedDate:"Nov 16, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010060.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010060.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010060.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010060.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010060.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010060.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010060.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010060.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010060.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010060.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4349 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010060.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-sec-0228"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-sec-0045"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-sec-0046"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-sec-0070"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-sec-0222"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/appendices#CD010060-sec-0233"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/table_n/CD010060StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/table_n/CD010060StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#CD010060-cr-0002">Smita Pattanaik</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#CD010060-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Ravimohan S Mavuduru</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#CD010060-cr-0004">Arabind Panda</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#CD010060-cr-0005">Joseph L Mathew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#CD010060-cr-0006">Mayank M Agarwal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#CD010060-cr-0007">Eu Chang Hwang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#CD010060-cr-0008">Jennifer A Lyon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#CD010060-cr-0009">Shrawan K Singh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information#CD010060-cr-0010">Arup K Mandal</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information/en#CD010060-sec-0241">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 November 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010060.pub2">https://doi.org/10.1002/14651858.CD010060.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010060-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010060-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010060-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010060-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010060-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010060-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010060-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010060-abs-0001" lang="en"> <section id="CD010060-sec-0001"> <h3 class="title" id="CD010060-sec-0001">Background</h3> <p>Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase inhibitors (PDEIs) that so far have been used mainly to treat erectile dysfunction were introduced to treat male LUTS. </p> </section> <section id="CD010060-sec-0002"> <h3 class="title" id="CD010060-sec-0002">Objectives</h3> <p>To assess the effects of PDEIs compared to placebo and other standard of care drugs (ABs and 5‐ARIs) in men with LUTS consistent with BPH. </p> </section> <section id="CD010060-sec-0003"> <h3 class="title" id="CD010060-sec-0003">Search methods</h3> <p>We conducted a systematic search of the Cochrane Central Register of Controlled Trials (CENTRAL)<i>,</i> MEDLINE, Embase, Web of Science, and clinical trials registries of the World Health Organization (WHO) and the National Institutes of Health (NIH) (updated 2 August 2018). We performed citation tracking and handsearching of abstracts and conference proceedings. We also contacted study authors to ask for additional information. </p> </section> <section id="CD010060-sec-0004"> <h3 class="title" id="CD010060-sec-0004">Selection criteria</h3> <p>We considered for inclusion in this systematic review randomised controlled trials (RCTs) comparing PDEIs versus placebo, ABs, or 5‐ARIs for at least four weeks in men with BPH‐LUTS. </p> </section> <section id="CD010060-sec-0005"> <h3 class="title" id="CD010060-sec-0005">Data collection and analysis</h3> <p>Three review authors independently screened the literature and extracted data. Primary outcomes were effects on urinary symptoms as assessed by the International Prostate Symptom Score (IPSS‐total; score ranging from 0 to 35, with higher values reflecting more symptoms), urinary bother as assessed by the Benign Prostatic Hyperplasia Impact Index (BPHII; score ranging from 0 to 13, with higher values reflecting more bother), and adverse events (AEs). We used GRADE to rate the quality of evidence. We considered short‐term (up to 12 weeks) and long‐term (12 weeks or longer) results separately. </p> </section> <section id="CD010060-sec-0006"> <h3 class="title" id="CD010060-sec-0006">Main results</h3> <p>We included a total of 16 randomised trials in this review. The results for primary outcomes are as follows. </p> <p><b>PDEI versus placebo:</b> PDEIs may result in a small improvement in IPSS‐total score (mean difference (MD) 1.89 lower, 95% confidence interval (CI) 2.27 lower to 1.50 lower; n = 4293; low‐quality evidence) compared to placebo, and may reduce the BPHII score slightly (MD 0.52 lower, 95% CI 0.71 lower to 0.33 lower; n = 3646; low‐quality evidence). Rates of AEs may be increased (risk ratio (RR) 1.42, 95% CI 1.21 to 1.67; n = 4386; low‐quality evidence). This corresponds to 95 more AEs per 1000 participants (95% CI 47 more to 151 more per 1000). Study results were limited to a treatment duration of six to 12 weeks. </p> <p><b>PDEI versus AB:</b> PDEIs and ABs probably provide similar improvement in IPSS‐total score (MD 0.22 higher, 95% CI 0.49 lower to 0.93 higher; n = 933; moderate‐quality evidence) and may have a similar effect on BPHII score (MD 0.03 higher, 95% CI 1.10 lower to 1.16 higher; n = 550; low‐quality evidence) and AEs (RR 1.35, 95% CI 0.80 to 2.30; n = 936; low‐quality evidence). This corresponds to 71 more AEs per 1000 participants (95% CI 41 fewer to 264 more per 1000). Study results were limited to a treatment duration of six to 12 weeks. </p> <p><b>PDEI and AB versus AB alone:</b> the combination of PDEI and AB may provide a small improvement in IPSS‐total score (MD 2.56 lower, 95% CI 3.92 lower to 1.19 lower; n = 193; low‐quality evidence) compared to AB alone. We found no evidence for BPHII scores. AEs may be increased (RR 2.81, 95% CI 1.53 to 5.17; n = 194; moderate‐quality evidence). This corresponds to 235 more AEs per 1000 participants (95% CI 69 more to 542 more per 1000). Study results were limited to treatment duration of four to 12 weeks. </p> <p><b>PDEI and AB versus PDEI alone:</b> the combination of PDEI and AB may provide a small improvement in IPSS‐total (MD 2.4 lower, 95% CI 6.47 lower to 1.67 higher; n = 40; low‐quality evidence) compared to PDEI alone. We found no data on BPHII or AEs. Study results were limited to a treatment duration of four weeks. </p> <p><b>PDEI and 5‐ARI versus 5‐ARI alone:</b> in the short term (up to 12 weeks), the combination of PDEI and 5‐ARI probably results in a small improvement in IPSS‐total score (MD 1.40 lower, 95% CI 2.24 lower to 0.56 lower; n = 695; moderate‐quality evidence) compared to 5‐ARI alone. We found no evidence on BPHII scores or AEs. In the long term (13 to 26 weeks), the combination of PDEI and 5‐ARI likely results in a small reduction in IPSS‐total score (MD 1.00 less, 95% CI 1.83 lower to 0.17 lower; n = 695; moderate‐quality evidence). We found no evidence about effects on BPHII scores. There may be no difference in rates of AEs (RR 1.07, 95% CI 0.84 to 1.36; n = 695; low‐quality evidence). This corresponds to 19 more AEs per 1000 participants (95% CI 43 fewer to 98 more per 1000). </p> <p>We found no trials comparing other combinations of treatments or comparing different PDEI agents. </p> </section> <section id="CD010060-sec-0007"> <h3 class="title" id="CD010060-sec-0007">Authors' conclusions</h3> <p>Compared to placebo, PDEI likely leads to a small reduction in IPSS‐total and BPHII sores, with a possible increase in AEs. There may be no differences between PDEI and AB with regards to improvement in IPSS‐total, BPHII, and incidence of AEs. There appears to be no added benefit of PDEI combined with AB compared to PDEI or AB alone or PDEI combined with 5‐ARI compared to ARI alone with regards to urinary symptoms. Most evidence was limited to short‐term treatment up to 12 weeks and of moderate or low certainty. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010060-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010060-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010060-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010060-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010060-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010060-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010060-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010060-abs-0005" lang="en"> <h3>Phosphodiesterase inhibitors for treatment of urinary problems in men with benign prostatic hyperplasia </h3> <p><b>Review question</b> </p> <p>What are the effects of phosphodiesterase inhibitors compared to other medications, in men with urinary symptoms, that are thought to be due to an enlarged prostate? </p> <p><b>Background</b> </p> <p>Problems related to urination, especially in older men, are often due to benign prostatic hyperplasia. Medications like alpha‐blockers and 5‐alpha reductase inhibitors are commonly used to treat these symptoms. They help to control symptoms but can have unwanted effects. Phosphodiesterase inhibitors are medications that have been used for a long time to help men have better erections. They may also help to improve urinary symptoms in men with benign prostatic hyperplasia. </p> <p><b>Search date</b> </p> <p>We searched randomised trials, that studied these treatments, up to August 2, 2018.</p> <p><b>Study characteristics</b> </p> <p>We found a total of 16 studies. They included mostly men, older than 60 years of age, with moderate, to severe urinary symptoms. Most studies were funded by the companies that make these drugs. </p> <p><b>Key results</b> </p> <p>Compared to placebo, phosphodiesterase inhibitors may make urinary symptoms a little better and reduce bother, but may also cause more unwanted drug effects. </p> <p>There is probably no difference between phosphodiesterase inhibitors and alpha‐blockers when it comes to improving urinary symptoms, and there may be no difference with regards to how bothersome symptoms are, or unwanted drug effects. </p> <p>Taking a phosphodiesterase inhibitor with an alpha‐blocker may improve urinary symptoms slightly more than taking alpha‐blockers alone. We found no evidence regarding urinary bother. However, combination treatment probably causes a lot more unwanted drug effects. </p> <p>Taking a phosphodiesterase inhibitor with an alpha‐blocker may improve urinary symptoms slightly more than taking a phosphodiesterase inhibitor alone. We found no evidence regarding bother or unwanted drug effects. </p> <p>In the short term (up to 12 weeks), the combination of a phosphodiesterase inhibitor with a 5‐alpha reductase inhibitor probably makes urinary symptoms a little better compared to taking a 5‐alpha reductase inhibitor alone, but the effect may be too small to notice. We found no evidence on bother, nor on rates of unwanted drug effects. When taken longer (13 to 26 weeks), combination treatment probably also improves urinary symptoms slightly to a degree that may not be noticeable. We found no evidence regarding urinary bother. Unwanted drug effects may be similar. </p> <p>We found no evidence for other combination treatments or comparing different phosphodiesterase inhibitors. Most studies investigated only short‐term use of these drugs (up to 12 weeks); therefore, long‐term effects are largely unknown. </p> <p><b>Quality of evidence</b> </p> <p>We mostly rated the quality of evidence as moderate or low, meaning that we are somewhat or quite unsure of the true results. The real effects may be similar or quite different. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010060-sec-0228" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010060-sec-0228">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010060-sec-0290">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010060-sec-0228"></div> <h3 class="title" id="CD010060-sec-0229">Implications for practice</h3> <section id="CD010060-sec-0229"> <p>Current best evidence suggests that a PDEI (tadalafil) used for treatment of BPH‐LUTS over a short period of 12 weeks provides a relatively very small improvement in urinary symptoms and quality of life compared to placebo at the cost of increased risk of AEs. The available body of evidence lacks information on whether such modest improvement can be maintained for longer periods as compared with an AB. The nature and incidence of long‐term AEs with PDEIs are not well known. </p> <p>The efficacy and safety of PDEIs may be similar to ABs for BPH‐LUTS. However, our confidence in these estimates is low. </p> <p>PDEI combined with AB does not appear to add benefit for improvement of urinary symptoms, but it may result in a minor improvement when combined with 5‐ARI in men with a larger prostate. </p> </section> <h3 class="title" id="CD010060-sec-0230">Implications for research</h3> <section id="CD010060-sec-0230"> <p>We found evidence of moderate to low quality for the efficacy and safety outcomes with short‐term use of a PDEI (tadalafil) in men with BPH‐LUTS. We frequently downgraded for issues such as study limitations, inconsistency, clinically important imprecision, and heterogeneity, although not for publication bias. Future trials should be conducted with greater methodological rigor and must be published irrespective of the direction of their findings. In addition, they must be adequately powered, must be stratified to permit meaningful subgroup analyses, and must evaluate drugs for longer periods to assess their efficacy as well as safety. </p> <p>In eight of 11 RCTs included in this systematic review, the placebo group successfully met the <a href="./references#CD010060-bbs2-0073" title="American Urology Association (AUA). Benign prostatic hyperplasia (BPH) guideline update 2010. http://www.auanet.org/content/guidelines‐and‐quality‐care/clinical‐guidelines/main‐reports/bph‐management/chap_1_GuidelineManagementof(BPH).pdf (accessed August 2011). ">AUA 2010</a> definition of minimum clinically important difference (MCID), improving urinary symptoms by more than 3 points on the IPSS‐total scale (single best and universally accepted outcome measure for evaluation and treatment of urinary symptoms in BPH). Therefore, technically, this fulfilled the AUA criteria for an effective intervention for BPH‐LUTS. Robust placebo response based on IPSS‐total scores merits consideration of revision of the MCID for BPH‐LUTS. The MCID for BPH‐LUTS was proposed more than two decades back (<a href="./references#CD010060-bbs2-0074" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154:1770‐4. ">Barry 1995</a>), and it has been endorsed by the AUA. Further research may be needed to set new MCID criteria, which should take into account the extent of placebo response. </p> <p>With emerging concerns about use of PDEIs and the incidence of melanoma (<a href="./references#CD010060-bbs2-0089" title="DengT , DuanX , LiuB , LanY , CaiC , ZhangT , et al. Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta‐analysis. Neoplasma2018;65:216‐21. ">Deng 2018</a>; <a href="./references#CD010060-bbs2-0097" title="FengS , ZhouL , LiuQ , HeQ , LiaoB , WeiX , et al. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma? A systematic review and meta‐analysis. Medicine (Baltimore)2018;97:e9601. ">Feng 2018</a>; <a href="./references#CD010060-bbs2-0111" title="HanX , HanY , ZhengY , SunQ , MaT , DaiL , ZhangJ , XuL . Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta‐analysis of observational studies. OncoTargets and Therapy2018;11:711‐20. ">Han 2018</a>; <a href="./references#CD010060-bbs2-0126" title="LianY , YinH , PollakMN , CarrierS , PlattRW , SuissaS , AzoulayL . Phosphodiesterase type 5 inhibitors and the risk of melanoma skin cancer. European Urology2016;70:808‐15. ">Lian 2016</a>; <a href="./references#CD010060-bbs2-0128" title="LoebS , FolkvaljonY , LambeM , RobinsonD , GarmoH , IngvarC , StattinP . Use of phaosphopdiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA2015;313:2449‐55. ">Loeb 2015</a>; <a href="./references#CD010060-bbs2-0129" title="LoebS , VentimigliaE , SaloniaA , FolkvaljonY , StattinP . Meta‐analysis of association between phaosphodiesterase inhibitors (PDEIs) and risk of melanoma. Journal of the National Cancer Institute2017;109:doi:10.1093/inci/djx086. ">Loeb 2017</a>; <a href="./references#CD010060-bbs2-0134" title="MatthewsA , LanganSM , DouglasIJ , SmeethL , BhaskaranK . Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: Matched cohort study using primary care data from the UK clinical practice research datalink. PLoS Med2016;13:e1002037. ">Matthews 2016</a>; <a href="./references#CD010060-bbs2-0146" title="PottegardA , SchmidtSA , OlesenAB , AchacosoN , Van DenEedenSK , HallasJ , et al. Use of sildenafil or other phosphodiesterase inhibitors and risk of mealanoma. British Journal of Cancer2016;115:895‐900. ">Pottegard 2016</a>; <a href="./references#CD010060-bbs2-0164" title="TangH , WuW , FuS , ZhaiS , SongY , HanJ . Phosphodiesterase type 5 inhibitors and risk of melanoma: a meta‐analysis. Journal of the American Academy of Dermatology2017;77:480‐8. ">Tang 2017</a>; <a href="./references#CD010060-bbs2-0172" title="WangJ , ShenY , WangJ , . Xue Y , LiaoL , ThapaS , JiK . Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta‐analysis and systematic review. Oncotarget2017;8:46461‐7. [Meta‐analysis indicating Risk of Melanoma] ">Wang 2017</a>; <a href="./references#CD010060-bbs2-0175" title="WrońskiS . The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase–5 inhibitors. Central European Journal of Urology2014;67(3):314‐8. [non‐systematic review] ">Wronski 2014</a>), studies tracking the long‐term health outcomes of PDEI users to assess for rare yet serious AEs are important. Longitudinal studies and drug‐specific registries should be considered, as RCTs are unlikely to be of adequate power or duration to detect such AEs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010060-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010060-sec-0036"></div> <div class="table" id="CD010060-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">PDEI compared to placebo for lower urinary tract symptoms consistent with benign prostatic hyperplasia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>PDEI compared to placebo for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI </p> <p><b>Comparator:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score<br/> Assessed with International Prostate Symptom Score<br/> Scale from 0 (best: not at all) to 35 (worst: almost always)<br/> Follow up: range 6 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4293<br/> (11 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total scores ranged from ‐5.1 to ‐1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.89 lower<br/> (2.27 lower to 1.5 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPHII score<br/> Assessed with BPHII questionnaire </p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)<br/> Follow‐up: range 6 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3646<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in BPHII scores ranged from ‐2 to ‐0.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.52 lower<br/> (0.71 lower to 0.33 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Assessed with any event<br/> Follow‐up: range 6 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4386<br/> (11 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.42<br/> (1.21 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 more per 1000<br/> (47 more to 151 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MCID: minimum clinically important difference; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Downgraded for possible publication bias based on funnel plot asymmetry. </p> <p><sup>c</sup>Clinically important imprecision; 95% CI crosses MCID of 0.5. </p> <p><sup>d</sup>Clinically important heterogeneity with I² of 50%. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010060-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">PDEI compared to alpha‐blockers for LUTS associated with BPH</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>PDEI compared to alpha‐blockers for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI </p> <p><b>Comparator:</b> alpha‐blockers </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with alpha‐blockers</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score<br/> Assessed with International Prostate Symptom Score </p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: range 8 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>933<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total scores ranged from ‐5.7 to ‐ 5.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.22 higher<br/> (0.49 lower to 0.93 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPHII score<br/> Assessed with BPHII questionnaire </p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)<br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in BPHII score was ‐1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/> (1.1 lower to 1.16 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 8 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>786<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.35<br/> (0.80 to 2.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 more per 1000<br/> (41 fewer to 264 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Clinically important heterogeneity. </p> <p><sup>c</sup>Clinically important imprecision likely due to inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010060-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">PDEI plus alpha‐blocker compared to alpha‐blockers alone for LUTS associated with BPH (short‐term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination of PDEI with alpha‐blocker compared to alpha‐blockers alone for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI + alpha‐blockers </p> <p><b>Comparator:</b> alpha‐blockers </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with alpha‐blockers alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI plus alpha‐blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score<br/> Assessed with International Prostate Symptom Score </p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)</p> <p>Follow‐up: range 4 to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total scores ranged from ‐6.7 to ‐3.62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.56 lower<br/> (3.92 lower to 1.19 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPHII score<br/> Assessed with BPHII questionnaire </p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects<br/> Follow‐up: range 4 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>194<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.81<br/> (1.53 to 5.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235 more per 1000<br/> (69 more to 542 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MCID: maximum clinically important difference; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Clinically important imprecision; 95% CI crosses MCID of 3.0 </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010060-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">PDEI plus an alpha‐blocker compared to PDEI alone for LUTS associated with BPH (short‐term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination of PDEI with an alpha‐blocker compared to PDEI alone for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI + alpha‐blockers </p> <p><b>Comparator:</b> PDEI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDEI alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI plus an alpha‐blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score</p> <p>Assessed with International Prostate Symptom Score</p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)</p> <p>Follow‐up: mean 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total score was ‐3.95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.4 lower<br/> (6.47 lower to 1.67 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPHII score</p> <p>Assessed with BPHII questionnaire</p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Downgraded for clinically important imprecision; 95% CI crosses MCID of 3. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010060-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (short‐term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination of PDEI with 5‐ARI compared to 5‐ARI alone for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI + 5‐ARI </p> <p><b>Comparator:</b> 5‐ARI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ARI alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI + 5‐ARI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score</p> <p>Assessed with International Prostate Symptom Score</p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)</p> <p>Follow‐up: mean 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total score was ‐3.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.4 lower<br/> (2.24 lower to 0.56 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>BPHII score</p> <p>Assessed with BPHII questionnaire</p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> 5‐ARI: 5‐alpha reductase inhibitor; BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Downgraded for clinically important imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010060-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (long‐term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination of PDEI with 5‐ARI compared to 5‐ARI alone for LUTS consistent with BPH in long‐term use (26 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI + 5‐ARI </p> <p><b>Comparator:</b> 5‐ARI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ARI alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI + 5‐ARI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score</p> <p>Assessed with International Prostate Symptom Score</p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)</p> <p>Follow‐up: mean 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total score was ‐4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1 lower<br/> (1.83 lower to 0.17 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>BPHII score</p> <p>Assessed with BPHII questionnaire</p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>695<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.84 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 more per 1000<br/> (43 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> 5‐ARI: 5‐alpha reductase inhibitor; BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Downgraded for clinically important imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010060-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010060-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010060-sec-0251">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD010060-sec-0037"></div> <section id="CD010060-sec-0038"> <h3 class="title" id="CD010060-sec-0038">Description of the condition</h3> <p>Benign prostatic hyperplasia (BPH) commonly presents with lower urinary tract symptoms (LUTS) (<a href="./references#CD010060-bbs2-0104" title="GarrawayWM , CollinsGN , LeeRJ . High prevalence of benign prostatic hypertrophy in the community. Lancet1991;338(8765):469‐71. ">Gerraway 1991</a>). Erectile dysfunction (ED) is often associated with BPH‐LUTS and negatively impacts the quality of life in aging males (<a href="./references#CD010060-bbs2-0155" title="RosenR , AltweinJ , BoyleP , KirbyRS , LukacsB , MeulemanE , et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM‐7). European Urology2003;44(6):637‐49. ">Rosen 2003</a>). Large‐scale epidemiological studies conducted across various ethnic backgrounds have described a strong association between LUTS and ED (<a href="./references#CD010060-bbs2-0079" title="BraunM , WassmerG , KlotzT , ReifenrathB , MathersM , EngelmannU . Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. International Journal of Impotence Research2000;12(6):305–11. ">Braun 2000</a>; <a href="./references#CD010060-bbs2-0080" title="BraunMH , SommerF , HauptG , MathersMJ , ReifenrathB , EngelmannUH . Lower urinary tract symptoms and erectile dysfunction: co‐morbidity or typical 'aging male' symptoms? Results of the 'Cologne male survey'. European Urology2003;44(5):588–94. ">Braun 2003</a>; <a href="./references#CD010060-bbs2-0124" title="LiMK , GarciaLA , RosenR . Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU International2005;96(9):1339–54. ">Li 2005</a>; <a href="./references#CD010060-bbs2-0132" title="Martin‐MoralesA , Sanchez‐CruzJJ , Saenz de TejadaI , Roudriguez‐VelaL , Jimenez‐CruzJF , Burgos‐RodriguezR . Prevalence and independent risk factors for erectile dysfunction in Spain: results of Epidemiologia de la Disfunction Erectil Masculina study. Journal of Urology2001;166(2):569‐74. ">Martin‐Morales 2001</a>; <a href="./references#CD010060-bbs2-0142" title="MondulAM , RimmEB , GiovannucciE , GlasserDB , PlatzEA . A prospective study of lower urinary tract symptoms and erectile dysfunction. Journal of Urology2008;179(6):2321–6. ">Mondul 2008</a>; <a href="./references#CD010060-bbs2-0155" title="RosenR , AltweinJ , BoyleP , KirbyRS , LukacsB , MeulemanE , et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM‐7). European Urology2003;44(6):637‐49. ">Rosen 2003</a>; <a href="./references#CD010060-bbs2-0156" title="RosenRC , WeiJT , AlthofSE , SeftelAD , MinerM , PerelmanMA . Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology2009;73(3):562–566. ">Rosen 2009</a>). The presence of risk factors like diabetes, hypertension, obesity, metabolic syndrome, cardiovascular illness, depression, and previous pelvic surgery increases the prevalence of both BPH‐LUTS and ED in older men (<a href="./references#CD010060-bbs2-0104" title="GarrawayWM , CollinsGN , LeeRJ . High prevalence of benign prostatic hypertrophy in the community. Lancet1991;338(8765):469‐71. ">Gerraway 1991</a>). However, LUTS has been proposed as an independent risk factor for ED independent of ageing and other comorbidity‐related risk factors (<a href="./references#CD010060-bbs2-0079" title="BraunM , WassmerG , KlotzT , ReifenrathB , MathersM , EngelmannU . Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. International Journal of Impotence Research2000;12(6):305–11. ">Braun 2000</a>; <a href="./references#CD010060-bbs2-0131" title="MacfarlaneGJ , BottoH , SagnierP , TeillacP , RichardF , BoyleP . The relationship between sexual life and urinary condition in the French community. Journal of Clinical Epidemiology1996;49(10):1171–6. ">MacFarlane 1996</a>; <a href="./references#CD010060-bbs2-0136" title="McVaryKT . Erectile dysfunction and lower urinary tract symptoms secondary to BPH. European Urology2005;48(Suppl 8):838‐45. ">McVary 2005a</a>; <a href="./references#CD010060-bbs2-0145" title="PonholzerA , TemmlC , ObermayrR , MadersbacherS . Association between lower urinary tract symptoms and erectile dysfunction. Urology2004;64(6):772–6. ">Ponholzer 2004</a>; <a href="./references#CD010060-bbs2-0155" title="RosenR , AltweinJ , BoyleP , KirbyRS , LukacsB , MeulemanE , et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM‐7). European Urology2003;44(6):637‐49. ">Rosen 2003</a>). It has also been proposed that ED is more frequent in individuals with severe LUTS, and that the severity of both conditions is often concordant (<a href="./references#CD010060-bbs2-0136" title="McVaryKT . Erectile dysfunction and lower urinary tract symptoms secondary to BPH. European Urology2005;48(Suppl 8):838‐45. ">McVary 2005a</a>; <a href="./references#CD010060-bbs2-0137" title="McVaryKT , RademakerA , LloydGL , GannP . Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2005;174(4 pt 1):1327‐433. ">McVary 2005b</a>; <a href="./references#CD010060-bbs2-0142" title="MondulAM , RimmEB , GiovannucciE , GlasserDB , PlatzEA . A prospective study of lower urinary tract symptoms and erectile dysfunction. Journal of Urology2008;179(6):2321–6. ">Mondul 2008</a>). Several theories have been proposed to suggest a plausible biological link between LUTS and ED (<a href="./references#CD010060-bbs2-0071" title="AnderssonKE , deGroatWC , McVaryKT , LueTF , MaggiM , RoehrbornCG , et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourology and Urodynamics2011;30(3):292‐301. ">Andersson 2011</a>), although the association between BPH‐LUTS and ED in elderly men does not necessarily establish a cause‐and‐effect relationship. The efficacy of phosphodiesterase inhibitors (PDEIs) in alleviating BPH‐LUTS also supports the suggestion of a common pathophysiology affecting simultaneously, the vascular and autonomic systems of pelvic structures, like bladder, prostatic tissue, and urethra (<a href="./references#CD010060-bbs2-0108" title="GulianoF , UckertÈS , Mario MaggiM , Lori BirderLe , KisselJ , ViktrupL . The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. European Urology2013;63(3):506‐16. ">Guliano 2012</a>). BPH‐LUTS‐ED is increasingly considered a disease complex ‐ a popular concept in the urology fraternity, with the potential for treatment with a single designer drug (<a href="./references#CD010060-bbs2-0084" title="CalogeroAE , BurgioG , CondorelliRA , CondorelliRA , CannarellaR , LaVigneraS . Lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction: from physiology to clinical aspects. Aging Male2018;1:1‐9. ">Calogero 2018</a>; <a href="./references#CD010060-bbs2-0112" title="HatzimouratidisK . A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Therapeutic Advances in Urology2014;6:135‐7. [non‐systematic review] ">Hatzimouratidis 2014</a>). </p> <p>In the last two decades, evidence emerging from preclinical studies suggests a unified pathophysiology and the presence of molecular targets in anatomical structures associated with both conditions (<a href="./references#CD010060-bbs2-0098" title="FibbiB , MorelliA , VignozziL , FilippiS , ChavalmaneA , DeVitaG , et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. Jpurnal of Sexual Medicine2010;7(1 pt 1):59‐69. ">Fibbi 2010</a>; <a href="./references#CD010060-bbs2-0099" title="FilippiS , MorelliA , SandnerP , FibbiB , MancinaR , MariniM , et al. Characterization and functional role of androgen‐dependent PDE5 activity in the bladder. Endocrinology2007;148(3):1019–29 . ">Filippi 2007</a>; <a href="./references#CD010060-bbs2-0113" title="HedlundP . Nitric oxide/cGMP‐mediated effects in the outflow region of the lower urinary tract ‐ is there a basis for pharmacological targeting of cGMP?. World Journal of Urology2005;23(6):362‐7. ">Hedlund 2005</a>; <a href="./references#CD010060-bbs2-0118" title="KediaGT , UckertS , KediaM , KuczykMA . Effects of phosphodiesterase inhibitors on contraction induced by endothelin‐1 of isolated human prostatic tissue. Urology2009;73(6):1397‐401. ">Kedia 2009</a>; <a href="./references#CD010060-bbs2-0119" title="KediaGT , ÜckertS , OelkeM , SonnenbergJE , SohnM , KuczykMA , HedlundP . Expression and distribution of phosphodiesterase (PDE) isoenzymes in the human urethra. Urology2015;85(4):946.e1‐6. ">Kedia 2011a</a>; <a href="./references#CD010060-bbs2-0120" title="KediaGT , SonnenbergJE , KuczykMA , UckertS . In vitro functional responses of isolated human urethral tissue to phosphodiesterase(PDE) inhibitors. European Urology2011;10(Suppl):291‐2. ">Kedia 2011b</a>; <a href="./references#CD010060-bbs2-0165" title="TrussMC , UckertS , StiefCG , KuczykM , JonasU . Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle identification and characterization. Urology Research1996;24(3):123‐8. ">Truss 1996</a>; <a href="./references#CD010060-bbs2-0167" title="UckertS , SandnerP , SiglK , UlbrichE , StiefC , KuczykM . Is there a role of the phosphodiesterase type 5 (PDE5) in the control of detrusor smooth muscle? A functional and molecular biology study. Journal of Urology2009;181:152‐68. ">Uckert 2007</a>; <a href="./references#CD010060-bbs2-0168" title="UckertS , Polat‐YururH , SchellerF , KediaG , KuczykM . Stimulation of cyclic nucleotide production enhances the relaxation induced by phosphodiesterase (PDE) inhibitors of isolated human prostate tissue. Journal of Urology2009;181:507‐12. ">Uckert 2009</a>). Proposed common pathophysiological mechanisms for BPH‐LUTS and ED include (1) insufficient nitric oxide (NO) availability, (2) overactivity of Rho‐kinase, (3) autonomic dysregulation, (4) atherosclerotic pelvic vascular disease, (5) inflammation of lower urinary tract tissue, and (6) alteration in the androgenic environment. Reduced availability of NO could result from reduced endothelial nitric oxide synthase (eNOS) or neuronal nitric oxide synthase (nNOS) or its increased degradation due to the presence of reactive oxygen species (<a href="./references#CD010060-bbs2-0075" title="BartonM , CosentinoF , BrandesRP , MoreauP , ShawS , LuscherTF . Anatomic heterogeneity of vascular aging:role of nitric oxide and endothelin. Hypertension1997;30(4):817–24. ">Barton 1997</a>; <a href="./references#CD010060-bbs2-0083" title="CaiH , HarrisonDG . Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circulation Research2000;87(10):840–4. ">Cai 2000</a>). It has been reported that NOS expression and subsequent reduction in NO are reduced in the transition zone of the prostate in BPH, compared to the normal prostate (<a href="./references#CD010060-bbs2-0078" title="BlochW , KlotzT , LochC , SchmidtG , EngelmannU , AddicksK . Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate1997;33(1):1–8. ">Bloch 1997</a>). Reduced NO has been linked with prostatic smooth muscle hyperplasia, increasing smooth muscle contractile forces at the bladder neck and prostatic urethra, hypoxia of the pelvic organs, and autonomic dysregulation due to inadequate dilatation of the vasa vasorum and the vasa nervorum (<a href="./references#CD010060-bbs2-0108" title="GulianoF , UckertÈS , Mario MaggiM , Lori BirderLe , KisselJ , ViktrupL . The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. European Urology2013;63(3):506‐16. ">Guliano 2012</a>; <a href="./references#CD010060-bbs2-0144" title="OrabiH , AlbersenM , LueTF . Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management. International Journal of Impotence Research2011;23(3):99‐108. ">Orabi 2011</a>). Hypoxia upregulates the Rho‐A/Rho‐A calcium‐sensitising kinase (ROCK) system, and it has been proposed to increase smooth muscle proliferation while inhibiting smooth muscle contractility (<a href="./references#CD010060-bbs2-0148" title="ReesRW , FoxwellNA , RalphDJ , KellPD , MoncadaS , CellekS . Y‑27632, a Rho‐kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. Journal of Urology2003;170(6 Pt 1):2517‐22. ">Ree 2003</a>). Many of these converging mechanisms are believed to cause microvascular dysfunction altering normal endothelial and neural function and thereby affecting "global pelvic physiology". This has been put forth as the common pathophysiological denominator for LUTS and ED (<a href="./references#CD010060-bbs2-0085" title="CellekS , CameronNE , CotterMA , FryCH , IloD . Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH–LUTS. Nature Reviews Urology2014;11(4):231‐41. ">Celleck 2014</a>). However, the relative contribution of each of these proposed mechanisms leading to microvascular dysfunction resulting in BPH‐LUTS and/or ED is not known, although improvement in ED with treatment of LUTS has been observed, and vice versa (<a href="./references#CD010060-bbs2-0100" title="FornariA , GresslerM , NeisA , CunhaI , OliveiraL , CarboniC . The impact of urinary incontinence on male erectile dysfunction. Journal of Sexual Medicine2017;14:e264. ">Fonari 2017</a>). </p> <p>Endothelial dysfunction affecting the NO/cyclic guanosine monophosphate (cGMP) system has proved to play a central role in the pathophysiology of ED. The dramatic results of treatment with phosphodiesterase inhibitors have confirmed the proof of concept (<a href="./references#CD010060-bbs2-0138" title="McVaryK . Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. British Journal of Urology International2006;97(suppl 2):23‐8. ">McVary K 2006</a>). The NO/cGMP pathway operating in the detrusor, bladder neck, prostatic tissue, prostatic urethra, penile tissue, penile urethra, and lower urinary tract vasculature has been the proposed target of PDEI in the context of BPH‐LUTS‐ED (<a href="./references#CD010060-bbs2-0098" title="FibbiB , MorelliA , VignozziL , FilippiS , ChavalmaneA , DeVitaG , et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. Jpurnal of Sexual Medicine2010;7(1 pt 1):59‐69. ">Fibbi 2010</a>; <a href="./references#CD010060-bbs2-0099" title="FilippiS , MorelliA , SandnerP , FibbiB , MancinaR , MariniM , et al. Characterization and functional role of androgen‐dependent PDE5 activity in the bladder. Endocrinology2007;148(3):1019–29 . ">Filippi 2007</a>; <a href="./references#CD010060-bbs2-0113" title="HedlundP . Nitric oxide/cGMP‐mediated effects in the outflow region of the lower urinary tract ‐ is there a basis for pharmacological targeting of cGMP?. World Journal of Urology2005;23(6):362‐7. ">Hedlund 2005</a>; <a href="./references#CD010060-bbs2-0118" title="KediaGT , UckertS , KediaM , KuczykMA . Effects of phosphodiesterase inhibitors on contraction induced by endothelin‐1 of isolated human prostatic tissue. Urology2009;73(6):1397‐401. ">Kedia 2009</a>; <a href="./references#CD010060-bbs2-0119" title="KediaGT , ÜckertS , OelkeM , SonnenbergJE , SohnM , KuczykMA , HedlundP . Expression and distribution of phosphodiesterase (PDE) isoenzymes in the human urethra. Urology2015;85(4):946.e1‐6. ">Kedia 2011a</a>; <a href="./references#CD010060-bbs2-0120" title="KediaGT , SonnenbergJE , KuczykMA , UckertS . In vitro functional responses of isolated human urethral tissue to phosphodiesterase(PDE) inhibitors. European Urology2011;10(Suppl):291‐2. ">Kedia 2011b</a>; <a href="./references#CD010060-bbs2-0165" title="TrussMC , UckertS , StiefCG , KuczykM , JonasU . Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle identification and characterization. Urology Research1996;24(3):123‐8. ">Truss 1996</a>; <a href="./references#CD010060-bbs2-0167" title="UckertS , SandnerP , SiglK , UlbrichE , StiefC , KuczykM . Is there a role of the phosphodiesterase type 5 (PDE5) in the control of detrusor smooth muscle? A functional and molecular biology study. Journal of Urology2009;181:152‐68. ">Uckert 2007</a>; <a href="./references#CD010060-bbs2-0168" title="UckertS , Polat‐YururH , SchellerF , KediaG , KuczykM . Stimulation of cyclic nucleotide production enhances the relaxation induced by phosphodiesterase (PDE) inhibitors of isolated human prostate tissue. Journal of Urology2009;181:507‐12. ">Uckert 2009</a>). </p> </section> <section id="CD010060-sec-0039"> <h3 class="title" id="CD010060-sec-0039">Description of the intervention</h3> <p>The current standard of pharmacological management for BPH‐LUTS includes alpha‐1 blockers (generically referred to as alpha‐blockers (ABs) in this review) with or without 5‐alpha reductase inhibitors (5‐ARIs) (<a href="./references#CD010060-bbs2-0073" title="American Urology Association (AUA). Benign prostatic hyperplasia (BPH) guideline update 2010. http://www.auanet.org/content/guidelines‐and‐quality‐care/clinical‐guidelines/main‐reports/bph‐management/chap_1_GuidelineManagementof(BPH).pdf (accessed August 2011). ">AUA 2010;</a><a href="./references#CD010060-bbs2-0095" title="EAU guidelines on management of non‐neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). http://uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/(accessed 2016). ">EAU 2016</a>). Anticholinergic drugs are sometimes prescribed to provide additional relief for overactive bladder (OAB)‐like symptoms. </p> <section id="CD010060-sec-0040"> <h4 class="title">Alpha‐blockers (ABs)</h4> <p>An important target for treatment of BPH‐LUTS involves alpha‐1 receptors (1A, 1B, and1D) present in the smooth muscles at the bladder neck and the prostatic tissue. These act as internal sphincter. Alpha‐1 blockers lower the sympathetic tone on smooth muscles at the bladder neck and the prostatic fibromuscular stroma, thereby attenuating the dynamic component of the obstruction and improving urinary outflow (<a href="./references#CD010060-bbs2-0140" title="MilaniS , DjavanB . Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha‐adrenoceptor antagonists. BJU International2005;95(Suppl 4):29‐36. ">Milani 2005</a>). They improve the total International Prostate Symptom Score (IPSS‐total) by 30% to 40% compared to 10% to 20% with placebo (<a href="./references#CD010060-bbs2-0091" title="DjavanB , ChappleC , MilaniS , MarbergerM . State of the art on the efficacy and tolerability of alpha1‐adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology2004;64(6):1081‐8. ">Djavan 2004</a>), and they increase the maximum urinary flow rate (Qmax) by 20% to 25%. Improvement in IPSS‐total is about 50%, and improvement in Qmax is up to 40% in open‐label studies (<a href="./references#CD010060-bbs2-0094" title="OelkeM , BachmannA , DescazeaudA , EmbertonM , GravasS , MichelMC , et al. EAU Guidelines on the treatment and follow‐up of non‐neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology2013;64(1):118‐40. ">EAU 2013</a>). Available drugs include alfuzosin, doxazocin, tamsulosin, terazosin, and silodosin. These agents are considered equally efficacious, and the older agents should preferably be prescribed because of cost‐effectiveness considerations (<a href="./references#CD010060-bbs2-0073" title="American Urology Association (AUA). Benign prostatic hyperplasia (BPH) guideline update 2010. http://www.auanet.org/content/guidelines‐and‐quality‐care/clinical‐guidelines/main‐reports/bph‐management/chap_1_GuidelineManagementof(BPH).pdf (accessed August 2011). ">AUA 2010</a>; <a href="./references#CD010060-bbs2-0094" title="OelkeM , BachmannA , DescazeaudA , EmbertonM , GravasS , MichelMC , et al. EAU Guidelines on the treatment and follow‐up of non‐neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology2013;64(1):118‐40. ">EAU 2013</a>). Adverse events (AEs) experienced with the use of ABs are mediated by both central and peripheral mechanisms, which include dizziness, headache, asthaenia, postural hypotension, syncope, peripheral oedema, and retrograde ejaculation (<a href="./references#CD010060-bbs2-0090" title="DjavanB , MarbergerM . A meta‐analysis on the efficacy and tolerability of alpha1‐adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology1999;36(1):1‐13. ">Djavan 1999</a>). Rates of discontinuation due to side effects range from 4% to 10% (<a href="./references#CD010060-bbs2-0090" title="DjavanB , MarbergerM . A meta‐analysis on the efficacy and tolerability of alpha1‐adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology1999;36(1):1‐13. ">Djavan 1999</a>). Although these drugs have shown satisfactory improvement in LUTS and urinary flow, they have led to no improvement in ED. The efficacy of these drugs is reported to be maintained for about four years (<a href="./references#CD010060-bbs2-0135" title="McConnellJD , RoehrbornCG , BautistaOM , AndrioleGLJr , DixonCM , KusekJW , et al. The long‐term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine2003;349(25):2387‐98. ">McConnell 2003</a>; <a href="./references#CD010060-bbs2-0153" title="RoehrbornCG . Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2‐year placebo‐controlled study. BJU International2006;97(4):734‐41. ">Roehrborn 2006</a>). </p> </section> <section id="CD010060-sec-0041"> <h4 class="title">5‐Alpha reductase inhibitors (5‐ARIs)</h4> <p>These drugs inhibit the conversion of testosterone to 5‐hydroxy testosterone. 5‐ARIs are used in patients with an enlarged prostate, along with ABs to attenuate androgen‐induced prostatic growth. They exert their effects by decreasing the mass of the prostate by 18% to 20%, thereby acting on the static component of the obstruction (<a href="./references#CD010060-bbs2-0092" title="DjavanB ,  MargreiterM ,  DianatSS . An algorithm for medical management in male lower urinary tract symptoms. Current Opinion in Urology2011;21(1):5‐12. ">Djavan 2011;</a><a href="./references#CD010060-bbs2-0160" title="ShibataY , AraiS , MiyazawaY , ShutoT , NomuraM , SekineY , et al. Effects of steroidal antiandrogen or 5‐alpha‐reductase inhibitor on prostate tissue hormone content. Prostate2017;77:672‐80. ">Shibata 2017</a>). They have also been shown to reduce serum prostate‐specific antigen (PSA) levels by 50% over six months to one year of treatment (<a href="./references#CD010060-bbs2-0094" title="OelkeM , BachmannA , DescazeaudA , EmbertonM , GravasS , MichelMC , et al. EAU Guidelines on the treatment and follow‐up of non‐neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology2013;64(1):118‐40. ">EAU 2013</a>). These agents offer 15% to 30% improvement in maximum urinary flow rate compared to 10% to 15% with placebo (<a href="./references#CD010060-bbs2-0154" title="RoehrbornCG , BoyleP , NickelJC , HoefnerK , AndrioleG , ARIA3001 , ARIA3002 , and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5‐alpha‐reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology2002;60(3):434‐41. ">Roerborn 2002</a>). They have a variable tolerability profile. The main side effects include ED, decreased libido, ejaculatory problems, and gynaecomastia (<a href="./references#CD010060-bbs2-0072" title="AndrioleGL , KirbyR . Safety and tolerability of the dual 5alpha‐reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. European Urology2003;44(1):82‐8. ">Andriole 2003</a>), which is explained by the pharmacological action of the drug. </p> <p>Both ABs and 5‐ARIs alone, or in combination, are somewhat satisfactory in alleviating LUTS symptoms, but they do not improve and may lead to worsening of co‐existing male sexual dysfunction (<a href="./references#CD010060-bbs2-0082" title="BrookesST , DonovanJL , PetersTJ , AbrahamP , NealDE . Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised control trial. BMJ2002;324(7345):1059‐61. ">Brookes 2002</a>). It has also been reported that men treated with combination treatment have continued medical treatment for BPH longer than those given single‐drug treatment (<a href="./references#CD010060-bbs2-0149" title="RensingAJ , KuxhausenA , VetterJ , StropeSA . Differences in the treatment of benign prostatic hyperplasia: comparing the primary care physician and the urologist. Urology Practice2017;4:193‐9. ">Rensing 2017</a>). </p> </section> <section id="CD010060-sec-0042"> <h4 class="title">Phosphodiesterase inhibitors (PDEIs)</h4> <p>Phosphodiesterases (PDEs) comprise a group of 11 enzymes (PDE₁‐₁₁) expressed in a variety of tissues. They increase the intracellular level of cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP) by decreasing their degradation. PDE₅ is the prevalent enzyme in the penile vasculature and in other pelvic tissues. PDE₅ inhibitors do not have any direct vasorelaxant properties, but they increase NO released at neuronal‐smooth muscle junctions (<a href="./references#CD010060-bbs2-0076" title="BischoffE . Potency, selectivity, and consequences of non selectivity of PDE inhibition. Interational Journal of Impotence Research2004;16:S11‐S14. ">Bischoff 2004</a>). The US Food and Drug Administration (FDA) has approved four PDEI agents ‐ sildenafil (<a href="./references#CD010060-bbs2-0171" title="USFood , DrugAdministration . Drugs@FDA: FDA Approved Drug Products: Viagra (sildenafil citrate). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020895s036lbl.pdf. Released 27 March 1988 (accessed 21 December 2016). ">Viagra 1988</a>), tadalafil (<a href="./references#CD010060-bbs2-0086" title="USFood , DrugAdministration . Drugs@FDA: FDA Approved Drug Products. Cialis (tadalafil). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021368. Released 21 November 2003 (accessed 21 December 2016). ">Cialis 2003</a>), vardenafil (<a href="./references#CD010060-bbs2-0123" title="USFood , DrugAdministration . Drugs@FDA: FDA Approved Drug Products. Levitra (vardenafil hydrochloride). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021400, Released 19 August 2003 (accessed 21 December 2016). ">Levitra 2003</a>; <a href="./references#CD010060-bbs2-0162" title="USFood , DrugAdministration . Drug Approval Package: Staxyn (vardenafil hydrochloride). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179_staxyn_toc.cfm. Released 17 June 2010 (accessed 21 December 2016). ">Staxyn 2010</a>), and avanafil (<a href="./references#CD010060-bbs2-0163" title="USFood , DrugAdministration . FDA approves Stendra for erectile dysfunction. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=202276. Released 27 April 2012 (accessed 21 December 2016). ">Stendra 2012</a>) ‐ for treatment of ED, but has approved only two agents for use in pulmonary arterial hypertension ‐ sildenafil ‐ as described in <a href="./references#CD010060-bbs2-0150" title="USFood , DrugAdministration . Drugs@FDA: FDA Approved Drug Products. Revatio (sildenafil citrate). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=022473. Released 18 November 2009 (accessed 21 December 2016). ">Revatio 1998</a> ‐ and tadalafil ‐ as reported in <a href="./references#CD010060-bbs2-0068" title="USFood , DrugAdministration . Drugs@FDA: FDA Approved Drug Products. Adcirca (tadalafil). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=022332. Released 22 May 2009 (accessed 21 December 2016). ">Adicirca 2009</a>. Approved doses of drugs to be used for ED on an "as and when required" basis are sildenafil 25, 50, or 100 mg; tadalafil 10 or 20 mg; vardenafil 10 or 20 mg; and avanafil 25, 50, or 100 mg before sexual intercourse. These drugs appear to have equivalent efficacy in the treatment of ED; therefore, the class effect is well established (<a href="./references#CD010060-bbs2-0088" title="CoronaG ,  MondainiN ,  UngarA ,  RazzoliE ,  RossiA ,  FuscoF . Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. Journal of Sexual Medicine2011;8(12):3418‐32. ">Corona 2011</a>). They differ in their profile of PDE isoenzyme inhibition (and hence their side effect profile) and in their duration of action (<a href="./references#CD010060-bbs2-0130" title="LueTF , BroderickGA . Campbell‐Walsh Urology. 9th Edition. Philadelphia: Saunders Elsevier, 2007. ">Lue 2007</a>). Tadalafil is superior to others due to its longer duration of action (t₁/₂ = 17.5 hours; total duration of action = 36 hours), and it causes fewer visual (700 times higher selectivity to inhibit PDE₅ than PDE₆ present in retina) and musculoskeletal side effects (minimal inhibition of DE₁₁) (<a href="./references#CD010060-bbs2-0139" title="MeherotraN , GuptaM , KovarA , MeibohmB . The role of pharmacokinetics and pharmacodynamics in phosphodiesterase‐5 inhibitor therapy. International Journal of Impotence Research2007;19(3):253‐64. ">Meherotra 2007</a>; <a href="./references#CD010060-bbs2-0152" title="RezvanfarMA , RahimiHR , AbdollahiM . ADMET considerations for phosphodiesterase‐5 inhibitors. Expert Opinion on Drug Metabolism and Toxicology2012;10(8):1231‐45. ">Rezvanfar 2014</a>). Tadalafil has been approved by the FDA (in October 2011) for treatment of BPH‐LUTS with or without ED, at a dose of 2.5 or 5 mg daily (<a href="./references#CD010060-bbs2-0096" title="FDA approves Cialis to treat benign prostatic hyperplasia. http://wayback.archive‐it.org/7993/20161024202117/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm274642.htm (accessed on 20th Jan 2014 ). ">FDA 2011</a>). </p> </section> </section> <section id="CD010060-sec-0043"> <h3 class="title" id="CD010060-sec-0043">How the intervention might work</h3> <p><a href="./references#CD010060-bbs2-0165" title="TrussMC , UckertS , StiefCG , KuczykM , JonasU . Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle identification and characterization. Urology Research1996;24(3):123‐8. ">Truss 1996</a> first reported the presence of PDE₅ in the detrusor muscle using chromatographic methods. Immunolabelling and immunohistochemical studies have shown that PDE is expressed in the detrusor muscle, in pelvic vessels supplying these smooth muscles, in vascular smooth muscle of the prostatic tissue, and in the prostatic urethra (<a href="./references#CD010060-bbs2-0115" title="HoKM , McMurrayG , BradingAF , NobleJG , NyL , AnderssonKE . Nitric oxide synthase in the heterogeneous population of intramural striated muscle fibres of the human membranous urethral sphincter. Journal of Urology1998;159(3):1091‐6. ">Ho 1998</a>; <a href="./references#CD010060-bbs2-0166" title="UckertS , OelkeM , StiefCG , AndersonKE , JonasU , HedlundP . Immunohistochemical distribution of cAMP‐ and cGMP‐phosphodiesterase (PDE) isoenzymes in the human prostate. European Urology2006;49:740–5. ">Uckert 2006;</a><a href="./references#CD010060-bbs2-0169" title="UckertS , OelkeM . Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. British Journal of Clinical Pharmacology2011;72(2):197‐204. ">Uckert 2011</a>). Human prostatic glandular and subglandular areas have been shown to express both PDE₅ and PDE₁₁ (<a href="./references#CD010060-bbs2-0098" title="FibbiB , MorelliA , VignozziL , FilippiS , ChavalmaneA , DeVitaG , et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. Jpurnal of Sexual Medicine2010;7(1 pt 1):59‐69. ">Fibbi 2010</a>). <a href="./references#CD010060-bbs2-0102" title="GacciM , EardleyI , GiulianoF , HatzichristouD , KaplanSA , MaggiM , et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology2011; Vol. 60:809‐25. [Review ‐ analysis] ">Gacci 2011</a> and <a href="./references#CD010060-bbs2-0143" title="OgerS , Behr‐RousselD , GornyD , LebretT , ValidireP , CathelineauX , et al. Signalling pathways involved in sildenafil‐induced relaxation of human bladder dome smooth muscle. Britiah Journal of Pharmacology2010;160(5):1135‐43. ">Oger 2010</a> found that expression of PDE₅‐RNA was much less in prostatic tissue than in detrusor and penile tissue. cGMP and nitric oxide are important inhibitory neurotransmitters in the smooth muscle of the urethra, and strong PDE₅ immunoreactivity has been demonstrated in the smooth muscle cells of the prostatic and non‐prostatic urethra (<a href="./references#CD010060-bbs2-0098" title="FibbiB , MorelliA , VignozziL , FilippiS , ChavalmaneA , DeVitaG , et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. Jpurnal of Sexual Medicine2010;7(1 pt 1):59‐69. ">Fibbi 2010</a>; <a href="./references#CD010060-bbs2-0117" title="KediaGT , UckertS , JonasU , KuczykMA , BurchardtM . The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World Journal of Urology2008;26(6):603‐9. ">Kedia 2008</a>). For bladder detrusor function, cAMP seems more important than cGMP, but PDE₅ immunoreactivity has been noted in endothelial and smooth muscle cells of the vasculature and in smooth muscle cells of the muscle bundles (<a href="./references#CD010060-bbs2-0099" title="FilippiS , MorelliA , SandnerP , FibbiB , MancinaR , MariniM , et al. Characterization and functional role of androgen‐dependent PDE5 activity in the bladder. Endocrinology2007;148(3):1019–29 . ">Filippi 2007</a>). Isolated tissue experiments have shown the relaxant effect of PDE₅ on the bladder neck (<a href="./references#CD010060-bbs2-0077" title="BittencourtJA , TanoT , GajarSA , ResendeAC , deLemos NetoM , DamiãoR , et al. Relaxant effects of sildenafil on the human isolated bladder neck. Urology2009;73(2):427–30. ">Bittencourt 2009</a>; <a href="./references#CD010060-bbs2-0107" title="GiulianoF , RouprêtM , DoridotG , de laTailleA . Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia. Progress in Urology2013;23(5):283‐95. [therpeutic review] ">Guiliano 2013b</a>; <a href="./references#CD010060-bbs2-0173" title="WerkstromV , HedlundP , LeeT , AnderssonKE . Vardenaﬁl‐induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder. BJU International2009;104(11):1740–5. ">Werkstrom 2009</a>). The presence of PDE₅ has been demonstrated in the lower urinary tract vasculature, localised to smooth muscle cells of larger arteries, endothelial cells lining the arterial lumen, and the endothelium of smaller arteries (<a href="./references#CD010060-bbs2-0098" title="FibbiB , MorelliA , VignozziL , FilippiS , ChavalmaneA , DeVitaG , et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. Jpurnal of Sexual Medicine2010;7(1 pt 1):59‐69. ">Fibbi 2010</a>). PDEs are found to be present at various sites in the lower urinary tract, namely, the urinary bladder (bladder dome comprising the detrusor ‐ bladder neck smooth muscles forming the internal sphincter); the prostate (prostatic smooth muscles in the transitional zone surrounding the prostatic urethra ‐ prostatic glandular epithelial cells and stromal tissue); the urethra (urethral smooth muscles); and blood vessels and nerve endings supplying these structures (<a href="./references#CD010060-bbs2-0102" title="GacciM , EardleyI , GiulianoF , HatzichristouD , KaplanSA , MaggiM , et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology2011; Vol. 60:809‐25. [Review ‐ analysis] ">Gacci 2011</a>). Expressions of PDE in the lower urinary tract seem to be ubiquitous, although the density of these enzymes may vary from place to place. The extensive presence of PDE enzymes, especially PDE₅, in lower urinary tract tissue, and their effects on various smooth muscles are favourable findings suggesting a new drug target for treatment of LUTS consistent with BPH. However, It is not clear if their preponderance suggests their dominance in controlling LUT physiology and subsequent pathophysiology. </p> <p><a href="./references#CD010060-bbs2-0054" title="SairamK , KulinskayaE , McNicholasTA , BousteadGB , HanburyDC . Sildenafil influences lower urinary tract symptoms. BJU International2002;90(9):836‐9. ">Sairam 2002</a> presented the first evidence for the proof of concept in humans in an observational study. Since then, evidence in favour of PDE₅ inhibition in BPH‐LUTS has been accumulating from preclinical and clinical studies. Clinical studies have been conducted in populations of varied ethnic origin and have demonstrated a beneficial effect of PDEI in BPH‐LUTS with variable success. </p> </section> <section id="CD010060-sec-0044"> <h3 class="title" id="CD010060-sec-0044">Why it is important to do this review</h3> <p> <ul id="CD010060-list-0001"> <li> <p>The current standard of medical treatment for LUTS consistent with BPH (AB with or without 5‐ARI) is somewhat satisfactory as far as efficacy is concerned, but is poorly tolerated because of vascular side effects (<a href="./references#CD010060-bbs2-0121" title="LabordeEE , McVaryKT . Medical management of lower urinary tract symptoms. Review of Urology2009;11(Suppl 1):S19‐S25. ">Laborde 2009</a>). The efficacy of these drugs tends to decrease over time (<a href="./references#CD010060-bbs2-0135" title="McConnellJD , RoehrbornCG , BautistaOM , AndrioleGLJr , DixonCM , KusekJW , et al. The long‐term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine2003;349(25):2387‐98. ">McConnell 2003;</a><a href="./references#CD010060-bbs2-0153" title="RoehrbornCG . Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2‐year placebo‐controlled study. BJU International2006;97(4):734‐41. ">Roehrborn 2006</a>). Moreover, they adversely affect male sexual function, causing decreased libido (3% to 6% with 5‐ARI), ED (6% to 8% with 5‐ARI), decreased ejaculatory volume (1% to 4% with 5‐ARI), and retrograde ejaculation (8% to 28% with AB) (<a href="./references#CD010060-bbs2-0121" title="LabordeEE , McVaryKT . Medical management of lower urinary tract symptoms. Review of Urology2009;11(Suppl 1):S19‐S25. ">Laborde 2009</a>). </p> </li> <li> <p>PDEIs have shown their efficacy in relieving LUTS symptoms in various types of clinical studies including observational studies, uncontrolled clinical trials, randomised open‐label trials, and randomised placebo‐controlled trials. </p> </li> <li> <p>PDEIs, ABs, and 5‐ARIs act through different components in the pathophysiology of LUTS consistent with BPH. The PDE₅ inhibitor, tadalafil, is a relatively new addition, and a thorough examination of its efficacy is needed to assist clinicians in choosing the best drug and drug combination for treatment. </p> </li> <li> <p>Long‐term effects of PDEIs in maintaining their efficacy in LUTS, effects on disease progression, and adverse outcomes of their use are not clear. </p> </li> </ul> </p> <p>Therefore, a systematic review of emerging evidence is needed to allow an overall assessment of the efficacy and safety of these agents. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010060-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010060-sec-0045">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010060-sec-0259">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010060-sec-0045"></div> <p>To assess the effects of PDEIs compared to placebo and other standard of care drugs (ABs and 5‐ARIs) in men with LUTS consistent with BPH. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010060-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010060-sec-0046">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010060-sec-0260">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010060-sec-0046"></div> <section id="CD010060-sec-0047"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010060-sec-0048"> <h4 class="title">Types of studies</h4> <p>We considered for inclusion in the review, randomised controlled clinical trials (RCTs) in which participants and study investigators and/or outcome assessors were masked to the interventions. Studies that evaluated one (or more) of the below mentioned outcome measures were deemed eligible for analysis. We included eligible studies regardless of their publication status or language of publication. </p> </section> <section id="CD010060-sec-0049"> <h4 class="title">Types of participants</h4> <p>We looked for studies including men with BPH and complaints of significant LUTS as evaluated by an International Prostate Symptom Score‐total (IPSS‐total) of 12 or more (from the American Urologic Association (AUA)) with or without concomitant ED. </p> </section> <section id="CD010060-sec-0050"> <h4 class="title">Types of interventions</h4> <p>Studies conducted the following comparisons.</p> <p> <ul id="CD010060-list-0002"> <li> <p>PDEI versus placebo (used for at least 4 weeks).</p> </li> <li> <p>PDEI versus other standard medical treatment for BPH‐LUTS (AB and 5‐ARI).</p> </li> <li> <p>PDEI in combination with other standard medical treatment for BPH‐LUTS versus either treatment alone. </p> </li> </ul> </p> <p>Specific comparison groups were as follows.</p> <p> <ul id="CD010060-list-0003"> <li> <p>PDEI versus placebo.</p> </li> <li> <p>PDEI versus AB.</p> </li> <li> <p>PDEI versus 5‐ARI.</p> </li> <li> <p>PDEI + AB versus PDEI alone.</p> </li> <li> <p>PDEI + AB versus AB alone.</p> </li> <li> <p>PDEI + 5‐ARI versus PDEI alone.</p> </li> <li> <p>PDEI + 5‐ARI versus 5‐ARI alone.</p> </li> <li> <p>PDEI + AB + 5‐ARI versus AB + 5‐ARI.</p> </li> <li> <p>Comparison of different PDEI agents for treatment of BPH‐LUTS.</p> </li> </ul> </p> </section> <section id="CD010060-sec-0051"> <h4 class="title">Types of outcome measures</h4> <section id="CD010060-sec-0052"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010060-list-0004"> <li> <p>Total International Prostate Symptom (IPSS‐total) score</p> </li> <li> <p>Benign Prostatic Hyperplasia Impact Index (BPHII) score</p> </li> <li> <p>Adverse events (AEs)</p> </li> </ul> </p> </section> <section id="CD010060-sec-0053"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010060-list-0005"> <li> <p>IPSS‐quality of life score (IPSS‐QOL)</p> </li> <li> <p>Acute urinary retention (AUR)</p> </li> <li> <p>Surgical interventions</p> </li> <li> <p>Other treatment‐related harms</p> </li> </ul> </p> <p>All outcomes were assessed for short‐term (up to 12 weeks) and long‐term (12 weeks and longer) use. We reported minimal clinically important differences (MCIDs) to show clinical relevance. For IPSS‐total, we used an MCID of 3 (<a href="./references#CD010060-bbs2-0073" title="American Urology Association (AUA). Benign prostatic hyperplasia (BPH) guideline update 2010. http://www.auanet.org/content/guidelines‐and‐quality‐care/clinical‐guidelines/main‐reports/bph‐management/chap_1_GuidelineManagementof(BPH).pdf (accessed August 2011). ">AUA 2010</a>; <a href="./references#CD010060-bbs2-0074" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154:1770‐4. ">Barry 1995</a>); for BPHII, we used an MCID of 0.5 (<a href="./references#CD010060-bbs2-0074" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154:1770‐4. ">Barry 1995</a>). </p> </section> </section> </section> <section id="CD010060-sec-0054"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010060-sec-0055"> <h4 class="title">Electronic searches</h4> <p>We first searched electronic databases in October 2014; we periodically updated the search during conduct of the review, conducting the final update in August 2018. Our search included the Cochrane Central Register of Controlled Trials (CENTRAL; updated 2018 August 2) in the <a href="http://www.cochranelibrary.com" target="_blank">Wiley Cochrane Library;</a> MEDLINE (<a href="http://ovid.com/site/catalog/databases/901.jsp" target="_blank">Ovid®</a>) (updated 2 August 2018); Embase (<a href="http://www.embase.com" target="_blank">Elsevier</a>) (updated 2 August 2018); and Science Citation Index Expanded via <a href="http://ipscience.thomsonreuters.com" target="_blank">Web of Science™</a> (updated 2 August 2018). We also searched the clinical trials registries <a href="http://www.clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> and the World Health Organization International Clinical Trials Registry Platform (<a href="http://WHO ICTRP" target="_blank">WHO ICTRP</a>) (updated 13 August 2018). We have detailed the search strategies used in Appendices 1 to 5 (<a href="./appendices#CD010060-sec-0234">Appendix 1</a>; <a href="./appendices#CD010060-sec-0235">Appendix 2</a>; <a href="./appendices#CD010060-sec-0236">Appendix 3</a>; <a href="./appendices#CD010060-sec-0237">Appendix 4</a>; <a href="./appendices#CD010060-sec-0238">Appendix 5</a>). </p> </section> <section id="CD010060-sec-0056"> <h4 class="title">Searching other resources</h4> <p>We inspected the references lists of all included RCTs and selected relevant reviews to look for more trials. We asked the authors of eligible RCTs for additional data from their study if these data were not reported in the published manuscripts. We asked investigators of unpublished trials for additional information. We handsearched relevant peer‐reviewed journals (<i>Journal of Urology, BJU International, European Urology, Journal of Sexual Medicine, Urology Gold</i>; from January 2010 to August 2, 2018) and abstract books including contributions presented at congresses of international societies (e.g. American Urological Association, International Continence Society; from January 2010 to August 2, 2018) for additional information. </p> </section> </section> <section id="CD010060-sec-0057"> <h3 class="title" id="CD010060-sec-0057">Data collection and analysis</h3> <section id="CD010060-sec-0058"> <h4 class="title">Selection of studies</h4> <p>Four review authors (SP, RM, AP, and MMA) independently assessed relevant titles and abstracts, identified by the literature search, against predefined inclusion criteria. The same four review authors investigated all potentially relevant records as full text, mapped records to studies, and classified studies as included studies or excluded studies. We resolved conflicts by discussion and by consensus. </p> <p>We reviewed all English and non‐English papers. We corresponded with original study authors to request any relevant additional information needed to determine the eligibility of a study for inclusion. When we identified that more than one publication of a trial existed, we grouped reports together and used the most complete data set. We sought help from the Cochrane Urology Group in resolving issues when needed. We have outlined the results of our search in <a href="#CD010060-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010060-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010060-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010060-sec-0059"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (SP, RM, and AP) independently abstracted data using a standardised data abstraction form that had been pilot‐tested. Extracted data included study design; time period when the study was conducted; study setting; participant inclusion and exclusion criteria; participant age; sample size for each intervention group; details of interventions; details of outcomes relevant to the review; how outcomes were measured; time points at which they were measured; details of funding sources; declarations of interest among primary study authors; any published protocols; and any other study details relevant to risk of bias assessment. Data analysis was based on available trial data relevant to comparisons and outcomes of interest. We contacted authors of the primary studies for clarification of data and/or additional information if relevant data were missing from the published manuscripts. We finalised data analysis after discussion among the review authors (JLM, MMA, SKS, and AKM), and we resolved disagreements by consensus and in consultation with the Cochrane Urology Group.  </p> </section> <section id="CD010060-sec-0060"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two independent review authors (SP and JLM) assessed the quality and risk of bias (ROB) of included studies, without blinding to authorship or journal. We assessed the following items using the Cochrane method for assessing risk of bias (<a href="./references#CD010060-bbs2-0114" title="HigginsJPT , AltmanDG , SterneJAC . Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). London, UK: Cochrane Wiley‐Blackwell Publication, 2011. ">Higgins 2011</a>), along with the 'Risk of bias' tool provided in RevMan 5.3.5 (<a href="./references#CD010060-bbs2-0151" title="Review Manager (RevMan) 5.3.5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2014. ">Revman 2014</a>). </p> <p> <ul id="CD010060-list-0006"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective reporting.</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>We judged risk of bias domains as low risk, high risk, or unclear risk, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010060-bbs2-0114" title="HigginsJPT , AltmanDG , SterneJAC . Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). London, UK: Cochrane Wiley‐Blackwell Publication, 2011. ">Higgins 2011</a>). We assessed risk of bias for each outcome within and across studies. We noted that the risk of bias for random sequence generation and allocation concealment was consistent across outcomes. However, we assessed risk of bias for blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting on an outcome‐specific basis, as the risk of bias of each of these domains is likely to vary by outcome. </p> <p>Based on the nature of the outcomes, we grouped them into (1) IPSS‐total, BPHII, and IPSS‐QOL; (2) AEs and other treatment‐related harms; and (3) AUR and need for surgical intervention for assessment of risk of bias. </p> <p>We have generated 'Risk of bias tables' for each included study and have presented a 'Risk of bias summary' in <a href="#CD010060-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD010060-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010060-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD010060-sec-0061"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager 5.3 to analyse data (<a href="./references#CD010060-bbs2-0151" title="Review Manager (RevMan) 5.3.5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2014. ">Revman 2014</a>). We combined data from RCTs for meta‐analyses. We calculated the mean difference (MD) with 95% confidence interval (95% CI) for continuous outcomes and the risk ratio (RR) with 95% CI for dichotomous outcomes. </p> </section> <section id="CD010060-sec-0062"> <h4 class="title">Unit of analysis issues</h4> <p>We considered parallel‐design randomised controlled clinical trials as well as cross‐over studies for inclusion in the review. We performed data extraction and analysis and risk of bias assessments for cross‐over trials as per Section 16.4, in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010060-bbs2-0114" title="HigginsJPT , AltmanDG , SterneJAC . Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). London, UK: Cochrane Wiley‐Blackwell Publication, 2011. ">Higgins 2011</a>). The individual participant is considered a unit in this type of analysis, hence the unit of analysis issue is not relevant for this review. </p> </section> <section id="CD010060-sec-0063"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors of papers with missing data (studies, outcomes, summary data, individuals, measures of variance, or study level characteristics) to request missing or unreported data. We performed analysis using the intention‐to‐treat (ITT) principle. When we could not obtain data from the authors of incompletely reported papers, we excluded them from the review, citing the specific reason for the same. However, if pooled data were available for such studies, we included them in the analysis as published literature. </p> </section> <section id="CD010060-sec-0064"> <h4 class="title">Assessment of heterogeneity</h4> <p>We regarded an I² value &gt; 50% as showing considerable heterogeneity, and we dealt with this by using the random‐effects model. Alternatively if we judged that clinical or study design heterogeneity was present, we conducted subgroup analyses to assess the robustness of pooled outcomes and conclusions. </p> </section> <section id="CD010060-sec-0065"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain the protocols of included studies to assess selective outcome reporting. We constructed funnel plots (trial effect vs trial size) for comparisons including at least 10 studies to investigate the possibility of publication bias. We also looked at other relevant sources of bias. </p> </section> <section id="CD010060-sec-0066"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model for analysis unless we noted statistically significant heterogeneity (I² &gt; 50%) between studies. We employed a random‐effects model if heterogeneity existed. We used the inverse variance method for meta‐analysis of continuous outcomes and the Cochran‐Mantel‐Haenzsel method for meta‐analysis of dichotomous outcomes. When a meta‐analysis was not possible or was not appropriate, we prepared a narrative synthesis. </p> </section> <section id="CD010060-sec-0067"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted the following subgroup analyses.</p> <p> <ul id="CD010060-list-0007"> <li> <p>Participants with or without ED.</p> </li> <li> <p>Different PDEIs, namely, tadalafil versus vardenafil versus sildenafil.</p> </li> <li> <p>Different doses of PDEIs.</p> </li> </ul> </p> </section> <section id="CD010060-sec-0068"> <h4 class="title">Sensitivity analysis</h4> <p> <ul id="CD010060-list-0008"> <li> <p>We excluded RCTs without a run‐in period</p> </li> </ul> </p> <p>Among the included RCTs, some had incorporated a two‐ to four‐week run‐in period before providing the randomised study intervention. The placebo and/or active drug run‐in period represents a potential source of bias because this may lead to selection of participants who are more compliant and/or less likely to experience AE. Therefore, we conducted a sensitivity analysis to explore the effect of the pre‐intervention run‐in period on effect size for various outcomes. </p> <section id="CD010060-sec-0069"> <h5 class="title">'Summary of findings' table</h5> <p>We rated the overall quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework, which takes into account criteria related not only to internal validity: study limitations (risk of bias), inconsistency, imprecision, and publication bias; but also to external validity: indirectness of results (<a href="./references#CD010060-bbs2-0109" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , SchünemannHJ , GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7654):924‐6. ">Guyatt 2008</a>). For each comparison, two review authors (SP and RM) independently rated the quality of evidence for each outcome as high, moderate, low, or very low, using <a href="./references#CD010060-bbs2-0106" title="GRADEpro GDT: GRADEpro Guideline Development Tool [software]. Hamilton, ON: McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from gradepro.org. ">GRADEproGDT</a> software. SP, RM, and JLM constructed 'Summary of findings' tables and resolved discrepancies by consensus or, if needed, via arbitration by other review authors (AP, SKS, and AKM). For each comparison, we have presented a summary of evidence for the main outcomes in a 'Summary of findings' table. This provides key information about the best estimate of the magnitude of effect in relative terms and absolute differences for each relevant comparison of alternative management strategies, numbers of participants and studies addressing each important outcome, and the rating of overall confidence in effect estimates for each outcome (<a href="./references#CD010060-bbs2-0110" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADEevidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011</a>; <a href="./references#CD010060-bbs2-0158" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. www.cochranehandbook.org, 2011. ">Schünemann 2011</a>; <a href="./references#CD010060-bbs2-0159" title="SchünemannH , BrożekJ , GuyattG , OxmanA (editors) . Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. The GRADE Working Group, Updated October 2013. ">Schünemann 2013</a>)<i>.</i> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010060-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010060-sec-0070"></div> <section id="CD010060-sec-0071"> <h3 class="title">Description of studies</h3> <p>We have outlined search results in <a href="#CD010060-fig-0001">Figure 1</a>. As per the protocol, we used nine comparison groups to evaluate the efficacy and safety of PDEI compared to placebo or existing treatments (alone or in combination). We segregated the included studies as per the comparison groups. Of the nine comparison groups, we could identify no studies for four groups. </p> <p> <ul id="CD010060-list-0009"> <li> <p>PDEI versus 5‐ARI (group 3).</p> </li> <li> <p>PDEI + 5‐ARI versus PDEI alone (group 6).</p> </li> <li> <p>PDEI + AB + 5‐ARI versus AB + 5‐ARI (group 8).</p> </li> <li> <p>Comparison of different PDEIs for treatment of BPH‐LUTS (group 9).</p> </li> </ul> </p> <p>We have presented detailed descriptions of the interventions in <a href="#CD010060-tbl-0007">Table 1</a>, and we have described baseline characteristics of the included studies in <a href="#CD010060-tbl-0008">Table 2</a>. </p> <div class="table" id="CD010060-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study (year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) (route, frequency, total dose/d)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) appropriate as applied in a clinical practice setting<sup>a</sup> (description)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator(s) (route, frequency, total dose/d)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator(s) appropriate as applied in a clinical practice setting<sup>a</sup> (description)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Casabe (2014)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>+ finasteride 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and finasteride were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>+ finasteride 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finasteride was used in this study as per clinical practice setting</p> <p>Placebo; N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Regadas (2013)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d + tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and tamsulosin were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>+ placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> <p>Placebo; N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Brock (2013a)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo once daily</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yokoyama (2013)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> <p>oral</p> <p>I2: tadalafil 5 mg/d</p> <p>oral</p> <p>I3: tamsulosin 0.2 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Egerdie (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> <p>oral</p> <p>I2: tadalafil 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gacci (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tamsulosin 0.4 mg/d</p> <p>+ vardenafil 10 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and vardenafil were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oelke (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>oral</p> <p>I2: tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and tamsulosin were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Takeda (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> <p>oral</p> <p>I2: tadalafil 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kim (2011)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>oral</p> <p>I2: tamsulosin 0.2 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and tamsulosin were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dmochowski (2010)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tamsulosin 20 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil is approved for use in BPH‐LUTS at 2.5 mg and 5 mg per day</p> <p>Tadalafil dose used in this study is higher than that used in the clinical practice setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prost (2011)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tuncel (2010)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: sildenafil 25 mg/4 times weekly + tamsulosin 0.4 mg/d</p> <p>oral</p> <p>I2: sildenafil 25 mg/4 times weekly oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sildenafil and tamsulosin were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bechara (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 20 mg/d + tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil is approved for use in BPH‐LUTS at 2.5 mg and 5 mg per day</p> <p>Tadalafil dose used in this study is higher than that used in clinical practice setting</p> <p>Tamsulosin was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>+ placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> <p>Placebo; N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tamsulosin 0.4 mg/d + placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> <p>For placebo; N/CPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C2: tadalafil 20 mg/d + tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil is approved for use in BPH‐LUTS at 2.5 mg and 5 mg per day</p> <p>Tadalafil dose used in this study was higher than that used in clinical practice setting</p> <p>Tamsulosin was used in this study as per clinical practice setting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Roehrborn (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> <p>oral</p> <p>I2: tadalafil 5 mg/d</p> <p>oral</p> <p>I3: tadalafil 10 mg/d</p> <p>oral</p> <p>I4: tadalafil 20 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil is approved for use in BPH‐LUTS at 2.5 mg and 5 mg per day</p> <p>This is a dose‐ranging study; tadalafil doses used in this study for I3 and I4 were higher than those used in clinical practice setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stief (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: vardenafil 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vardenafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>McVary (2007a)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: sildenafil 50 to 100 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sildenafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>McVary (2007b)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 to 20 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil dose used in this study in the dose escalation phase was higher than that used in clinical practice setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><sup>a</sup>The term 'clinical practice setting' refers to the specification of the intervention/comparator as used in the course of a standard medical treatment (such as dose, dose escalation, dosing scheme, provision for contraindications, and other important features). </p> <p>BPH: benign prostatic hyperplasia; C: comparator; I: intervention; LUTS: lower urinary tract symptoms; N/CPS: no specification of clinical practice setting possible. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD010060-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study (year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of intervention (duration of follow‐up) (days, months, years...)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial period (year to year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ethnic groups (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of disease (mean/range years (SD), or as reported)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Casabe (2014)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>+ finasteride 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> <p>(for primary endpoint)</p> <p>Study continued maintaining blinding until 26 weeks (for secondary endpoints)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years with BPH‐LUTS; IPSS ≥ 13</p> <p>Qmax 4 to 15 mL/s</p> <p>Prostatic volume ≥ 30 cc</p> <p>Naive to 5‐ARI therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>November 2010</p> <p>to</p> <p>September 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>USA, Canada, Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whites</p> <p>(85.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black/African American (10.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Native American (2.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>+ finasteride 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (3.9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Regadas (2013)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>+ tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men &gt; 45 years, BOOI &gt; 20 IPSS &gt; 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>October 2010</p> <p>to</p> <p>September 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>+ placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Brock (2013a)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men ≥ 45 years</p> <p>BPH‐LUTS &gt; 6 months</p> <p>IPSS ≥ 13</p> <p>Qmax 4 to 15 mL/s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Yokoyama (2013)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years; BPH‐LUTS &gt; 6 months</p> <p>IPSS &gt; 13</p> <p>Qmax 4 to 15 mL/s</p> <p>Prostate volume &gt; 20 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Japan</p> <p>Korea</p> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan (55.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Korea (29.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I3: tamsulosin 0.2 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Taiwan (14.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Egerdie (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Men ≥ 45 years, ≥ 3 months h/o ED, ≥ 6 months h/o BPH‐LUTS (LUTS + ED)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Europe</p> <p>Mexico</p> <p>USA/Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C2: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asian (2.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hispanic (15%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (0.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Gacci (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tamsulosin 0.4 mg/d</p> <p>+ vardenafil 10 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men with persistent storage/irritative symptoms after tamsulosin 0.4 mg treatment for 2 weeks; IPSS‐storage ≥ 8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Oelke (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Men ≥ 45 years, BPH‐LUTS &gt; 6 months, IPSS ≥ 13, Qmax 4 to 15 mL/s before placebo lead‐in period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>December 2009</p> <p>to</p> <p>January 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Australia, Austria, Belgium, France, Germany, Greece, Italy, Mexico, The Netherlands, Poland </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tamsulosin</p> <p>0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black or African American (0.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>American Indian/Alaska Native (23.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Takeda (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks, followed by a 42‐week open‐label extension phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>&gt; 45 years, IPSS &gt; 13, Qmax 4 to 15 mL/s, prostate volume &gt; 20 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Asian (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tadalafil 5 mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Kim (2011)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Men ≥ 45 years, h/o BPH‐LUTS for 6 months or longer, IPSS ≥ 13, Qmax &gt; 5 and &lt; 15 after the washout period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Asian (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tamsulosin 0.2 mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Dmochowski (2010)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tamsulosin 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 40 years, longer than 6 months h/o BPH‐LUTS; IPSS ≥ 13, with or without BOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>USA, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (12.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hispanic (8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (3.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Prost (2011)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years, BPH‐LUTS &gt; 6 months</p> <p>IPSS &gt; 13 and Qmax 4 to 15 mL/s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Argentina, Germany, Italy, Mexico, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black or African American (2.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>American Indian or Alaska Native (5.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Tuncel (2010)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: sildenafil 25 mg/4 times weekly + tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>IPSS &gt; 12, IIEF &lt; 21 (SIHM &lt; 21) treatment‐naive and all participants had ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: sildenafil 25 mg/4 times weekly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bechara (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 20 mg/d + tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>45 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men ≥ 50 years, h/o BPH &gt; 6 months, IPSS ≥ 12, <sup>6</sup>PSA ≤ 4 ng/mL, <sup>2</sup>Qmax &gt; 5 and &lt; 15 for a minimum voided volume of 125 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>September 2007</p> <p>to</p> <p>February 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Argentina</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tamsulosin 0.4 mg/d + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Roehrborn (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years, BPH‐LUTS &gt; 6 months, IPSS &gt; 13, Qmax 4 to 15 mL/s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>North America, Europe, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hispanic (11.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I3: tadalafil 10 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (2.42%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I4: tadalafil 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (0.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Stief (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>I1: vardenafil 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Men &gt; 45 to 64 years, BPH‐LUTS &gt; 6 months, IPSS &gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>October 2005</p> <p>to</p> <p>June 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black Americans (0.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (0.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>McVary (2007b)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years, h/o BPH‐LUTS 6 months with IPSS &gt; 13, Qmax &gt; 4 to &lt; 15 mL/s for a voided volume of 125 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>November 2004</p> <p>to</p> <p>July 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (9.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hispanic (6.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (2.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>McVary (2007a)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: sildenafil 50 to 100 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men ≥ 45 years, with IPSS &gt; 12 and IIEF score &lt; 25</p> <p>All participants had ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>March 2004</p> <p>to</p> <p>May 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (82%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (11.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asian (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>‐ denotes not reported; "‐" denotes missing information.</p> <p>BOO: bladder outflow obstruction; BOOI: Bladder Outflow Obstruction Index; C: comparator; I: intervention; IIEF: International Index of Erectile Function; PSA: prostate‐specific antigen; Qmax: maximum urinary flow rate; SD: standard deviation; SHIM: Sexual Health Inventory for Males. </p> </td> </tr> </tbody> </table> </div> <section id="CD010060-sec-0072"> <h4 class="title">PDEI versus placebo</h4> <p>Through our search strategy, we identified 11 RCTs meeting the inclusion criteria (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0057" title="TamimiNA , MincikI , HaughieS , LambJ , CrosslandA , EllisP . A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU International2010;106(5):674‐80. ">Tamimi 2010</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). We did not include one RCT, as we could not obtain data from study authors or could not impute data from available published literature (<a href="./references#CD010060-bbs2-0057" title="TamimiNA , MincikI , HaughieS , LambJ , CrosslandA , EllisP . A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU International2010;106(5):674‐80. ">Tamimi 2010</a>). We included in the analysis a total of 11 RCTs with 4293 participants (1576 in the placebo group, and 2717 in the PDEI treatment group). All RCTs were multi‐centric clinical trials. They included elderly men with LUTS consistent with BPH living in various parts of North America, Europe, South America, Japan, and Korea. Five of the 11 RCTs were multi‐national (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Among the other studies, one was conducted in the USA (<a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>), two in Japan (<a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), one in Korea (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>), and one in Germany (<a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>). </p> <p>All included RCTs reported the racial origin of participants. About 85% to 87% of participants belonged to the white race, and 4% to 6% belonged to the black race, as reported in seven RCTs (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a><a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>). The remaining participants (7% to 11%) were Asian men included in three RCTs (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011;</a><a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). </p> <p>RCTs included men older than 45 years with symptoms of BPH‐LUTS, irrespective of their ED status. The mean age of participants in PDEI and placebo groups was 69.1 ± 8.4 and 62.02 ± 8.8 years, respectively. Two RCTs included participants with both BPH‐LUTS and ED (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>). Included participants had moderate to severe LUTS at the qualifying visit. Mean IPSS‐total score in PDEI and placebo groups was 17.6 ± 5.5 and 17.5 ± 5.6, respectively. Baseline characteristics included baseline LUTS severity, ED severity, prior AB or 5‐ARI use, uroflow parameters, post‐void residue (PVR), PSA, and demographic features. Six of the 11 RCTs reported participant characteristics including LUTS severity, proportions of participants with ED, severity of ED, and prior AB use status. Six RCTs did not report any of these participant characteristics (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). The mean duration of BPH‐LUTS and/or ED also was not described in many of the RCTs (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Men with a history of BPH‐LUTS longer than six months were considered for inclusion. RCTs had excluded participants with Qmax &lt; 4 mL/s and &gt; 15 mL/s, PSA &gt; 10 ng/mL or positive prostatic biopsy with PSA between 4 and 10 ng/mL, use of 5‐ARIs within the last three to six months, and other pelvic diseases or history of pelvic surgery within the preceding six months. </p> <p>Nine of the 11 RCTs used the long‐acting PDEI, tadalafil, whereas <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a> used sildenafil and <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a> used vardenafil. We were able to find one study that examined use of gisadenafil but were unable to retrieve data required for the meta‐analysis (<a href="./references#CD010060-bbs2-0057" title="TamimiNA , MincikI , HaughieS , LambJ , CrosslandA , EllisP . A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU International2010;106(5):674‐80. ">Tamimi 2010</a>). We identified no studies for avanafil or udenafil. The dose of tadalafil studied ranged from 2.5 to 20 mg once daily, for sildenafil 50 to 100 mg once daily, and vardenafil 10 mg twice daily. The dose of tadalafil used most commonly was 5 mg per day (i.e. the FDA‐approved highest dose for BPH‐LUTS) (<a href="./references#CD010060-bbs2-0087" title="FDA Approved Drug Products. Cialis (tadalafil). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf (accessed 10 April 2017). ">Cialis 2011</a>). Four RCTs included an additional arm given 2.5 mg per day (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). <a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a> studied only one dose of tadalafil ‐ 20 mg per day ‐ and the primary outcome was the urodynamic parameter. <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>, a dose‐ranging study, compared all dosages, namely, 2.5, 5, 10, or 20 mg per day, against placebo. <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a> used sildenafil in a dose titration design but did not report the number of participants using 50 or 100 mg of the drug. </p> <p>Most RCTs were short‐term efficacy studies. The maximum study duration was 12 weeks (in 10/11 RCTs) and the minimum duration was eight weeks (<a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>). Two studies had an open‐label extension (OLE) phase of up to 42 weeks ‐ in <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a> ‐and 64 weeks in <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>. These studies used tadalafil at a dose of 5 mg per day in the OLE. Seven of 11 RCTs included a treatment‐free washout period of four weeks for participants who were already receiving treatment at screening (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), but <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a> reported a washout period of two weeks. After the washout, investigators subjected these participants to a four‐week single‐blind placebo run‐in period. However, the treatment‐naïve participants were not subjected to any wash‐out but only a four‐week single‐blind placebo run‐in period. Three of 11 RCTs did not follow this pattern for enrolment. Two of them used only a drug‐free washout period (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>), but they did not include a placebo run‐in period. <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a> neither included a washout period nor a run‐in period. This study also did not specify whether participants were naïve or experienced to treatment. </p> <p>The primary outcome in most RCTs was effect of PDEIs on LUTS, but for <a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>, the primary outcome was change in the urodynamic parameter for bladder outlet obstruction (BOO), and change in erectile function was the secondary outcome. </p> <p>Pharmaceutical manufacturers of the active drugs (PDEIs) sponsored eight of 11 included RCTs comparing PDEIs versus placebo (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), and manufacturers of the investigational drug presumably sponsored the remaining two RCTs, although published reports included no statement on trial sponsorship (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>). Apart from providing the logistics, study sponsors made significant contributions to design and conduct of the study, data acquisition, data analysis, interpretation of results, and preparation and final approval of the manuscript. </p> </section> <section id="CD010060-sec-0073"> <h4 class="title">PDEI versus AB</h4> <p>We included four RCTs comprising 933 participants for this comparison (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Three of these RCTs were included in the previous comparison and had three arms, namely, PDEI, AB, and placebo (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). The only remaining RCT compared PDEI, AB, and a combination of the two (<a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). Three RCTs used tadalafil 5 mg as the PDEI (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), and one used sildenafil 25 mg (<a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a> included an additional tadalafil 2.5 mg arm. All researchers used PDEI as once‐daily therapy, but the sildenafil study ‐ <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> ‐ used it four times weekly. The AB in all included studies was tamsulosin, although the dose was not uniform across studies. Two RCTs used 0.2 mg once daily (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), whereas the other two used 0.4 mg once daily (<a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). All participants included in <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> were treatment naïve; the other studies did not specify so and included a mixed cohort of previously treated and untreated participants. The tadalafil studies incorporated a drug washout period, followed by a placebo run‐in period (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). All studies examined short‐term treatment provided over eight to 12 weeks. </p> </section> <section id="CD010060-sec-0074"> <h4 class="title">PDEI versus 5‐ARI</h4> <p>We found no studies that met the inclusion criteria for this comparison.</p> </section> <section id="CD010060-sec-0075"> <h4 class="title">PDEI + AB versus AB alone</h4> <p>For this comparison, we included four RCTs involving a total of 193 participants (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>; <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). All RCTs compared treatments in parallel design, except <a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>, which used a cross‐over design. The duration of studies varied from 30 days to 12 weeks. PDEIs used were not uniform across studies. <a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a> used tadalafil 20 mg/d and <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a> 5 mg/d, <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> used sildenafil 25 mg/4 times a week, and <a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a> used vardenafil 10 mg/d. The AB used was uniform in type and dose across studies (tamsulosin 0.4 mg/d). Two of the four RCTs were placebo controlled and included a placebo arm along with the AB alone arm (<a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>; <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>); the other two RCTs were not placebo controlled (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). Two RCTs included a placebo run‐in period (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>), and the other two did not (<a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). Participants included in <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> were treatment naïve, whereas remaining RCTs did not specify this. </p> </section> <section id="CD010060-sec-0076"> <h4 class="title">PDEI + AB versus PDEI alone</h4> <p>Only one RCT, conducted in Turkey, was eligible for inclusion (<a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). It included a total of 60 participants and three arms (sildenafil 25 mg four times a week vs tamsulosin 0.4 mg once a day vs sildenafil 25 mg four times a week + tamsulosin 0.4 mg per day). The duration of the study was eight weeks, and it included all treatment‐naïve participants with both BPH‐LUTS and ED. This study did not include a placebo run‐in period, and participants directly entered the randomisation phase. </p> </section> <section id="CD010060-sec-0077"> <h4 class="title">PDEI + 5‐ARI versus 5‐ARI alone</h4> <p>Only one study qualified for inclusion in this group (<a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a>). This study included 695 participants and was conducted in North America, Europe, and Latin America. The duration of the study was 26 weeks. Participants underwent a drug‐free washout period of four weeks, followed by a four‐week placebo run‐in period, before randomisation. Participants were randomised to tadalafil 5 mg plus finasteride 5 mg per day or placebo plus finasteride 5 mg per day. Included participants had a larger prostate volume of 30 mL or greater and were naïve to 5‐ARI therapy but not to other LUTS treatments, namely, alpha‐blockers or anticholinergics. </p> </section> <section id="CD010060-sec-0078"> <h4 class="title">PDEI + 5‐ARI versus PDEI alone</h4> <p>We found no studies that met the inclusion criteria for this comparison.</p> </section> <section id="CD010060-sec-0079"> <h4 class="title">PDEI + AB + 5‐ARI versus AB + 5‐ARI</h4> <p>We found no studies that met the inclusion criteria for this comparison.</p> </section> <section id="CD010060-sec-0080"> <h4 class="title">Comparison of different PDEI agents for treatment of BPH‐LUTS</h4> <p>We found no studies that met the inclusion criteria for this comparison.</p> </section> <section id="CD010060-sec-0081"> <h4 class="title">Results of the search</h4> <p>We conducted the original search in May 2014 and updated the search through 20 February 2018. We have provided detailed results of the search in <a href="#CD010060-fig-0001">Figure 1</a>. </p> </section> <section id="CD010060-sec-0082"> <h4 class="title">Included studies</h4> <p>We included a total of 16 RCTs in the review. We have described the characteristics of included studies in the <a href="./references#CD010060-sec-0247" title="">Characteristics of included studies</a> section and in <a href="#CD010060-tbl-0007">Table 1</a> and <a href="#CD010060-tbl-0008">Table 2</a>. We grouped studies by comparison. Some RCTs had more than two arms and hence were eligible for inclusion in more than one comparison group. Analysis of PDEI versus placebo included 11 RCTs; PDEI versus alpha‐blockers four RCTs; combination of PDEI and AB versus AB alone four RCTs; combination of PDEI and alpha‐blockers versus PDEI alone one RCT; and combination of PDEI and 5‐ARI versus 5‐ARI alone one RCT. </p> </section> <section id="CD010060-sec-0083"> <h4 class="title">Excluded studies</h4> <p>We excluded RCTs not meeting the inclusion criteria for this review. We described the characteristics of excluded studies and reasons for exclusion in the <a href="./references#CD010060-sec-0248" title="">Characteristics of excluded studies</a> section. </p> </section> </section> <section id="CD010060-sec-0084"> <h3 class="title">Risk of bias in included studies</h3> <p>We have described below risk of bias assessment by comparison. We have presented in <a href="#CD010060-fig-0002">Figure 2</a> a summary of this assessment. </p> <section id="CD010060-sec-0085"> <h4 class="title">PDEI versus placebo</h4> <section id="CD010060-sec-0086"> <h5 class="title">Allocation (selection bias)</h5> <section id="CD010060-sec-0087"> <h6 class="title">Random sequence generation</h6> <p>We judged seven of the 11 included RCTs as having unclear risk of bias (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). </p> </section> <section id="CD010060-sec-0088"> <h6 class="title">Allocation concealment</h6> <p>We judged nine of 11 RCTs as having unclear risk of bias (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Three RCTs used an interactive voice response system or opaque, sealed, and numbered envelopes; hence we rated them as having low risk of bias. </p> </section> </section> <section id="CD010060-sec-0089"> <h5 class="title">Blinding</h5> <section id="CD010060-sec-0090"> <h6 class="title">Blinding of participants and personnel (performance bias)</h6> <p>We deemed risk of bias as unclear for six of 11 RCTs for IPSS‐total, BPHII, IPSS‐QOL, AEs, and treatment‐related harms (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). However we judged AUR and need for surgical interventions as having low risk of bias for all included RCTs. </p> </section> <section id="CD010060-sec-0091"> <h6 class="title">Blinding of outcome assessment (detection bias)</h6> <p>Risk of bias for IPSS‐total, BPHII, IPSS‐QOL, AEs, and treatment‐related harms was unclear for eight of 11 RCTs (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). However due to the nature of the outcomes of AUR and need for surgical intervention, we judged all included RCTs to have low risk of detection bias. </p> </section> </section> <section id="CD010060-sec-0092"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p>Eight of 11 RCTs had unclear risk of bias for IPSS‐total, BPHII, IPSS‐QOL, AEs, and treatment‐related harms (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Seven of 11 RCTs had unclear risk of bias for AUR and need for surgical interventions (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>) . </p> </section> <section id="CD010060-sec-0093"> <h5 class="title">Selective reporting (reporting bias)</h5> <p>We judged one of the 11 included RCTs to have unclear risk of selective reporting bias for IPSS‐total, BPHII, and IPSS‐QOL (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>). None of the included studies had selective reporting bias for AEs, treatment‐related harms, AUR, or need for surgical intervention. </p> </section> <section id="CD010060-sec-0094"> <h5 class="title">Other bias</h5> <p>We judged seven of the 11 included RCTs to have unclear risk of other bias for all outcomes because they used study designs that employed a placebo run‐in period (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). </p> </section> </section> <section id="CD010060-sec-0095"> <h4 class="title">PDEI versus alpha‐blockers</h4> <section id="CD010060-sec-0096"> <h5 class="title">Allocation (selection bias)</h5> <section id="CD010060-sec-0097"> <h6 class="title">Random sequence generation</h6> <p>Three of the four included RCTs did not adequately describe the method used for random sequence generation; hence we judged them to have unclear risk of selection bias (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>) . </p> </section> <section id="CD010060-sec-0098"> <h6 class="title">Allocation concealment</h6> <p>Three of the four included RCTs did not adequately describe the method used for allocation concealment; hence we judged them to have unclear risk of selection bias (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). </p> </section> </section> <section id="CD010060-sec-0099"> <h5 class="title">Blinding</h5> <section id="CD010060-sec-0100"> <h6 class="title">Blinding of participants and personnel (performance bias)</h6> <p>We judged three of four RCTs to have unclear risk of performance bias for IPSS‐total, BPHII, IPSS‐QOL, AEs, and treatment‐related harms (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). We determined that none of the RCTs had performance bias for AUR or need for surgical intervention. </p> </section> <section id="CD010060-sec-0101"> <h6 class="title">Blinding of outcome assessment (detection bias)</h6> <p>We judged three of four RCTs to have unclear risk of detection bias for IPSS‐total, BPHII, IPSS‐QOL, AEs, and treatment‐related harms (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). We determined that none of the RCTs had detection bias for AUR or need for surgical intervention. </p> </section> </section> <section id="CD010060-sec-0102"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p>Two of four included RCTs had unclear risk of attrition bias for all outcomes (<a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). </p> </section> <section id="CD010060-sec-0103"> <h5 class="title">Selective reporting (reporting bias)</h5> <p>We judged all four included RCTs to have low risk of selective reporting bias for all outcomes. </p> </section> <section id="CD010060-sec-0104"> <h5 class="title">Other bias</h5> <p>Three of four included RCTs employed placebo or an active drug run‐in period before randomisation; hence we judged them to have unclear risk of other bias (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). </p> </section> </section> <section id="CD010060-sec-0105"> <h4 class="title">PDEI + AB versus AB alone</h4> <section id="CD010060-sec-0106"> <h5 class="title">Allocation (selection bias)</h5> <section id="CD010060-sec-0107"> <h6 class="title">Random sequence generation</h6> <p>Three of the four included RCTs did not adequately describe the method used for random sequence generation; hence we judged them to have unclear risk of bias (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). </p> </section> <section id="CD010060-sec-0108"> <h6 class="title">Allocation concealment</h6> <p>No RCTs adequately described the method used; hence we judged them to have unclear risk of bias (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>; <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). </p> </section> </section> <section id="CD010060-sec-0109"> <h5 class="title">Blinding</h5> <section id="CD010060-sec-0110"> <h6 class="title">Blinding of participants and personnel (performance bias)</h6> <p>We judged two of four RCTs to have unclear risk of performance bias for IPSS‐total, BPHII, IPSS‐QOL, AEs, and treatment‐related harms (<a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). We determined that no RCTs had performance bias for AUR or need for surgical intervention. </p> </section> <section id="CD010060-sec-0111"> <h6 class="title">Blinding of outcome assessment (detection bias)</h6> <p>We judged two of four included RCTs to have unclear risk of bias (<a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). However we determined that risk of detection bias was low for AUR and need for surgical interventions for all four studies, as they are less susceptible to such bias. </p> </section> </section> <section id="CD010060-sec-0112"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p>We determined that none of the four RCTs had attrition bias for any outcomes.</p> </section> <section id="CD010060-sec-0113"> <h5 class="title">Selective reporting (reporting bias)</h5> <p>We judged two of the four included studies to have unclear risk of selective reporting bias for quality of life assessments (BPHII and IPSS‐QOL), AEs, and treatment‐related harms (<a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>; <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>). We determined that all four RCTs had low risk of bias for AE, AUR, and need for surgical intervention. </p> </section> <section id="CD010060-sec-0114"> <h5 class="title">Other bias</h5> <p>We judged two of the four included RCTs to have unclear risk of other bias for all outcomes: one RCT because of lack of a washout period between two cross‐over phases (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>), and the other for including an active drug run‐in period (<a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>). </p> </section> </section> <section id="CD010060-sec-0115"> <h4 class="title">PDEI + alpha‐blockers versus PDEI alone</h4> <p>We identified only one RCT for this comparison (<a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010)</a>. </p> <section id="CD010060-sec-0116"> <h5 class="title">Allocation (selection bias)</h5> <section id="CD010060-sec-0117"> <h6 class="title">Random sequence generation</h6> <p>We judged this RCT to have unclear risk of selection bias for all outcomes because study authors did not describe the method used. </p> </section> <section id="CD010060-sec-0118"> <h6 class="title">Allocation concealment</h6> <p>We judged risk of bias as unclear for allocation concealment for all outcomes.</p> </section> </section> <section id="CD010060-sec-0119"> <h5 class="title">Blinding</h5> <section id="CD010060-sec-0120"> <h6 class="title">Blinding of participants and personnel (performance bias)</h6> <p>We judged the risk of performance bias as unclear for IPSS‐total, BPHII, IPSS‐QOL, and AE assessments, as study authors did not clearly describe whether participants and treatment administrators were masked to the interventions. However we judged the risk of performance bias to be low for AUR and need for surgical intervention, as they are less susceptible to such bias. </p> </section> <section id="CD010060-sec-0121"> <h6 class="title">Blinding of outcome assessment (detection bias)</h6> <p>We judged the risk of detection bias as unclear for IPSS‐total, BPHII, IPSS‐QOL, and AE assessments, as study authors did not clearly describe whether outcome assessors were masked to the interventions. However we judged the risk of detection bias to be low for AUR and need for surgical intervention, as they are less susceptible to such bias. </p> </section> </section> <section id="CD010060-sec-0122"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p>We judged the risk of attrition bias to be low for all outcomes, as study authors reported no loss to follow‐up and reported outcomes for all randomised participants. </p> </section> <section id="CD010060-sec-0123"> <h5 class="title">Selective reporting (reporting bias)</h5> <p>We judged the risk of selective reporting bias to be low for all outcomes.</p> </section> <section id="CD010060-sec-0124"> <h5 class="title">Other bias</h5> <p>We detected no significant risk of other bias.</p> </section> </section> <section id="CD010060-sec-0125"> <h4 class="title">PDEI + 5‐ARI versus 5‐ARI alone</h4> <p>We included only one RCT for this comparison (<a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a>). </p> <section id="CD010060-sec-0126"> <h5 class="title">Allocation (selection bias)</h5> <section id="CD010060-sec-0127"> <h6 class="title">Random sequence generation</h6> <p>We judged this RCT to have unclear risk of bias.</p> </section> <section id="CD010060-sec-0128"> <h6 class="title">Allocation concealment</h6> <p>Researchers used an interactive voice response system in allocating interventions to participants; therefore we judged allocation concealment to be adequate. </p> </section> </section> <section id="CD010060-sec-0129"> <h5 class="title">Blinding</h5> <section id="CD010060-sec-0130"> <h6 class="title">Blinding of participants and personnel (performance bias)</h6> <p>We judged the risk of performance bias as unclear for IPSS‐total, BPHII, IPSS‐QOL, and AE assessments, as study authors did not clearly describe whether participants and treatment administrators were masked to the interventions. However we judged the risk of performance bias to be low for AUR and need for surgical intervention, as they are less susceptible to such bias. </p> </section> <section id="CD010060-sec-0131"> <h6 class="title">Blinding of outcome assessment (detection bias)</h6> <p>We judged the risk of detection bias as unclear for IPSS‐total, BPHII, IPSS‐QOL, and AE assessments, as study authors did not clearly describe whether outcome assessors were masked to the interventions. However we judged the risk of detection bias to be low for AUR and need for surgical intervention, as they are less susceptible to such bias. </p> </section> </section> <section id="CD010060-sec-0132"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p>This RCT had significant attrition of participants in both PDEI and combination groups. Therefore, we judged the risk of bias to be unclear for IPSS‐total, BPHII, IPSS‐QOL, AEs, AUR, and need for surgical intervention. </p> </section> <section id="CD010060-sec-0133"> <h5 class="title">Selective reporting (reporting bias)</h5> <p>This study reported all relevant outcomes; hence we judged the risk of selective reporting bias to be low. </p> </section> <section id="CD010060-sec-0134"> <h5 class="title">Other bias</h5> <p>Participants underwent a placebo run‐in before randomisation. This may have led to selection of more compliant participants and hence may have compromised external validity. Therefore, we judged the risk of bias to be unclear for IPSS‐total, BPHII, IPSS‐QOL, AEs, treatment‐related harms, AUR, and need for surgical intervention. </p> </section> </section> </section> <section id="CD010060-sec-0135"> <h3 class="title" id="CD010060-sec-0135">Effects of interventions</h3> <p>See: <a href="./full#CD010060-tbl-0001"><b>Summary of findings for the main comparison</b> PDEI compared to placebo for lower urinary tract symptoms consistent with benign prostatic hyperplasia</a>; <a href="./full#CD010060-tbl-0002"><b>Summary of findings 2</b> PDEI compared to alpha‐blockers for LUTS associated with BPH</a>; <a href="./full#CD010060-tbl-0003"><b>Summary of findings 3</b> PDEI plus alpha‐blocker compared to alpha‐blockers alone for LUTS associated with BPH (short‐term)</a>; <a href="./full#CD010060-tbl-0004"><b>Summary of findings 4</b> PDEI plus an alpha‐blocker compared to PDEI alone for LUTS associated with BPH (short‐term)</a>; <a href="./full#CD010060-tbl-0005"><b>Summary of findings 5</b> PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (short‐term)</a>; <a href="./full#CD010060-tbl-0006"><b>Summary of findings 6</b> PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (long‐term)</a> </p> <section id="CD010060-sec-0136"> <h4 class="title">PDEI versus placebo</h4> <section id="CD010060-sec-0137"> <h5 class="title">Short‐term (up to 12 weeks) efficacy and safety of PDEI compared to placebo</h5> <p>Eleven RCTs assessed the effects of PDEIs compared to placebo for short‐term use (eight to 12 weeks). </p> <section id="CD010060-sec-0138"> <h6 class="title">Primary outcomes</h6> <section id="CD010060-sec-0139"> <p><b>IPSS‐total score</b></p> <p>PDEIs may result in a small improvement in IPSS (MD 1.89 lower, 95% CI 2.27 lower to 1.50 lower; 11 trials; low‐quality evidence; <a href="./references#CD010060-fig-0010" title="">Analysis 1.1;</a><a href="#CD010060-fig-0003">Figure 3</a><a href="#CD010060-fig-0004">Figure 4</a><a href="./full#CD010060-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the quality of evidence for study limitations and possible publication bias. The duration of treatment ranged from eight to 12 weeks. All included trials reported the mean change in IPSS‐total score from baseline. </p> <div class="figure" id="CD010060-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.1 Change in IPSS‐total: main analysis." data-id="CD010060-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.1 Change in IPSS‐total: main analysis. </p> </div> </div> </div> <div class="figure" id="CD010060-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 PDEI versus placebo, outcome: 1.1 Change in IPSS‐total: main analysis." data-id="CD010060-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 PDEI versus placebo, outcome: 1.1 Change in IPSS‐total: main analysis. </p> </div> </div> </div> </section> <section id="CD010060-sec-0140"> <p><b>BPHII score</b></p> <p>PDEIs may result in a lower BPHII score (MD 0.52 lower, 95% CI 0.71 lower to 0.33 lower; eight trials; low‐quality evidence; <a href="./references#CD010060-fig-0015" title="">Analysis 1.6</a>; <a href="#CD010060-fig-0005">Figure 5</a>; <a href="./full#CD010060-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the quality of evidence for study limitations and imprecision, assuming an MCID of 0.5 (<a href="./references#CD010060-bbs2-0074" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154:1770‐4. ">Barry 1995</a>). </p> <div class="figure" id="CD010060-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.6 Change in BPHII: main analysis." data-id="CD010060-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.6 Change in BPHII: main analysis. </p> </div> </div> </div> </section> <section id="CD010060-sec-0141"> <p><b>Adverse events</b></p> <p>PDEIs may increase AEs (RR 1.42, 95% CI 1.21 to 1.67; 11 trials; low‐quality evidence; <a href="./references#CD010060-fig-0019" title="">Analysis 1.10</a>; <a href="#CD010060-fig-0006">Figure 6</a>; <a href="./full#CD010060-tbl-0001">summary of findings Table for the main comparison</a>). This corresponds to 95 more AEs per 1000 men (95% CI 47 more to 151 more). We downgraded the quality of evidence for study limitations and clinically important inconsistency. We were concerned about possible publication bias but decided not to downgrade further. </p> <div class="figure" id="CD010060-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.10 Any AE with short‐term use." data-id="CD010060-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.10 Any AE with short‐term use. </p> </div> </div> </div> </section> </section> <section id="CD010060-sec-0142"> <h6 class="title">Secondary outcomes</h6> <section id="CD010060-sec-0143"> <p><b>IPSS‐QOL score</b></p> <p>PDEI probably results in a small improvement in IPSS‐QOL (MD 0.26 lower, 95 CI 0.35 lower to 0.16 lower; nine trials; moderate‐quality evidence; <a href="./references#CD010060-fig-0024" title="">Analysis 1.15</a>; <a href="#CD010060-fig-0007">Figure 7</a>). We downgraded the quality of evidence for study limitations. </p> <div class="figure" id="CD010060-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Change in IPSS‐QOL with PDEI versus placebo" data-id="CD010060-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Change in IPSS‐QOL with PDEI versus placebo</p> </div> </div> </div> </section> <section id="CD010060-sec-0144"> <p><b>Acute urinary retention</b></p> <p>Six of 11 RCTs did not report AUR. Reporting of AUR in five other RCTs was not uniform across PDEI and placebo groups (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a> reported no AUR observed in any of three treatment groups (tadalafil 2.5, 5 mg, and placebo). <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a> reported no incidence of AUR in the tadalafil 5 mg treatment group, but they did not report the same for the placebo group. <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a> reported that one participant in the placebo group had AUR requiring catheterisation, but this RCT did not mention the incidence in any of the four tadalafil treatment groups. <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a> reported that one participant (74 years) in the tadalafil 5 mg group reported a severe adverse event (AUR) after 4.5 months of randomisation. This participant required catheterisation and had concomitant prostatitis. <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a> reported that one participant in the placebo group had urinary retention but did not mention the incidence in the tadalafil 2.5 and 5 mg groups. </p> </section> <section id="CD010060-sec-0145"> <p><b>Surgical interventions</b></p> <p>None of the 11 RCTs, including 4386 participants in PDEI or placebo groups, reported the need for surgical intervention during the treatment period. </p> </section> <section id="CD010060-sec-0146"> <p><b>Other treatment‐related harms</b></p> <p>All included RCTs reported AEs as patient‐reported safety outcomes. Treatment‐related AEs most commonly reported were headache, flushing, dizziness, syncope, body pain, myalgia, back pain, nasopharyngitis, dyspepsia, epigastric discomfort, abdominal pain, and diarrhoea. </p> <p>AEs related to vasodilatation (headache, flushing, dizziness, syncope, orthostatic hypotension, nasopharyngitis) </p> <p>All 11 RCTs reported these AEs, although the extent of reporting varied. Researchers reported a total of 252 AEs related to vasodilatation in 2757 participants in the PDEI group and 115 in 1629 participants in the placebo group. The risk of AE due to vasodilatation was significantly higher in the PDEI group (RR 1.44, 95% CI 1.18 to 1.76; <a href="#CD010060-tbl-0009">Table 3</a>). </p> <div class="table" id="CD010060-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Other treatment‐related harms ‐ PDEI versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of the subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number</p> <p>of RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary estimate</p> <p>RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (1.18 to 1.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to body pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.44 (1.98 to 5.98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to GI tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.19 (5.80 to 34.72)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs leading to treatment discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.20 (1.38 to 3.51)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse event; CI: confidence interval; GI: gastrointestinal; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </div> </div> <p>AEs related to body pain (myalgia, body pain, back pain, leg pain) </p> <p>Ten of 11 RCTs (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>) reported AEs related to body pain. Researchers reported a total of 107 AEs related to body pain in 2658 participants in the PDEI group and 15 in 1449 participants in the placebo group. The RR of developing body pain was significantly higher with PDEI compared to placebo (RR 3.44, 95% CI 1.98 to 5.98; <a href="#CD010060-tbl-0009">Table 3</a>). </p> <p>AEs related to GI tract (dyspepsia, gastroesophageal reflux disease (GERD), epigastric discomfort, abdominal pain, diarrhoea) </p> <p>Eight of 11 RCTs reported AEs related to GI tract (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>). The number of AEs related to the GI tract was 120 in 1884 participants treated with PDEI compared to 2 in 1111 participants treated with placebo. The RR of developing GI‐related AEs was significantly higher with PDEIs compared to placebo (RR 14.19, 95% CI 5.80 to 34.72; <a href="#CD010060-tbl-0009">Table 3</a>). </p> <p>Number of treatment discontinuations possibly due to AEs </p> <p>Ten out of 11 RCTs (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>) reported possible treatment discontinuation due to AEs. A total of 95 of 2649 participants in the PDEI group withdrew from treatment because of AEs, as did 21 of 1516 in the placebo group. The risk of treatment discontinuation due to AEs was higher in the PDEI group (RR 2.20, 95% CI 1.38 to 3.51; <a href="#CD010060-tbl-0009">Table 3</a>). </p> </section> </section> <section id="CD010060-sec-0147"> <h6 class="title">Subgroup analyses</h6> <section id="CD010060-sec-0148"> <p><b>In participants with or without ED</b></p> <p><b>IPSS‐total score</b> </p> <p>Data were available from five RCTs for participants with ED (MD ‐2.55, 95% CI ‐3.33 to ‐1.77; n = 1486) (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>), and three RCTs provided data for participants without ED (MD ‐2.10, 95% CI ‐3.39 to ‐0.81; n = 330) (<a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>). The test for interaction was not significant (P = 0.56; <a href="./references#CD010060-fig-0011" title="">Analysis 1.2</a>; <a href="#CD010060-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD010060-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="IPSS‐total subgroup analysis (PDEI vs placebo)." data-id="CD010060-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>IPSS‐total subgroup analysis (PDEI vs placebo).</p> </div> </div> </div> <p><b>BPHII score</b> </p> <p>Data were available from five RCTs for participants with ED (MD ‐0.81, 95% CI ‐1.12 to ‐0.49; n = 1480) (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>), and three RCTs provided data for participants without ED (MD ‐0.40, 95% CI ‐0.98 to 0.18; n = 329) (<a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>). The test for interaction was not significant (P = 0.23; <a href="./references#CD010060-fig-0016" title="">Analysis 1.7</a>; <a href="#CD010060-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD010060-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Summary forest plot of subgroups for change in BPHII (PDEI Vs Placebo)" data-id="CD010060-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary forest plot of subgroups for change in BPHII (PDEI Vs Placebo)</p> </div> </div> </div> <p><b>Adverse events</b> </p> <p>Data were available from four RCTs for participants with ED (<a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>), and three RCTs provided data for participants without ED (<a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>). The RR for AEs with PDEIs for participants with ED was 1.36 (95% CI 1.11 to 1.68; n = 1120), and the RR for AEs for participants without ED was 1.73 (95% CI 1.33 to 2.24; n = 338). The test for interaction was not significant (P = 0.16; <a href="./references#CD010060-fig-0020" title="">Analysis 1.11</a>; <a href="#CD010060-fig-0006">Figure 6</a>). </p> </section> <section id="CD010060-sec-0149"> <p><b>Different PDEIs (tadalafil, sildenafil, vardenafil)</b></p> <p>Nine of 11 RCTs compared tadalafil versus placebo (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). One RCT used sildenafil (<a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>), and one RCT used vardenafil (<a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>). </p> <p><b>IPSS‐total score</b> </p> <p>The MD for improvement in IPSS‐total score for tadalafil was ‐1.80 (95% CI ‐2.20 to ‐1.39; n = 3738), for sildenafil ‐4.40 (95% CI ‐6.96 to ‐1.84; n = 341), and for vardenafil ‐2.20 (95% CI ‐3.57 to ‐0.83; n = 315). The test for interaction was not significant (P = 0.13; <a href="./references#CD010060-fig-0012" title="">Analysis 1.3;</a><a href="#CD010060-fig-0009">Figure 9</a>). </p> <p><b>BPHII score</b> </p> <p>The MD for improvement in BPHII was ‐0.50 (95% CI ‐0.67 to ‐0.33; n = 3738; seven RCT) with tadalafil, and ‐1.10 (95% CI ‐2.11 to ‐0.09; n = 341; one RCT) with sildenafil. No data were available for vardenafil. The test for interaction was not significant (P = 0.25; <a href="./references#CD010060-fig-0017" title="">Analysis 1.8;</a><a href="#CD010060-fig-0009">Figure 9</a>). </p> <p><b>Adverse events</b> </p> <p>The MD in the RR of any AE for tadalafil was 1.44 (95% CI 1.19 to 1.75; n = 3796; nine RCT), for sildenafil 1.22 (95% CI 0.99 to 1.51; n = 341), and for vardenafil 1.86 (95% CI 1.11 to 3.11; n = 315). The test for interaction was not significant (P = 0.25; <a href="./references#CD010060-fig-0021" title="">Analysis 1.12;</a><a href="#CD010060-fig-0009">Figure 9</a>). </p> </section> <section id="CD010060-sec-0150"> <p><b>Different doses of PDEIs</b></p> <p>Nine RCTs compared tadalafil to placebo (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Researchers administered tadalafil in doses of 2.5, 5, 10, or 20 mg daily; the most commonly used dose of tadalafil was 5 mg per day (seven of nine trials used this dose). <a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a> used 20 mg daily, <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a> used a dose escalation pattern starting with 5 mg and reaching up to 20 mg tadalafil but did not report the median dose used. <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a> used sildenafil at a dose of 50 mg per day, titrated to 100 mg per day for participants who could tolerate this. however, this study did not report the median dose of sildenafil. <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a> used vardenafil at a dose of 10 mg twice daily. </p> <p>Study authors analysed dose‐related effects only for tadalafil. Available data were insufficient for assessment of the same for sildenafil and vardenafil (<a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>). </p> <p><b>IPSS‐total score</b> </p> <p>The MD for improvement in IPSS‐total with tadalafil 2.5 mg/d was ‐1.31 (95% CI ‐2.19 to ‐0.42]; n = 1396) (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), with 5 mg/d ‐1.88 (95% CI ‐2.33 to ‐1.42; n = 2452) (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), with 10 mg/d ‐3.43 (95% CI ‐4.79 to ‐2.07; n = 426) (<a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>), and with 20 mg/d ‐3.29 (95% CI ‐4.44 to ‐2.14; n = 589) (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>). The test of interaction was significant (P = 0.008). Investigators observed a dose‐dependent increase in improvement in IPSS‐total score from 2.5 mg/d to 10 mg/d and observed the ceiling in effect size by increasing the dose up to 20 mg/d (<a href="./references#CD010060-fig-0013" title="">Analysis 1.4</a>; <a href="#CD010060-fig-0008">Figure 8</a>). </p> <p><b>BPHII score</b> </p> <p>The MD for improvement in IPSS‐total with tadalafil 2.5 mg/d was ‐0.28 (95% CI ‐0.61 to 0.04; n = 997) (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), with 5 mg/d ‐0.47 (95% CI ‐0.70 to ‐0.25; n = 2139) (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), with 10 mg/d ‐0.58 (95% CI ‐1.15 to ‐0.01; n = 426) (<a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>), and with 20 mg/d ‐0.62 (95% CI ‐1.2 to ‐0.09) (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>). Researchers noted an indication of a dose‐dependent improvement in BPHII for tadalafil from 2.5 mg/d through 20 mg/d; but the test for interaction was non‐significant (P = 0.64; <a href="./references#CD010060-fig-0018" title="">Analysis 1.9</a>; <a href="#CD010060-fig-0009">Figure 9</a>). </p> <p><b>Adverse events</b> </p> <p>The RR of any AE with tadalafil 2.5 mg/d was 1.23 (95% CI 1.03 to 1.46; n = 1405), with 5 mg/d 1.35 (95% CI 1.12 to 1.63; n = 2471), with 10 mg/d 1.63 (95% CI 1.19 to 2.24; n = 427), and with 20 mg/d 1.93 (95% CI 1.53 to 2.44; n = 620). The test for interaction was significant (P = 0.02), suggesting an increase in AE with increasing doses of tadalafil. </p> </section> </section> <section id="CD010060-sec-0151"> <h6 class="title">Sensitivity analyses</h6> <p>We conducted sensitivity analysis for RCTs with placebo or an active drug run‐in period before the randomised intervention was provided. We included eight RCTs in the sensitivity analysis for reduction in IPSS‐total (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), and the MD between PDEI and placebo was similar to the main analysis (‐1.84, 95% CI ‐2.30 to ‐1.39; n = 3567; <a href="./references#CD010060-fig-0014" title="">Analysis 1.5</a>). </p> <p>We did not conduct a sensitivity analysis for BPHII, as it was the same as in the main analysis (all studies included a run‐in period). </p> <p>Sensitivity analysis for AEs included eight RCTs (<a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0015" title="TakedaM , NishizawaO , ImaokaT , MorisakiY , ViktrupL . Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12 week placebo‐controlled dose‐finding study with a 42 week open‐label extension. LUTS: Lower Urinary Tract Symptoms2012;4(3):110‐19. ">Takeda 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), and the RR of AEs with PDEIs versus placebo was similar to the main analysis (1.36, 95% CI 1.13 to 1.65; n = 3956; <a href="./references#CD010060-fig-0023" title="">Analysis 1.14</a>). </p> <p>Overall, we detected no differences between the effect sizes obtained in sensitivity analyses and in the main analyses. </p> </section> </section> <section id="CD010060-sec-0152"> <h5 class="title">Long‐term (up to one year) efficacy and safety of PDEI compared to placebo</h5> <p>The maximum duration of RCTs comparing PDEI to placebo was 12 weeks. No long‐term comparative effectiveness data were available for any outcomes. </p> </section> </section> <section id="CD010060-sec-0153"> <h4 class="title">PDEI versus AB</h4> <p>Four RCTs comprising 936 participants compared PDEI monotherapy versus AB monotherapy (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Three RCTs used tadalafil, and one used sildenafil (<a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). Duration of treatment ranged from eight to 12 weeks. </p> <section id="CD010060-sec-0154"> <h5 class="title">Short‐term (up to 12 weeks) efficacy and safety of PDEI compared to AB</h5> <section id="CD010060-sec-0155"> <h6 class="title">Primary outcomes</h6> <section id="CD010060-sec-0156"> <p><b>IPSS‐total score</b></p> <p>There is probably no difference between PDEI and AB for improvement in IPSS scores (MD 0.35 higher, 95% CI 0.28 lower to 0.98 higher; four trials; moderate‐quality evidence; <a href="./references#CD010060-fig-0033" title="">Analysis 2.1</a>; <a href="./full#CD010060-tbl-0002">summary of findings Table 2</a>). We downgraded the quality of evidence for study limitations. </p> </section> <section id="CD010060-sec-0157"> <p><b>BPHII score</b></p> <p>There may be no difference between PDEI and AB for improvement in BPHII scores (MD 0.03 higher, 95% CI 1.1 lower to 1.16 higher; two trials; low‐quality evidence; <a href="./references#CD010060-fig-0037" title="">Analysis 2.5</a>; <a href="./full#CD010060-tbl-0002">summary of findings Table 2</a>). We downgraded the quality of evidence for study limitations and clinically important heterogeneity. We assumed the apparent imprecision to be secondary to observed inconsistency and did not downgrade further. Two trials with 403 participants reported this outcome (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). </p> </section> <section id="CD010060-sec-0158"> <p><b>Adverse events</b></p> <p>Researchers most commonly reported AEs such as headache, myalgia, back pain, dizziness, dyspepsia, and nasopharyngitis. Trial results show 100 AEs reported in 397 participants on PDEIs compared to 79 AEs reported in 391 participants in the AB group. Rates of AEs may be similar (RR 1.35, 95% CI 0.80 to 2.30; four trials; low‐quality evidence; <a href="./references#CD010060-fig-0041" title="">Analysis 2.9</a>; <a href="./full#CD010060-tbl-0002">summary of findings Table 2</a>). This corresponds to 71 more AEs per 100 men (95% CI 41 fewer to 264 more). We downgraded the quality of evidence for study limitations and clinically important inconsistency. We assumed the apparent imprecision to be secondary to observed inconsistency and did not downgrade further. </p> </section> </section> <section id="CD010060-sec-0159"> <h6 class="title">Secondary outcomes</h6> <section id="CD010060-sec-0160"> <p><b>IPSS‐QOL score</b></p> <p>PDEIs and ABs may have similar effects on IPSS‐QOL (MD 0.1 lower, 95% CI 0.48 lower to 0.29 higher; four RCT; low‐quality evidence; <a href="./references#CD010060-fig-0042" title="">Analysis 2.10</a>). We downgraded the quality of evidence for study limitations and clinically important heterogeneity. </p> </section> <section id="CD010060-sec-0161"> <p><b>Acute urinary retention</b></p> <p>None of the four RCTs comprising 936 participants reported AUR as an event.</p> </section> <section id="CD010060-sec-0162"> <p><b>Surgical intervention</b></p> <p>None of the four RCTs comprising 936 participants reported if there was any need for surgical intervention during the treatment period. </p> </section> <section id="CD010060-sec-0163"> <p><b>Other treatment‐related harms</b></p> <p>AEs related to vasodilatation </p> <p>Researchers reported a total of 18 AEs related to vasodilatation in the PDEI group among 397 participants and seven AEs in the AB group among 391 participants. Risk of reporting vasodilatation‐related AEs was significantly higher with tadalafil than with tamsulosin (RR 2.42, 95% CI 1.05 to 5.56; n = 746; <a href="./references#CD010060-fig-0046" title="">Analysis 2.14</a>; <a href="#CD010060-tbl-0010">Table 4</a>). </p> <div class="table" id="CD010060-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Other treatment‐related harms ‐ PDEI versus alpha‐blockers</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of the subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number</p> <p>of RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary estimate</p> <p>RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42 (1.05 to 5.56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to body pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (0.38 to 8.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to GI tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.87 (0.58 to 41.22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs leading to retreatment discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.31 to 5.05)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse event; CI: confidence interval; GI: gastrointestinal; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </div> </div> <p>AEs related to body pain<br/> The number of AEs related to body pain was four among 378 participants treated with PDEIs compared to two among 369 participants treated with ABs. The risk of developing body pain was similar in PDEI and AB treatment groups (RR 1.75, 95% CI 0.38 to 8.18; n = 747; <a href="./references#CD010060-fig-0047" title="">Analysis 2.15</a>; <a href="#CD010060-tbl-0010">Table 4</a>). </p> <p>AEs related to GI tract </p> <p>Three of the four RCTs reported AEs related to the upper GI tract (dyspepsia, GERD, epigastric discomfort, diarrhoea). The number of AEs related to the GI tract was four among 397 participants treated with PDEIs compared to zero among 389 participants treated with placebo. The odds of developing GI AEs were similar in PDEI and AB treatment groups (RR 4.87, 95% CI 0.58 to 41.22; n = 746; <a href="./references#CD010060-fig-0048" title="">Analysis 2.16</a>; <a href="#CD010060-tbl-0010">Table 4</a>). </p> <p>AEs leading to treatment discontinuation </p> <p>A total of four of 397 participants in the PDEI group discontinued treatment compared to three of 391 in the AB group. The risk of treatment discontinuation was similar with PDEIs or ABs (RR 1.26, 95% CI 0.31 to 5.05; n = 786; <a href="./references#CD010060-fig-0049" title="">Analysis 2.17</a>; <a href="#CD010060-tbl-0010">Table 4</a>). </p> </section> </section> <section id="CD010060-sec-0164"> <h6 class="title">Subgroup analyses</h6> <section id="CD010060-sec-0165"> <p><b>Participants with and without ED</b></p> <p><a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> enrolled participants with BPH‐LUTS and ED. The MD obtained in this study was 1.40 (95% CI ‐2.24 to 5.04). The other studies included BPH‐LUTS participants irrespective of their ED status. Therefore, data were insufficient for analysis of any outcomes. </p> </section> <section id="CD010060-sec-0166"> <p><b>Different PDEI</b></p> <p>Results show appreciable heterogeneity among included RCTs with regard to doses of PDEI and AB used. Three RCTs used tadalafil 5 mg daily (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), and one used sildenafil four times a week (<a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). The dose of AB used was not uniform. <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a> used 0.4 mg per day of tamsulosin, whereas <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a> and <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a> used 0.2 mg per day of tamsulosin. </p> <p>Results show no differences between tadalafil and tamsulosin treatment groups for IPSS‐total (MD ‐0.13, 95% CI ‐0.65 to 0.91; n = 742) nor between sildenafil and tamsulosin groups (MD ‐1.40, 95% CI ‐2.24 to 5.04; n = 40; <a href="./references#CD010060-fig-0034" title="">Analysis 2.2</a>). </p> <p>Findings show no differences between tadalafil and tamsulosin for BPHII (MD 0.23, 95% CI ‐0.23 to 0.69; n = 403; <a href="./references#CD010060-fig-0038" title="">Analysis 2.6</a>) nor for AE (RR 1.35, 95% CI 0.80 to 2.30; n = 742; <a href="./references#CD010060-fig-0041" title="">Analysis 2.9</a>). </p> </section> <section id="CD010060-sec-0167"> <p><b>Dose effects of PDEIs</b></p> <p>Four comparison groups were available.</p> <p>Tadalafil 5 mg per day versus tamsulosin 0.4 mg per day </p> <p>We included only one RCT with 336 participants in this analysis (<a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>). Results show no differences between tadalafil 5 mg/d and tamsulosin 0.4 mg/d treatment groups for improvement in IPSS‐total (MD ‐0.60, 95% CI ‐1.98 to 0.78; n = 336; <a href="./references#CD010060-fig-0035" title="">Analysis 2.3</a>), BPHII (MD 0.24, 95% CI ‐0.40 to 0.88; n = 700; <a href="./references#CD010060-fig-0039" title="">Analysis 2.7</a>), and IPSS‐QOL (MD ‐0.30, 95% CI ‐0.02 to 0.58; n = 336; <a href="./references#CD010060-fig-0044" title="">Analysis 2.12</a>). </p> <p>Tadalafil 5 mg per day versus tamsulosin 0.2 mg per day </p> <p>We included two RCTs in this comparison (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Results show no differences between tadalafil 5 mg/d and tamsulosin 0.2 mg/d for improvement in IPSS‐total (MD ‐0.42, 95% CI ‐0.68 to 1.51; n = 406; <a href="./references#CD010060-fig-0035" title="">Analysis 2.3</a>), BPHII (MD 0.04, 95% CI ‐1.13 to 1.21; n = 403; <a href="./references#CD010060-fig-0039" title="">Analysis 2.7</a>), AE (RR 2.41, 95% CI 0.51 to 11.50; n = 406; <a href="./references#CD010060-fig-0041" title="">Analysis 2.9</a>), and IPSS‐QOL (MD 0.11, 95% CI ‐0.37 to 0.59; n = 406; <a href="./references#CD010060-fig-0044" title="">Analysis 2.12</a>). </p> <p>Tadalafil 2.5 mg per day versus tamsulosin 0.2 mg per day </p> <p>We included only one RCT in this analysis (<a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Results show no differences between tadalafil 2.5 mg/d and tamsulosin 0.2 mg/d treatment groups for improvement in IPSS‐total (MD ‐0.70, 95% CI ‐0.41 to 1.81; n = 303; <a href="./references#CD010060-fig-0035" title="">Analysis 2.3</a>), BPHII (MD 0.50, 95% CI ‐0.06 to 1.06; n = 297; <a href="./references#CD010060-fig-0039" title="">Analysis 2.7</a>), AE (RR 1.27, 95% CI 0.91 to 1.76; n = 306; <a href="./references#CD010060-fig-0041" title="">Analysis 2.9</a>), and IPSS‐QOL (MD 0.30, 95% CI 0.02 to 0.58; n = 303; <a href="./references#CD010060-fig-0044" title="">Analysis 2.12</a>). </p> <p>Sildenafil 25 mg 4 times a week versus tamsulosin 0.4 mg per day </p> <p>We included only one RCT in this analysis (<a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). Results show no differences between sildenafil 25 mg/d and tamsulosin 0.4 mg/d treatment groups for improvement in IPSS‐total (MD ‐1.40, 95% CI ‐2.24 to 5.04; n = 40; <a href="./references#CD010060-fig-0035" title="">Analysis 2.3</a>) nor in IPSS‐QOL (MD ‐0.80, 95% CI ‐1.78 to 0.18; n = 40; <a href="./references#CD010060-fig-0044" title="">Analysis 2.12</a>). </p> <p>The dosages used across studies were not uniform, and the therapeutic equivalence status of dosages used is not clear. We maintained the standard tadalafil dose (5 mg/d) as a constant factor for comparison of groups 2 and 3, which suggests no differences in any outcome measures. </p> </section> </section> <section id="CD010060-sec-0168"> <h6 class="title">Sensitivity analyses for trials with run‐in period</h6> <p>Sensitivity analysis included three trials (<a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>). Similar to the main analysis, results show no differences between PDEIs and ABs for IPSS‐total (MD 0.07, 95% CI ‐0.88 to 1.02; n = 742; <a href="./references#CD010060-fig-0036" title="">Analysis 2.4</a>); BPHII (MD 0.03, 95% CI ‐1.10 to 1.16; n = 554; <a href="./references#CD010060-fig-0040" title="">Analysis 2.8</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0017" title="YokoyamaO , YoshidaM , KimSC , WangCJ , ImaokaT , MorisakiY , et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men. International Journal of Urology2013;20(2):193‐201. ">Yokoyama 2013</a>), AEs (RR 1.35, 95% CI 0.80 to 2.30; n = 896), and IPSS‐QOL (MD ‐0.01, 95% CI ‐0.38 to 0.36; n = 742; <a href="./references#CD010060-fig-0045" title="">Analysis 2.13</a>). We found no data for AUR and need for surgical intervention. </p> </section> </section> <section id="CD010060-sec-0169"> <h5 class="title">Long‐term (up to one year) efficacy and safety of PDEIs compared to ABs</h5> <p>RCTs comparing PDEIs and ABs were 12 weeks in maximum duration. We found no available data for comparative long‐term efficacy and safety of these two classes of drugs used for BPH‐LUTS. </p> </section> </section> <section id="CD010060-sec-0170"> <h4 class="title">PDEI + AB versus AB alone</h4> <p>Four RCTs comprising 193 participants compared PDEI plus AB combination therapy versus AB monotherapy (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>; <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). Two of these RCTs used tadalafil (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>), one used sildenafil (<a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>), and one used vardenafil (<a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>). </p> <section id="CD010060-sec-0171"> <h5 class="title">Short‐term (up to 12 weeks) efficacy and safety of PDEI combination with AB compared to AB alone </h5> <section id="CD010060-sec-0172"> <h6 class="title">Primary outcomes</h6> <section id="CD010060-sec-0173"> <p><b>IPSS‐total</b></p> <p>PDEI in combination with an AB may result in a small improvement in IPSS‐total (MD 2.56 lower, 95% CI 3.92 lower to 1.19 lower; four trials, low‐quality evidence; <a href="./references#CD010060-fig-0050" title="">Analysis 3.1</a>; <a href="./full#CD010060-tbl-0003">summary of findings Table 3</a>), but we are unsure of this finding. We downgraded the quality of evidence for study limitations and clinically important imprecision, assuming an MCID of 3. </p> </section> <section id="CD010060-sec-0174"> <p><b>BPHII score</b></p> <p>We could not assess this score because none of the four RCTs included BPHII as an outcome. </p> </section> <section id="CD010060-sec-0175"> <p><b>Adverse events</b></p> <p>AE are probably increased when combination treatment is compared with AB alone (RR 2.81, 95% CI 1.53 to 5.17; four trials; moderate‐quality evidence). We downgraded the quality of evidence for study limitations (<a href="./references#CD010060-fig-0054" title="">Analysis 3.5</a>; <a href="./full#CD010060-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> <section id="CD010060-sec-0176"> <h6 class="title">Secondary outcomes</h6> <section id="CD010060-sec-0177"> <p><b>IPSS‐QOL score</b></p> <p>Two of the four RCTs reported IPSS‐QOL scores (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>), noting that combination therapy may improve IPSS‐QOL scores slightly (MD ‐1.08, 95% CI ‐1.92 to ‐0.23; n = 94). The quality of evidence was low. We downgraded for study limitations and imprecision (<a href="./references#CD010060-fig-0058" title="">Analysis 3.9</a>). </p> </section> <section id="CD010060-sec-0178"> <p><b>Acute urinary retention</b></p> <p>None of the four RCTs comprising 193 participants reported AUR as an event.</p> </section> <section id="CD010060-sec-0179"> <p><b>Surgical intervention</b></p> <p>None of the four RCTs comprising 193 participants reported if there was any need for surgical intervention for any participants during conduct of the RCT. </p> </section> <section id="CD010060-sec-0180"> <p><b>Other treatment‐related harms</b></p> <p>AEs related to vasodilatation </p> <p>Study authors reported a total of 27 AEs related to vasodilatation among 77 participants in the PDEI‐AB combination group and four AEs among 77 participants in the AB alone group. Risk of vasodilatation‐related AEs was higher with the combination treatment than with tamsulosin alone (RR 6.58, 95% CI 2.36 to 18.31; n = 154; <a href="./references#CD010060-fig-0062" title="">Analysis 3.13</a>; <a href="#CD010060-tbl-0011">Table 5</a>). </p> <div class="table" id="CD010060-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Other treatment‐related harms: PDEI + alpha‐blockers versus alpha‐blockers alone</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of the subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number</p> <p>of RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary estimate</p> <p>RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.80 (1.93 to 11.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to GI tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.00 (0.75 to 48.30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs leading to retreatment discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.13 to 70.53)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse event; CI: confidence interval; GI: gastrointestinal; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </div> </div> <p>AEs related to body pain </p> <p>None of the trials reported AEs related to body pain (<a href="#CD010060-tbl-0011">Table 5</a>). </p> <p>AEs related to upper GI tract </p> <p>Researchers reported a total of five AEs related to vasodilatation among 77 participants in the PDEI plus AB combination group and no AEs among 77 participants in the AB alone group. The risk of developing GI tract‐related AEs was similar with PDEI and AB combination treatment compared to AB alone (RR 6.57, 95% CI 0.75 to 56.34; n = 154; <a href="./references#CD010060-fig-0063" title="">Analysis 3.14</a>; <a href="#CD010060-tbl-0011">Table 5</a>). </p> <p>AEs leading to treatment discontinuation </p> <p>One participant in the combination treatment group discontinued treatment compared to none in the AB only treatment. Differences between groups were not significant (RR 3.00, 95% CI 0.13 to 70.53; n = 154; <a href="./references#CD010060-fig-0064" title="">Analysis 3.15</a>; <a href="#CD010060-tbl-0011">Table 5</a>). </p> </section> </section> <section id="CD010060-sec-0181"> <h6 class="title">Subgroup analyses</h6> <section id="CD010060-sec-0182"> <p><b>Participants with and without ED</b></p> <p><a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> enrolled participants with BPH‐LUTS and ED. The other RCTs included BPH‐LUTS participants irrespective of their ED status (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a>; <a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>). However, these studies neither stratified participants based on the presence or absence of ED nor reported outcomes by this subgroup. Therefore, available study data were insufficient for meaningful analysis of any outcomes. </p> </section> <section id="CD010060-sec-0183"> <p><b>Different PDEIs</b></p> <p><a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a> used tadalafil 20 mg/d and <a href="./references#CD010060-bbs2-0012" title="RegadasRP , Reges CerqueiraJBG , SucupiraDG , JosinoIR , NogueiraEA , JamacaruFVF , et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo‐controlled trial. International Urology and Nephrology2013;45(1):39‐43. ">Regadas 2013</a> 5 mg/d; <a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> used sildenafil 25 mg 4 times/week, and <a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>.used vardenafil 10 mg/d. All four RCTs used tamsulosin 0.4 mg/d as the AB for comparison. The test for interaction showed no differences between PDEI and tamsulosin combination groups versus tamsulosin alone (P = 0.67). </p> </section> <section id="CD010060-sec-0184"> <p><b>Dose effects of PDEIs</b></p> <p>Researchers observed no dose effect for tadalafil (5 mg/d and 20 mg/d) in combination with tamsulosin (0.4 mg/d) versus tamsulosin (0.4 mg/d) alone (P = 0.52) for improvement in IPSS‐total and AE. We could not assess the dose effect relationship for sildenafil and vardenafil, as available data were insufficient with only a single RCT for each (<a href="./references#CD010060-fig-0052" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD010060-sec-0185"> <h6 class="title">Sensitivity analysis</h6> <p>Of the four RCTs, two included a placebo run‐in period for all participants included in the study preceding the randomisation phase, in addition to a drug for the washout period for participants who were previously treated and were not naïve to the study drug (<a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>; <a href="./references#CD010060-bbs2-0006" title="GacciM , VittoriG , TosiN , GiampaloS , RossettiL , VignozziL , et al. A randomized placebo‐controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4mg vs. tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine2012;9(6):1624‐33. ">Gacci 2012</a>). The magnitude of improvement in IPSS‐total was similar to findings in the main analysis (MD ‐2.34, 95% CI ‐4.02 to ‐0.66; n = 114; <a href="./references#CD010060-fig-0053" title="">Analysis 3.4</a>). The RR of AEs was found to be similar (MD 2.80, 95% CI 1.50 to 5.21; n = 114). Only one study reported improvement in IPSS‐QOL with MD similar to the main analysis (‐0.70, 95% CI ‐2.40 to 1.00; n = 59; <a href="./references#CD010060-fig-0061" title="">Analysis 3.12</a>; <a href="./references#CD010060-bbs2-0001" title="BecharaA , RomanoS , CasabeA , HaimiS , DedolaP , HernandezC , et al. Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Tadalafil in the treatment of LUTS/BPH. pilot study. Journal of Sexual Medicine2008;5(9):2170‐8. ">Bechara 2008</a>). </p> </section> </section> <section id="CD010060-sec-0186"> <h5 class="title">Long‐term (up to one year) efficacy and safety of PDEI combination with AB versus AB alone </h5> <p>None of the RCT continued beyond 12 weeks; therefore no data are available for assessing the long‐term efficacy and safety of the combination of PDEI and AB versus AB alone for BPH‐LUTS. </p> </section> </section> <section id="CD010060-sec-0187"> <h4 class="title">PDEI + AB versus PDEI alone</h4> <p>Only one RCTs qualified for this comparison, with three intervention arms: tamsulosin 0.4 mg daily (n = 20), sildenafil 50 mg four times weekly plus tamsulosin 0.4 mg daily (n = 20), and sildenafil 50 mg four times weekly (<a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>). For analysis, we included group data from two arms comprising only 40 participants. The duration of the study was eight weeks, and all participants were naïve to the study drugs. </p> <section id="CD010060-sec-0188"> <h5 class="title">Short‐term (up to 12 weeks) efficacy and safety of PDEI combination with AB compared to PDEI alone </h5> <section id="CD010060-sec-0189"> <h6 class="title">Primary outcomes</h6> <section id="CD010060-sec-0190"> <p><b>IPSS‐total score</b></p> <p>PDEI in combination with an AB may result in small improvement in IPSS‐total compared to PDEI alone (MD 2.4 lower, 95% CI 6.47 lower to 1.67 higher; one trial; low‐quality evidence; <a href="./references#CD010060-fig-0065" title="">Analysis 4.1;</a><a href="./full#CD010060-tbl-0004">summary of findings Table 4</a>). We downgraded the quality of evidence for study limitations and clinically important imprecision, assuming an MCID of 3. </p> </section> <section id="CD010060-sec-0191"> <p><b>BPHII score</b></p> <p><a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a>, did not report this outcome. </p> </section> <section id="CD010060-sec-0192"> <p><b>Adverse events</b></p> <p><a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> reported no withdrawals due to AEs but did not report whether any AEs occurred. </p> </section> </section> <section id="CD010060-sec-0193"> <h6 class="title">Secondary outcomes</h6> <section id="CD010060-sec-0194"> <p><b>IPSS‐QOL score</b></p> <p>PDEI in combination with an AB may result in similar improvement in IPSS‐QOL (MD 0.4 lower, 95% CI 1.8 lower to 1.0 higher; one trial; low‐quality evidence) compared to PDEI alone. We downgraded for study limitations and clinically important imprecision, assuming an MCID of 0.5. </p> </section> <section id="CD010060-sec-0195"> <p><b>Acute urinary retention</b></p> <p><a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> did not report this outcome. </p> </section> <section id="CD010060-sec-0196"> <p><b>Surgical intervention</b></p> <p><a href="./references#CD010060-bbs2-0016" title="TuncelA , NalcaciogluV , EnerK , AslanY , AydinO , AtanA . Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World Journal of Urology2010;28(1):17‐22. ">Tuncel 2010</a> also did not report this outcome. </p> </section> </section> <section id="CD010060-sec-0197"> <h6 class="title">Subgroup analyses</h6> <p>We conducted no subgroup analyses, as the sample size was small and researchers did not report outcomes as per the subgroups. </p> </section> <section id="CD010060-sec-0198"> <h6 class="title">Sensitivity analysis</h6> <p>We performed no sensitivity analysis, as we included only one study for this comparison.</p> </section> </section> <section id="CD010060-sec-0199"> <h5 class="title">Long‐term (up to one year) efficacy and safety of PDEI combination with AB compared to PDEI alone </h5> <p>For this comparison, we identified only one RCT that was eight weeks in duration. No other long‐term data were available for this analysis. Hence the evidence is insufficient to determine comparative long‐term efficacy and safety of the PDEI combination with AB versus AB alone. </p> </section> </section> <section id="CD010060-sec-0200"> <h4 class="title">PDEI + 5‐ARI versus 5‐ARI alone</h4> <section id="CD010060-sec-0201"> <h5 class="title">Short‐term (up to 12 weeks) efficacy and safety of PDEI combination with 5‐ARI compared to 5‐ARI alone </h5> <p>Only one RCT qualified for inclusion in this analysis (<a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a>). This study compared tadalafil 5 mg plus finasteride 5 mg daily (n = 345) versus placebo plus finasteride 5 mg daily (n = 350) in a parallel‐group design. All participants were naïve to finasteride therapy. They underwent a four‐week drug‐free washout period followed by a four‐week placebo run‐in period before enrolment. The study was 26 weeks in duration. Study authors assessed the efficacy of treatments for IPSS‐total score at four, 12, and 26 weeks. </p> <section id="CD010060-sec-0202"> <h6 class="title">Primary outcomes</h6> <section id="CD010060-sec-0203"> <p><b>IPSS‐total score</b></p> <p>PDEI in combination with a 5‐ARI is likely to result in a small improvement in IPSS (MD 1.4 lower, 95% CI 2.84 lower to 1.16 lower; one RCT; moderate‐quality evidence) at 12 weeks. We downgraded for study limitations. </p> </section> <section id="CD010060-sec-0204"> <p><b>BPHII score</b></p> <p>The only study identified for this comparison did not evaluate BPHII scores; hence we found no data pertaining to this outcome (<a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a>). </p> </section> <section id="CD010060-sec-0205"> <p><b>Adverse events</b></p> <p><a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a> did not report AEs at 12 weeks. </p> </section> </section> <section id="CD010060-sec-0206"> <h6 class="title">Secondary outcomes</h6> <section id="CD010060-sec-0207"> <p><b>IPSS‐QOL score</b></p> <p>PDEI plus 5‐ARI probably has a similar effect on IPSS‐QOL (MD 0.2 lower, 95% CI 0.48 lower to 0.06 lower; one RCT; moderate‐quality evidence) at 12 weeks compared to 5‐ARI alone. We downgraded the quality of evidence for study limitations. </p> </section> <section id="CD010060-sec-0208"> <p><b>Acute urinary retention</b></p> <p><a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a> did not report AUR as an event during the study in either of the treatment groups at 12 weeks. </p> </section> <section id="CD010060-sec-0209"> <p><b>Surgical intervention</b></p> <p><a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a> also did not report if there was any need for surgical intervention for any participants at 12 weeks during conduct of the RCT. </p> </section> </section> </section> <section id="CD010060-sec-0210"> <h5 class="title">Long‐term (up to one year) efficacy and safety of PDEI combination with 5‐ARI compared to 5‐ARI alone </h5> <section id="CD010060-sec-0211"> <h6 class="title">Primary outcomes</h6> <section id="CD010060-sec-0212"> <p><b>IPSS‐total</b></p> <p>The combination of PDEI and 5‐ARI probably leads to minor improvement in IPSS‐total (MD 1.0 lower, 95% CI 1.84 lower to 0.86 lower; one trial; moderate‐quality evidence) compared to 5‐ARI alone after 24 weeks of treatment. We downgraded the quality of evidence for study limitations. </p> </section> <section id="CD010060-sec-0213"> <p><b>BPHII score</b></p> <p>The only study identified for this comparison did not evaluate BPHII scores; hence we found no data pertaining to this outcome (<a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a>). </p> </section> <section id="CD010060-sec-0214"> <p><b>Adverse events</b></p> <p>AEs may be similar in the long term (RR 1.07, 95% CI 0.84 to 1.36; one trial; low‐quality evidence). This corresponds to 19 more AEs per 1000 men (95% CI 43 fewer to 98 more). We downgraded the quality of evidence for study limitations and clinically important imprecision. </p> </section> </section> <section id="CD010060-sec-0215"> <h6 class="title">Secondary outcomes</h6> <section id="CD010060-sec-0216"> <p><b>IPSS‐QOL score</b></p> <p>The combination of PDEI and 5‐ARI probably improves IPSS‐QOL to a small degree (MD 0.2 lower, 95% CI 0.48 lower to 0.08 lower; one trial; moderate‐quality evidence) at 24 weeks compared to 5‐ARI alone. We downgraded the quality of evidence for study limitations. </p> </section> <section id="CD010060-sec-0217"> <p><b>Acute urinary retention</b></p> <p><a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a> did not report AUR as an event during the study in either treatment group. </p> </section> <section id="CD010060-sec-0218"> <p><b>Surgical intervention</b></p> <p><a href="./references#CD010060-bbs2-0003" title="CasabeA , RoehrbornCG , DaPozzoLF , ZepedaS , HendersonRJ , SorsaburuS , et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. Journal of Urology2014;191(3):727‐33. ">Casabe 2014</a> also did not report if there was any need for surgical intervention for any participants during conduct of the RCT. </p> </section> </section> <section id="CD010060-sec-0219"> <h6 class="title">Subgroup analyses</h6> <p>We were unable to conduct any of the preplanned subgroup analyses, as no data were available. </p> </section> <section id="CD010060-sec-0220"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform the sensitivity analyses, as we identified only a single RCT for this comparison. </p> <section id="CD010060-sec-0221"> <p><b>Other treatment‐related harms</b></p> <p>Results show a higher number of body pain‐related AEs (RR 2.70, 95% CI 1.07 to 6.81) in the combination treatment group (<a href="./references#CD010060-fig-0071" title="">Analysis 5.5</a>), but show no difference in AEs related to vasodilatation (RR 1.01, 95% CI 0.46 to 2.22), upper GI symptoms (RR 4.05, 95% CI 0.87 to 18.92), and treatment discontinuation (RR 0.63, 95% CI 0.21 to 1.91) between groups (<a href="./references#CD010060-fig-0070" title="">Analysis 5.4</a>; <a href="./references#CD010060-fig-0072" title="">Analysis 5.6</a>; <a href="./references#CD010060-fig-0073" title="">Analysis 5.7</a>). Data also show no difference in AEs related to sexual function (RR 0.51, 95% CI 0.17 to 1.4) between the finasteride and tadalafil combination group and the finasteride and placebo group (<a href="./references#CD010060-fig-0074" title="">Analysis 5.8;</a><a href="#CD010060-tbl-0012">Table 6</a>). </p> <div class="table" id="CD010060-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Other treatment‐related harms: PDEI + 5‐ARI versus 5‐ARI alone</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of the subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number</p> <p>of RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary estimate</p> <p>RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.46 to 2.22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to body pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.70 (1.07 to 6.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to GI tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.05 (0.87 to 18.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs leading to retreatment discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.21 to 1.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to sexual function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.17 to 1.46)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>5‐ARI: 5‐alpha reductase inhibitor; AE: adverse event; CI: confidence interval; GI: gastrointestinal; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </div> </div> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010060-sec-0222" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010060-sec-0222">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010060-sec-0284">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010060-sec-0222"></div> <section id="CD010060-sec-0223"> <h3 class="title" id="CD010060-sec-0223">Summary of main results</h3> <p>We found data from eligible randomised controlled trials (RCTs) to conduct analysis of five comparisons, with data largely limited to a short time horizon of 12 weeks of treatment. The preponderance of evidence pertains to the use of phosphodiesterase inhibitors (PDEIs) compared to placebo. </p> <p>Compared to placebo, PDEIs probably improve International Prostate Symptom Score (IPSS)‐total slightly over placebo with short‐term use over six to 12 weeks. They may also slightly improve quality of life (QOL) and may lead to increased rates of adverse events (AEs). We found no long‐term data on treatment beyond 12 weeks. </p> <p>Use of PDEIs and alpha‐blockers (ABs) in benign prostatic hyperplasia (BPH) probably provides similar improvement in IPSS‐total score and may lead to similar improvement in QOL. The incidence of AEs may be similar. We found no long‐term data on treatment beyond 12 weeks. </p> <p>The PDEI and AB combination may provide a small improvement in IPSS‐total score compared to either drug alone. We found no data on the Benign Prostatic Hyperplasia Impact Index (BPHII) nor on AEs. Effects on IPSS‐QOL may be similar. All study results were limited to treatment duration of four to 12 weeks. </p> <p>For short‐term use (up to 12 weeks), the combination of a PDEI and a 5‐alpha reductase inhibitor (5‐ARI) probably results in a very small improvement in IPSS‐total score compared to 5‐ARI alone. We found no evidence on BPHII scores or AEs. Effects on IPSS‐QOL are likely similar. With long‐term (13 to 26 weeks) use, the combination of PDEI and 5‐ARI likely results in a very small reduction in IPSS‐total score. We found no evidence about its effects on BPHII scores. There may be no difference in the rate of AEs, and effects on IPSS‐QOL are likely similar. </p> </section> <section id="CD010060-sec-0224"> <h3 class="title" id="CD010060-sec-0224">Overall completeness and applicability of evidence</h3> <p>We included 16 randomised controlled trials (RCTs) that address five comparisons. Limitations are as follows. </p> <p> <ul id="CD010060-list-0010"> <li> <p>Most studies were short‐duration efficacy studies (maximum of 12 weeks) and did not provide longer‐term data. This issue is relevant in that lower urinary tract symptoms (LUTS) typically are chronic in nature and medications are typically used for years. </p> </li> <li> <p>This review focused on the most patient‐important outcomes that could meaningfully be assessed in RCTs. We did not include non‐randomised studies, which are considered important for assessing long‐term and rare outcomes. Emerging evidence indicates that long‐term use of phosphodiesterase (PDE) may increase the risk of melanoma (<a href="./references#CD010060-bbs2-0089" title="DengT , DuanX , LiuB , LanY , CaiC , ZhangT , et al. Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta‐analysis. Neoplasma2018;65:216‐21. ">Deng 2018</a>; <a href="./references#CD010060-bbs2-0097" title="FengS , ZhouL , LiuQ , HeQ , LiaoB , WeiX , et al. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma? A systematic review and meta‐analysis. Medicine (Baltimore)2018;97:e9601. ">Feng 2018</a>; <a href="./references#CD010060-bbs2-0111" title="HanX , HanY , ZhengY , SunQ , MaT , DaiL , ZhangJ , XuL . Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta‐analysis of observational studies. OncoTargets and Therapy2018;11:711‐20. ">Han 2018</a>; <a href="./references#CD010060-bbs2-0125" title="LiWQ , QureshiAA , RobinsonKC , HanJ . Sildenafil use and increased risk of incidental melanoma in US men: a prospective cohort study. JAMA Internal Medicine2014;174(6):964‐70. ">Li 2014</a>; <a href="./references#CD010060-bbs2-0126" title="LianY , YinH , PollakMN , CarrierS , PlattRW , SuissaS , AzoulayL . Phosphodiesterase type 5 inhibitors and the risk of melanoma skin cancer. European Urology2016;70:808‐15. ">Lian 2016</a>; <a href="./references#CD010060-bbs2-0128" title="LoebS , FolkvaljonY , LambeM , RobinsonD , GarmoH , IngvarC , StattinP . Use of phaosphopdiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA2015;313:2449‐55. ">Loeb 2015</a>; <a href="./references#CD010060-bbs2-0129" title="LoebS , VentimigliaE , SaloniaA , FolkvaljonY , StattinP . Meta‐analysis of association between phaosphodiesterase inhibitors (PDEIs) and risk of melanoma. Journal of the National Cancer Institute2017;109:doi:10.1093/inci/djx086. ">Loeb 2017</a>; <a href="./references#CD010060-bbs2-0134" title="MatthewsA , LanganSM , DouglasIJ , SmeethL , BhaskaranK . Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: Matched cohort study using primary care data from the UK clinical practice research datalink. PLoS Med2016;13:e1002037. ">Matthews 2016</a>; <a href="./references#CD010060-bbs2-0146" title="PottegardA , SchmidtSA , OlesenAB , AchacosoN , Van DenEedenSK , HallasJ , et al. Use of sildenafil or other phosphodiesterase inhibitors and risk of mealanoma. British Journal of Cancer2016;115:895‐900. ">Pottegard 2016</a>; <a href="./references#CD010060-bbs2-0164" title="TangH , WuW , FuS , ZhaiS , SongY , HanJ . Phosphodiesterase type 5 inhibitors and risk of melanoma: a meta‐analysis. Journal of the American Academy of Dermatology2017;77:480‐8. ">Tang 2017</a>; <a href="./references#CD010060-bbs2-0174" title="WrishkoR , SorsaburuS , WongD . Safety, efficacy, and pharmacokinetic overview of low‐dose daily administration of tadalafil. Journal of Sexual Medicine2009;6(7):2039‐48. ">Wrishko 2009</a>; <a href="./references#CD010060-bbs2-0175" title="WrońskiS . The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase–5 inhibitors. Central European Journal of Urology2014;67(3):314‐8. [non‐systematic review] ">Wronski 2014</a>), but this topic is outside the scope of this review. </p> </li> <li> <p>More than 80% of study participants (8/11 RCTs) were men of Caucasian origin; 4% to 6% were black, and 8% to 11% were of Asian ethnicity (in three RCTs that recruited mainly in Japan and Korea). Outcomes for men of other ethnic backgrounds may differ. </p> </li> </ul> </p> </section> <section id="CD010060-sec-0225"> <h3 class="title" id="CD010060-sec-0225">Quality of the evidence</h3> <p>Despite a large number of RCTs across the five analysed comparisons, we found no high‐quality evidence for any outcome. The quality of evidence ranged mostly from moderate to low, with low‐quality evidence representing the most frequent category. The most common reasons for downgrading quality were study limitations, although we did not rate any domain as having high risk of bias; there was a preponderance of unclear risk of bias related to selection, performance, detection, and sometimes selective reporting bias, which in aggregate prompted us to downgrade by one level. Other reasons for downgrading were clinically important imprecision (when the minimal clinically important difference (MCID) or other assumed threshold of clinical relevance was crossed) and funnel plot asymmetry, raising concerns about publication bias. Overall, this indicates that our confidence in most effect estimates is limited; the true effect may be close to or substantially different from the reported estimate of the effect. </p> </section> <section id="CD010060-sec-0226"> <h3 class="title" id="CD010060-sec-0226">Potential biases in the review process</h3> <p>During the conduct of the review, we made several conscious deviations from the protocol with regards to inclusion of only RCTs that reported some use of blinding, and dropping of some secondary outcomes and preplanned subgroup analyses. We made these modifications to reduce the length of the review, to improve readability, and to focus on aspects that are most important for clinical practice. We believe that this is unlikely to have introduced bias into the process of conducting this systematic review. </p> <p>We conducted an extensive literature search and updated the search from time to time during conduct of the review. Although focus on the English language could be a potential limitation, we also looked for studies registered at ClinicalTrials.gov and the World Health Organization (WHO) clinical trial registries to identify potentially eligible studies. Therefore, it is unlikely that the review process would have been biased by missing studies. We noted certain limitations during the review process, such as the challenge of excluding non‐English language studies and grey literature from the review due to incomplete identification of these studies. However, this is a generic limitation associated with systematic reviews. Another limitation involved the detection of serious and/or rare AEs. This review included only RCTs, and review authors excluded other non‐randomised studies. This jeopardises the scope for comprehensive detection of AEs encountered in population‐based studies. The shorter duration of the included studies also contributes to non‐detection of long‐term usage‐related AEs. </p> <p>This review includes data from the included RCTs and notes that some information is missing from some of the included studies. Upon repeated attempts to obtain missing data from one RCT (<a href="./references#CD010060-bbs2-0057" title="TamimiNA , MincikI , HaughieS , LambJ , CrosslandA , EllisP . A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU International2010;106(5):674‐80. ">Tamimi 2010</a>), we failed. Nevertheless, this may not have affected the effect size of estimates, as we included data for 11 of the 12 RCTs in the primary analysis. </p> </section> <section id="CD010060-sec-0227"> <h3 class="title" id="CD010060-sec-0227">Agreements and disagreements with other studies or reviews</h3> <p>Several systematic and descriptive (narrative) reviews have been published in recent years on the efficacy and clinical use of PDEIs (specifically tadalafil) for BPH‐LUTS. These reviews have far outnumbered the original studies conducted over the last decade (<a href="./references#CD010060-bbs2-0069" title="AlsaikhanB , AlrabeeahK , CarrierS . Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations. International Journal of General Medicine2014;12(7):271‐6. [review] ">Alsaikhan 2014</a>; <a href="./references#CD010060-bbs2-0070" title="AnderssonKE , UckertS , StiefC , HedlundP . Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourology and Urodynamics2007;26(6 suppl):928‐33. ">Anderson 2007</a>; <a href="./references#CD010060-bbs2-0081" title="BrockGB , McVaryKT , RoehrbornCG , WattsS , NiX , ViktrupL , et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. Journal of Urology2014;191(2):405‐11. [PATHWAY ANALYSIS: post hoc analysis of Rhoerborn, Prost, Oelke and Egerdie] ">Brock 2014</a>; <a href="./references#CD010060-bbs2-0101" title="FüllhaseC , SolerR , GratzkeC . New strategies in treating male lower urinary tract symptoms. Current Opinion in Urology2014;24:29‐35. [Therapeutic review] ">Fullhase 2014</a>; <a href="./references#CD010060-bbs2-0102" title="GacciM , EardleyI , GiulianoF , HatzichristouD , KaplanSA , MaggiM , et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology2011; Vol. 60:809‐25. [Review ‐ analysis] ">Gacci 2011</a>; <a href="./references#CD010060-bbs2-0105" title="GovorovA , KasyanG , PriymakD , PushkarD , SorsaburuS . Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. Central European Journal of Urology2014;67(2):167‐77. [Expert review in Russian population] ">Govorov 2014</a>; <a href="./references#CD010060-bbs2-0108" title="GulianoF , UckertÈS , Mario MaggiM , Lori BirderLe , KisselJ , ViktrupL . The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. European Urology2013;63(3):506‐16. ">Guliano 2012</a>; <a href="./references#CD010060-bbs2-0112" title="HatzimouratidisK . A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Therapeutic Advances in Urology2014;6:135‐7. [non‐systematic review] ">Hatzimouratidis 2014</a>; <a href="./references#CD010060-bbs2-0116" title="JiangYH , LinVCH , LiaoCH , KuoHC . International Prostatic Symptom Score ‐ voiding/storage subscore ratio in association with total prostatic volume and maximum flow rate is diagnostic of bladder outlet‐related lower urinary tract dysfunction in men with lower urinary tract symptoms. PLoS ONE2013;8(3):e59176. ">Jiang 2013</a>; <a href="./references#CD010060-bbs2-0133" title="Martınez‐SalamancaJI , CarballidoJ , EardleyI , GiulianoF , GratzkeC , et al. Phosphodiesterase type 5 inhibitors in the management of non‐neurogenic male lower urinary tract symptoms: critical analysis of current evidence. European Urology2011;60(3):527‐35. [collaborative descriptive review] ">Martinez‐Salamanca 2011</a>; <a href="./references#CD010060-bbs2-0141" title="MillerMS . Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. Annals of Pharmacotherapy2013;47(2):158‐63. [drug information rounds] ">Miller 2013</a>; <a href="./references#CD010060-bbs2-0147" title="RadomskiSB . Update on medical therapy for male LUTS. Canadian Urology Association Journal2014;8(7‐8 Suppl 5):S148‐150. [non‐systematic review] ">Radomski 2014</a>; <a href="./references#CD010060-bbs2-0157" title="RussoA , LaCroceG , CapogrossoP , VentimigliaE , ColicchiaM , SerinoA , et al. Latest pharmacotherapy options for benign prostatic hyperplasia. Expert Opinion on Pharmacotherapy2014;15(16):2319‐28. [Expert opinion] ">Rosso 2015</a>; <a href="./references#CD010060-bbs2-0161" title="SilvaJ , SilvaCM , CruzF . Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?. Current Opinion in Urology2014;24(1):21‐8. [non‐systematic review] ">Silva 2014</a>; <a href="./references#CD010060-bbs2-0175" title="WrońskiS . The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase–5 inhibitors. Central European Journal of Urology2014;67(3):314‐8. [non‐systematic review] ">Wronski 2014</a>; <a href="./references#CD010060-bbs2-0170" title="ÜckertS , KuczykMA , OelkeM . Phosphodiesterase inhibitors in clinical urology. Expert Reviews in Clinical Pharmacology2013;6(3):323‐32. [Therapeutic review] ">Ukcert 2013</a>; <a href="./references#CD010060-bbs2-0176" title="YanH , ZongH , CuiY , LiN , ZhangY . The efficacy of PDE5 inhibitors alone or in combination with alpha‐blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta‐analysis. Journal of Sexual Medicine2014;11(6):1539‐45. ">Yan 2014</a>), with many of them recommending PDEI treatment for BPH‐LUTS, and a few expressing skepticism about this treatment. Meanwhile, it is not the intent of this review to make any recommendations about appropriate clinical use. </p> <p>A total of four meta‐analyses had been conducted to review the evidence showing effects of PDEIs versus placebo for BPH‐LUTS. </p> <p> <ul id="CD010060-list-0011"> <li> <p>The earliest systematic review ‐ <a href="./references#CD010060-bbs2-0122" title="LaydnerHK , OliveiraP , OliveiraCR , MakarawoTP , AndradeWS , TannusM , et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU International2011;107(7):1104‐9. [first systematic review] ">Laydner 2011</a> ‐ included four RCTs (<a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008;</a> n = 1880). This was only a narrative analysis, and review authors stated that a meta‐analysis could not be conducted because of heterogeneity issues. (However, we did not find statistical heterogeneity when analysing the data ourselves; I² = 21%.) Review authors concluded that PDEIs are useful in BPH‐LUTS to improve LUTS, erectile function, and quality of life. They conducted no meta‐analysis, and review authors were closely associated with the drug development process and initial clinical testing. </p> </li> <li> <p>Another systematic review ‐ <a href="./references#CD010060-bbs2-0127" title="LiuL , ZhengS , HanP , WeiQ . Phosphodiesterase‐5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta‐analysis. Urology2011;77(1):123‐9. [systematic review meta‐analysis] ">Liu 2011</a> ‐ included five RCTs (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>, n = 2074) out of which foru RCTs compared tadalafil to placebo (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>). This systematic review reported the MD for IPSS‐total as ‐2.57 (95% CI ‐3.15 to ‐1.98) for tadalafil and had methodological deficiencies with regard to its conduct. An issue arose regarding "unit of analysis" because the placebo group was included four times, spuriously increasing the sample size and hence compromising the accuracy of the estimates. Corrected analysis showed MD of ‐2.29 (95% CI ‐2.91 to ‐1.68). The effect size obtained in our study on a larger sample size (11 RCTs; n = 4293) was less than that noted in this analysis (‐1.80 vs ‐2.57). </p> </li> <li> <p><a href="./references#CD010060-bbs2-0103" title="GacciM , CoronaG , SalviM , VignozziL , McVaryKT , KaplanSA , et al. A systematic review and meta‐analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α‐blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol2012;61(5):994‐1003. ">Gacci 2012 b</a> was a systematic review that included data from four clinical trials (<a href="./references#CD010060-bbs2-0008" title="McVaryKT , MonningW , CampsJL , YoungJM , TsengL . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐blind trial. Journal of Urology2007;177(3):1071‐7. ">McVary 2007a</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; <a href="./references#CD010060-bbs2-0014" title="StiefCG , PorstH , NeuserD , BenekeM , UlbrichE . A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology2008;53(6):1236‐44. ">Stief 2008</a>; <a href="./references#CD010060-bbs2-0057" title="TamimiNA , MincikI , HaughieS , LambJ , CrosslandA , EllisP . A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU International2010;106(5):674‐80. ">Tamimi 2010;</a> n = 2749). The MD in IPSS‐total improvement with PDEI over placebo reported in this study was ‐2.8 (95% CI ‐3.6 to ‐2.1), whereas our analysis of a larger participant population revealed an MD of ‐1.89 (95% CI ‐2.28 to ‐1.64; n = 4293). </p> </li> <li> <p>The fourth systematic review meta‐analysis ‐ <a href="./references#CD010060-bbs2-0093" title="DongY , HaoL , ShiZ , WangG , ZhangZ , HanC . Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta‐analysis. Urology International2013;91(1):10‐8. ">Dong 2013</a> ‐ included seven RCTs using tadalafil or placebo (<a href="./references#CD010060-bbs2-0004" title="DmochowskiR , RoehrbornC , KliseS , XuL , KaminetskyJ , KrausS . Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12‐week clinical trial. Journal of Urology2010;183(3):1092‐7. ">Dmochowski 2010</a>; <a href="./references#CD010060-bbs2-0005" title="EgerdieRB , AuerbachS , RoehrbornCG , CostaP , GarzaMS , EslerAL , et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo‐controlled, double‐blind study. Journal of Sexual Medicine2012;9(1):271‐81. ">Egerdie 2012</a>; <a href="./references#CD010060-bbs2-0007" title="KimSC , ParkJK , KimSW , LeeSW , AhnTY , PaickJS , et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo‐controlled pilot study using Tamsulosin as an active control. LUTS: Lower Urinary Tract Symptoms2011;3(2):86‐93. ">Kim 2011</a>; <a href="./references#CD010060-bbs2-0009" title="McVaryKT , RoehrbornCG , KaminetskyJC , AuerbachSM , WachsB , YoungJM , et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology2007;177(4):1401‐07. ">McVary 2007b</a>; <a href="./references#CD010060-bbs2-0010" title="OelkeM , GiulianoF , MironeV , XuL , CoxD , ViktrupL . Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo‐controlled clinical trial. European Urology2012;61(5):917‐25. ">Oelke 2012</a>; <a href="./references#CD010060-bbs2-0011" title="PorstH , KimED , CasabéAR , MironeV , SecrestRJ , XuL , et al. Efficacy and safety of Tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double‐blind, placebo‐controlled trial. European Urology2011;60(5):1105‐13. ">Porst 2011</a>; <a href="./references#CD010060-bbs2-0013" title="RoehrbornCG , McVaryKT , Elion‐MboussaA , ViktrupL . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Journal of Urology2008;180(4):1228‐34. ">Roehrborn 2008</a>; n = 2913). The mean effect size on IPSS–total was found to be –2.35 (95% CI –2.83 to –1.88). A larger participant pool in our study showed a smaller effect size. </p> </li> </ul> </p> <p>Meanwhile, our review stands out on the basis of its methodological rigor, which includes a published, a priori protocol; a comprehensive literature search of the published and unpublished literature, irrespective of language of publication; the use of GRADE on a per‐outcome basis; and a focus on patient‐important outcomes and clinically important differences. We also would like to emphasise the strict conflict of interest policy of Cochrane, to which we adhered, whereas many other reviews have been published by review authors with recognised financial and/or intellectual conflicts of interest. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010060-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010060-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010060-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.1 Change in IPSS‐total: main analysis." data-id="CD010060-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.1 Change in IPSS‐total: main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 PDEI versus placebo, outcome: 1.1 Change in IPSS‐total: main analysis." data-id="CD010060-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 PDEI versus placebo, outcome: 1.1 Change in IPSS‐total: main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.6 Change in BPHII: main analysis." data-id="CD010060-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.6 Change in BPHII: main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.10 Any AE with short‐term use." data-id="CD010060-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PDEI versus placebo, outcome: 1.10 Any AE with short‐term use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Change in IPSS‐QOL with PDEI versus placebo" data-id="CD010060-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Change in IPSS‐QOL with PDEI versus placebo</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="IPSS‐total subgroup analysis (PDEI vs placebo)." data-id="CD010060-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>IPSS‐total subgroup analysis (PDEI vs placebo).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Summary forest plot of subgroups for change in BPHII (PDEI Vs Placebo)" data-id="CD010060-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Summary forest plot of subgroups for change in BPHII (PDEI Vs Placebo)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 1 IPSS‐total." data-id="CD010060-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 1 IPSS‐total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 2 IPSS‐total: subgroup analysis (with or without ED)." data-id="CD010060-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 2 IPSS‐total: subgroup analysis (with or without ED). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 3 IPSS‐total: subgroup analysis (different PDEI)." data-id="CD010060-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 3 IPSS‐total: subgroup analysis (different PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 4 IPSS‐total: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 4 IPSS‐total: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 5 IPSS‐total: sensitivity analysis (RCT without run‐in period excluded)." data-id="CD010060-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 5 IPSS‐total: sensitivity analysis (RCT without run‐in period excluded). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 6 BPHII." data-id="CD010060-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 6 BPHII.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 7 BPHII: subgroup analysis (with or without ED)." data-id="CD010060-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 7 BPHII: subgroup analysis (with or without ED). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 8 BPHII: subgroup analysis (different PDEI)." data-id="CD010060-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 8 BPHII: subgroup analysis (different PDEI).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 9 BPHII: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 9 BPHII: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 10 Any AE with short‐term use." data-id="CD010060-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 10 Any AE with short‐term use.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 11 Any AE with short‐term use: subgroup analysis (with or without ED)." data-id="CD010060-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 11 Any AE with short‐term use: subgroup analysis (with or without ED). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 12 Any AE with short‐term use: subgroup analysis (different PDEI)." data-id="CD010060-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 12 Any AE with short‐term use: subgroup analysis (different PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 13 Any AE with short‐term use: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 13 Any AE with short‐term use: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 14 Any AE with short‐term use: sensitivity analysis (RCT without run‐in period excluded)." data-id="CD010060-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 14 Any AE with short‐term use: sensitivity analysis (RCT without run‐in period excluded). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 15 IPSS‐QOL." data-id="CD010060-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 15 IPSS‐QOL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 16 IPSS‐QOL: subgroup analysis (with or without ED)." data-id="CD010060-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 16 IPSS‐QOL: subgroup analysis (with or without ED). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 17 IPSS‐QOL: subgroup analysis (different PDEI)." data-id="CD010060-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 17 IPSS‐QOL: subgroup analysis (different PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 18 IPSS‐QOL: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 18 IPSS‐QOL: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 19 IPSS‐QOL: sensitivity analysis (RCT without run‐in period excluded)." data-id="CD010060-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 19 IPSS‐QOL: sensitivity analysis (RCT without run‐in period excluded). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 20 Other treatment‐related harms: AE with short‐term use related to vasodilatation." data-id="CD010060-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 20 Other treatment‐related harms: AE with short‐term use related to vasodilatation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 21 Other treatment‐related harms: AE with short‐term use related to body pain." data-id="CD010060-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 21 Other treatment‐related harms: AE with short‐term use related to body pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 22 Other treatment‐related harms: AE with short‐term use related to upper GI tract." data-id="CD010060-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 22 Other treatment‐related harms: AE with short‐term use related to upper GI tract. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PDEI versus placebo, Outcome 23 Other treatment‐related harms: AE with short‐term use leading to treatment discontinuation." data-id="CD010060-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 PDEI versus placebo, Outcome 23 Other treatment‐related harms: AE with short‐term use leading to treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 1 IPSS‐total." data-id="CD010060-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 1 IPSS‐total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 2 IPSS‐total: subgroup analysis (different PDEI)." data-id="CD010060-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 2 IPSS‐total: subgroup analysis (different PDEI).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 3 IPSS‐total: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 3 IPSS‐total: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 4 IPSS‐total: sensitivity analysis (RCT without run‐in period excluded)." data-id="CD010060-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 4 IPSS‐total: sensitivity analysis (RCT without run‐in period excluded). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 5 BPHII." data-id="CD010060-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 5 BPHII.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 6 BPHII: subgroup analysis (different PDEI)." data-id="CD010060-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 6 BPHII: subgroup analysis (different PDEI).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 7 BPHII: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 7 BPHII: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 8 BPHII: sensitivity analysis (RCT without run‐in period excluded)." data-id="CD010060-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 8 BPHII: sensitivity analysis (RCT without run‐in period excluded). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 9 Any AE with short‐term use." data-id="CD010060-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 9 Any AE with short‐term use.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 10 IPSS‐QOL." data-id="CD010060-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 10 IPSS‐QOL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 11 IPSS‐QOL: subgroup analysis (different PDEIs)." data-id="CD010060-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 11 IPSS‐QOL: subgroup analysis (different PDEIs).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 12 IPSS‐QOL: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 12 IPSS‐QOL: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 13 IPSS‐QOL: sensitivity analysis (RCT without run‐in period excluded)." data-id="CD010060-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 13 IPSS‐QOL: sensitivity analysis (RCT without run‐in period excluded). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 14 Other treatment‐related harms: AE with short‐term use related to vasodilatation." data-id="CD010060-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 14 Other treatment‐related harms: AE with short‐term use related to vasodilatation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 15 Other treatment‐related harms: AE with short‐term use related to body pain." data-id="CD010060-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 15 Other treatment‐related harms: AE with short‐term use related to body pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 16 Other treatment‐related harms: AE with short‐term use related to upper GI tract." data-id="CD010060-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 16 Other treatment‐related harms: AE with short‐term use related to upper GI tract. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 PDEI versus AB, Outcome 17 Other treatment‐related harms: AE with short‐term use leading to treatment discontinuation." data-id="CD010060-fig-0049" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 PDEI versus AB, Outcome 17 Other treatment‐related harms: AE with short‐term use leading to treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 1 IPSS‐total." data-id="CD010060-fig-0050" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 1 IPSS‐total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 2 IPSS‐total: subgroup analysis (different PDEI)." data-id="CD010060-fig-0051" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 2 IPSS‐total: subgroup analysis (different PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 3 IPSS‐total: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0052" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 3 IPSS‐total: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 4 IPSS‐total: sensitivity analysis (RCTs without placebo run‐in period excluded)." data-id="CD010060-fig-0053" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 4 IPSS‐total: sensitivity analysis (RCTs without placebo run‐in period excluded). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 5 Any AE in short‐term use." data-id="CD010060-fig-0054" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 5 Any AE in short‐term use.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 6 Any AE in short‐term use: subgroup analysis (different PDEI)." data-id="CD010060-fig-0055" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 6 Any AE in short‐term use: subgroup analysis (different PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 7 Any AE with short‐term use: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0056" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 7 Any AE with short‐term use: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 8 Any AE with short‐term use: sensitivity analysis (RCT without run‐in period excluded)." data-id="CD010060-fig-0057" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 8 Any AE with short‐term use: sensitivity analysis (RCT without run‐in period excluded). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 9 IPSS‐QOL." data-id="CD010060-fig-0058" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 9 IPSS‐QOL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 10 IPSS‐QOL: subgroup analysis (different PDEIs)." data-id="CD010060-fig-0059" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 10 IPSS‐QOL: subgroup analysis (different PDEIs). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 11 IPSS‐QOL: subgroup analysis (different doses of PDEI)." data-id="CD010060-fig-0060" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 11 IPSS‐QOL: subgroup analysis (different doses of PDEI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 12 IPSS‐QOL: sensitivity analysis (RCT without placebo run‐in period excluded)." data-id="CD010060-fig-0061" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 12 IPSS‐QOL: sensitivity analysis (RCT without placebo run‐in period excluded). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 13 Other treatment‐related harms: AE with short‐term use related to vasodilatation." data-id="CD010060-fig-0062" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 13 Other treatment‐related harms: AE with short‐term use related to vasodilatation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 14 Other treatment‐related harms: AE with short‐term use related to upper GI tract." data-id="CD010060-fig-0063" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 14 Other treatment‐related harms: AE with short‐term use related to upper GI tract. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PDEI + AB versus AB alone, Outcome 15 Other treatment‐related harms: AE with short‐term use leading to treatment discontinuation." data-id="CD010060-fig-0064" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 PDEI + AB versus AB alone, Outcome 15 Other treatment‐related harms: AE with short‐term use leading to treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PDEI + AB versus PDEI alone, Outcome 1 IPSS‐total." data-id="CD010060-fig-0065" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 PDEI + AB versus PDEI alone, Outcome 1 IPSS‐total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PDEI + AB versus PDEI alone, Outcome 2 IPSS‐QOL." data-id="CD010060-fig-0066" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 PDEI + AB versus PDEI alone, Outcome 2 IPSS‐QOL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 1 IPSS‐total." data-id="CD010060-fig-0067" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 1 IPSS‐total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 2 IPSS‐QOL." data-id="CD010060-fig-0068" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 2 IPSS‐QOL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 3 Any AE with long‐term use (26 weeks)." data-id="CD010060-fig-0069" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 3 Any AE with long‐term use (26 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 4 Other treatment‐related harms: AE with long‐term use (26 weeks) related to vasodilatation." data-id="CD010060-fig-0070" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 4 Other treatment‐related harms: AE with long‐term use (26 weeks) related to vasodilatation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 5 Other treatment‐related harms: AE with long‐term use (26 weeks) related to body pain." data-id="CD010060-fig-0071" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 5 Other treatment‐related harms: AE with long‐term use (26 weeks) related to body pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 6 Other treatment‐related harms: AE with long‐term use (26 weeks) related to upper GI tract." data-id="CD010060-fig-0072" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 6 Other treatment‐related harms: AE with long‐term use (26 weeks) related to upper GI tract. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 7 Other treatment‐related harms: AE with long‐term use (26 weeks) leading to treatment discontinuation." data-id="CD010060-fig-0073" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 7 Other treatment‐related harms: AE with long‐term use (26 weeks) leading to treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010060-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/urn:x-wiley:14651858:media:CD010060:CD010060-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_t/tCD010060-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 8 Other treatment‐related harms: AE with long‐term use (26 weeks) related to sexual function." data-id="CD010060-fig-0074" src="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 PDEI + 5‐ARI versus 5‐ARI alone, Outcome 8 Other treatment‐related harms: AE with long‐term use (26 weeks) related to sexual function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/media/CDSR/CD010060/image_n/nCD010060-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010060-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">PDEI compared to placebo for lower urinary tract symptoms consistent with benign prostatic hyperplasia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>PDEI compared to placebo for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI </p> <p><b>Comparator:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score<br/> Assessed with International Prostate Symptom Score<br/> Scale from 0 (best: not at all) to 35 (worst: almost always)<br/> Follow up: range 6 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4293<br/> (11 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total scores ranged from ‐5.1 to ‐1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.89 lower<br/> (2.27 lower to 1.5 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPHII score<br/> Assessed with BPHII questionnaire </p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)<br/> Follow‐up: range 6 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3646<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in BPHII scores ranged from ‐2 to ‐0.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.52 lower<br/> (0.71 lower to 0.33 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Assessed with any event<br/> Follow‐up: range 6 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4386<br/> (11 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.42<br/> (1.21 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 more per 1000<br/> (47 more to 151 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MCID: minimum clinically important difference; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Downgraded for possible publication bias based on funnel plot asymmetry. </p> <p><sup>c</sup>Clinically important imprecision; 95% CI crosses MCID of 0.5. </p> <p><sup>d</sup>Clinically important heterogeneity with I² of 50%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">PDEI compared to placebo for lower urinary tract symptoms consistent with benign prostatic hyperplasia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010060-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">PDEI compared to alpha‐blockers for LUTS associated with BPH</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>PDEI compared to alpha‐blockers for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI </p> <p><b>Comparator:</b> alpha‐blockers </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with alpha‐blockers</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score<br/> Assessed with International Prostate Symptom Score </p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: range 8 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>933<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total scores ranged from ‐5.7 to ‐ 5.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.22 higher<br/> (0.49 lower to 0.93 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPHII score<br/> Assessed with BPHII questionnaire </p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)<br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in BPHII score was ‐1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/> (1.1 lower to 1.16 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: range 8 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>786<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.35<br/> (0.80 to 2.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 more per 1000<br/> (41 fewer to 264 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Clinically important heterogeneity. </p> <p><sup>c</sup>Clinically important imprecision likely due to inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">PDEI compared to alpha‐blockers for LUTS associated with BPH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010060-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">PDEI plus alpha‐blocker compared to alpha‐blockers alone for LUTS associated with BPH (short‐term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination of PDEI with alpha‐blocker compared to alpha‐blockers alone for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI + alpha‐blockers </p> <p><b>Comparator:</b> alpha‐blockers </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with alpha‐blockers alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI plus alpha‐blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score<br/> Assessed with International Prostate Symptom Score </p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)</p> <p>Follow‐up: range 4 to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total scores ranged from ‐6.7 to ‐3.62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.56 lower<br/> (3.92 lower to 1.19 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPHII score<br/> Assessed with BPHII questionnaire </p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects<br/> Follow‐up: range 4 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>194<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.81<br/> (1.53 to 5.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235 more per 1000<br/> (69 more to 542 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MCID: maximum clinically important difference; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Clinically important imprecision; 95% CI crosses MCID of 3.0 </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">PDEI plus alpha‐blocker compared to alpha‐blockers alone for LUTS associated with BPH (short‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010060-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">PDEI plus an alpha‐blocker compared to PDEI alone for LUTS associated with BPH (short‐term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination of PDEI with an alpha‐blocker compared to PDEI alone for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI + alpha‐blockers </p> <p><b>Comparator:</b> PDEI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDEI alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI plus an alpha‐blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score</p> <p>Assessed with International Prostate Symptom Score</p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)</p> <p>Follow‐up: mean 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total score was ‐3.95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.4 lower<br/> (6.47 lower to 1.67 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPHII score</p> <p>Assessed with BPHII questionnaire</p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Downgraded for clinically important imprecision; 95% CI crosses MCID of 3. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">PDEI plus an alpha‐blocker compared to PDEI alone for LUTS associated with BPH (short‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010060-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (short‐term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination of PDEI with 5‐ARI compared to 5‐ARI alone for LUTS consistent with BPH for short‐term use (up to 12 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI + 5‐ARI </p> <p><b>Comparator:</b> 5‐ARI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ARI alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI + 5‐ARI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score</p> <p>Assessed with International Prostate Symptom Score</p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)</p> <p>Follow‐up: mean 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total score was ‐3.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.4 lower<br/> (2.24 lower to 0.56 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>BPHII score</p> <p>Assessed with BPHII questionnaire</p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> 5‐ARI: 5‐alpha reductase inhibitor; BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Downgraded for clinically important imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (short‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010060-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (long‐term)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Combination of PDEI with 5‐ARI compared to 5‐ARI alone for LUTS consistent with BPH in long‐term use (26 weeks)</b> </p> <p><b>Patient:</b> men with LUTS consistent with BPH </p> <p><b>Setting:</b> outpatient </p> <p><b>Intervention:</b> PDEI + 5‐ARI </p> <p><b>Comparator:</b> 5‐ARI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ARI alone</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with PDEI + 5‐ARI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPSS‐total score</p> <p>Assessed with International Prostate Symptom Score</p> <p>Scale from 0 (best: not at all) to 35 (worst: almost always)</p> <p>Follow‐up: mean 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in IPSS‐total score was ‐4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1 lower<br/> (1.83 lower to 0.17 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>BPHII score</p> <p>Assessed with BPHII questionnaire</p> <p>Scale from 0 (best: none) to 13 (worst: a lot or all the time)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>695<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.84 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 more per 1000<br/> (43 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> 5‐ARI: 5‐alpha reductase inhibitor; BPH: benign prostatic hyperplasia; BPHII: Benign Prostatic Hyperplasia Impact Index; CI: confidence interval; IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; MD: mean difference; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations. </p> <p><sup>b</sup>Downgraded for clinically important imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">PDEI + 5‐ARI compared to 5‐ARI alone for LUTS associated with BPH (long‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010060-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study (year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) (route, frequency, total dose/d)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) appropriate as applied in a clinical practice setting<sup>a</sup> (description)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator(s) (route, frequency, total dose/d)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator(s) appropriate as applied in a clinical practice setting<sup>a</sup> (description)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Casabe (2014)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>+ finasteride 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and finasteride were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>+ finasteride 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finasteride was used in this study as per clinical practice setting</p> <p>Placebo; N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Regadas (2013)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d + tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and tamsulosin were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>+ placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> <p>Placebo; N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Brock (2013a)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo once daily</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Yokoyama (2013)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> <p>oral</p> <p>I2: tadalafil 5 mg/d</p> <p>oral</p> <p>I3: tamsulosin 0.2 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Egerdie (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> <p>oral</p> <p>I2: tadalafil 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gacci (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tamsulosin 0.4 mg/d</p> <p>+ vardenafil 10 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and vardenafil were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oelke (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>oral</p> <p>I2: tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and tamsulosin were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Takeda (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> <p>oral</p> <p>I2: tadalafil 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kim (2011)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>oral</p> <p>I2: tamsulosin 0.2 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil and tamsulosin were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dmochowski (2010)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tamsulosin 20 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil is approved for use in BPH‐LUTS at 2.5 mg and 5 mg per day</p> <p>Tadalafil dose used in this study is higher than that used in the clinical practice setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prost (2011)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tuncel (2010)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: sildenafil 25 mg/4 times weekly + tamsulosin 0.4 mg/d</p> <p>oral</p> <p>I2: sildenafil 25 mg/4 times weekly oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sildenafil and tamsulosin were used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bechara (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 20 mg/d + tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil is approved for use in BPH‐LUTS at 2.5 mg and 5 mg per day</p> <p>Tadalafil dose used in this study is higher than that used in clinical practice setting</p> <p>Tamsulosin was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>+ placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> <p>Placebo; N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tamsulosin 0.4 mg/d + placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tamsulosin was used in this study as per clinical practice setting</p> <p>For placebo; N/CPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C2: tadalafil 20 mg/d + tamsulosin 0.4 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil is approved for use in BPH‐LUTS at 2.5 mg and 5 mg per day</p> <p>Tadalafil dose used in this study was higher than that used in clinical practice setting</p> <p>Tamsulosin was used in this study as per clinical practice setting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Roehrborn (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> <p>oral</p> <p>I2: tadalafil 5 mg/d</p> <p>oral</p> <p>I3: tadalafil 10 mg/d</p> <p>oral</p> <p>I4: tadalafil 20 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil is approved for use in BPH‐LUTS at 2.5 mg and 5 mg per day</p> <p>This is a dose‐ranging study; tadalafil doses used in this study for I3 and I4 were higher than those used in clinical practice setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stief (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: vardenafil 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vardenafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>McVary (2007a)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: sildenafil 50 to 100 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sildenafil was used in this study as per clinical practice setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>McVary (2007b)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 to 20 mg/d</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tadalafil dose used in this study in the dose escalation phase was higher than that used in clinical practice setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/CPS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><sup>a</sup>The term 'clinical practice setting' refers to the specification of the intervention/comparator as used in the course of a standard medical treatment (such as dose, dose escalation, dosing scheme, provision for contraindications, and other important features). </p> <p>BPH: benign prostatic hyperplasia; C: comparator; I: intervention; LUTS: lower urinary tract symptoms; N/CPS: no specification of clinical practice setting possible. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010060-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study (year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of intervention (duration of follow‐up) (days, months, years...)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial period (year to year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ethnic groups (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of disease (mean/range years (SD), or as reported)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Casabe (2014)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>+ finasteride 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> <p>(for primary endpoint)</p> <p>Study continued maintaining blinding until 26 weeks (for secondary endpoints)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years with BPH‐LUTS; IPSS ≥ 13</p> <p>Qmax 4 to 15 mL/s</p> <p>Prostatic volume ≥ 30 cc</p> <p>Naive to 5‐ARI therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>November 2010</p> <p>to</p> <p>September 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>USA, Canada, Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whites</p> <p>(85.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black/African American (10.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Native American (2.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> <p>+ finasteride 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (3.9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Regadas (2013)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> <p>+ tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men &gt; 45 years, BOOI &gt; 20 IPSS &gt; 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>October 2010</p> <p>to</p> <p>September 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> <p>+ placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Brock (2013a)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men ≥ 45 years</p> <p>BPH‐LUTS &gt; 6 months</p> <p>IPSS ≥ 13</p> <p>Qmax 4 to 15 mL/s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Yokoyama (2013)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years; BPH‐LUTS &gt; 6 months</p> <p>IPSS &gt; 13</p> <p>Qmax 4 to 15 mL/s</p> <p>Prostate volume &gt; 20 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Japan</p> <p>Korea</p> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan (55.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Korea (29.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I3: tamsulosin 0.2 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Taiwan (14.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Egerdie (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Men ≥ 45 years, ≥ 3 months h/o ED, ≥ 6 months h/o BPH‐LUTS (LUTS + ED)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Europe</p> <p>Mexico</p> <p>USA/Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C2: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asian (2.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hispanic (15%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (0.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Gacci (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tamsulosin 0.4 mg/d</p> <p>+ vardenafil 10 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men with persistent storage/irritative symptoms after tamsulosin 0.4 mg treatment for 2 weeks; IPSS‐storage ≥ 8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: tamsulosin 0.4 mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Oelke (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Men ≥ 45 years, BPH‐LUTS &gt; 6 months, IPSS ≥ 13, Qmax 4 to 15 mL/s before placebo lead‐in period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>December 2009</p> <p>to</p> <p>January 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Australia, Austria, Belgium, France, Germany, Greece, Italy, Mexico, The Netherlands, Poland </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tamsulosin</p> <p>0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black or African American (0.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>American Indian/Alaska Native (23.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Takeda (2012)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks, followed by a 42‐week open‐label extension phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>&gt; 45 years, IPSS &gt; 13, Qmax 4 to 15 mL/s, prostate volume &gt; 20 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Asian (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tadalafil 5 mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Kim (2011)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Men ≥ 45 years, h/o BPH‐LUTS for 6 months or longer, IPSS ≥ 13, Qmax &gt; 5 and &lt; 15 after the washout period </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Asian (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tamsulosin 0.2 mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Dmochowski (2010)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tamsulosin 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 40 years, longer than 6 months h/o BPH‐LUTS; IPSS ≥ 13, with or without BOO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>USA, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (12.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hispanic (8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (3.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Prost (2011)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years, BPH‐LUTS &gt; 6 months</p> <p>IPSS &gt; 13 and Qmax 4 to 15 mL/s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>"‐"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Argentina, Germany, Italy, Mexico, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black or African American (2.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>American Indian or Alaska Native (5.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Tuncel (2010)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: sildenafil 25 mg/4 times weekly + tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>IPSS &gt; 12, IIEF &lt; 21 (SIHM &lt; 21) treatment‐naive and all participants had ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: sildenafil 25 mg/4 times weekly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bechara (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 20 mg/d + tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>45 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men ≥ 50 years, h/o BPH &gt; 6 months, IPSS ≥ 12, <sup>6</sup>PSA ≤ 4 ng/mL, <sup>2</sup>Qmax &gt; 5 and &lt; 15 for a minimum voided volume of 125 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>September 2007</p> <p>to</p> <p>February 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Argentina</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tamsulosin 0.4 mg/d + placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Roehrborn (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years, BPH‐LUTS &gt; 6 months, IPSS &gt; 13, Qmax 4 to 15 mL/s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>North America, Europe, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hispanic (11.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I3: tadalafil 10 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (2.42%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I4: tadalafil 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (0.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Stief (2008)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>I1: vardenafil 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Men &gt; 45 to 64 years, BPH‐LUTS &gt; 6 months, IPSS &gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>October 2005</p> <p>to</p> <p>June 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black Americans (0.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (0.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>McVary (2007b)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men &gt; 45 years, h/o BPH‐LUTS 6 months with IPSS &gt; 13, Qmax &gt; 4 to &lt; 15 mL/s for a voided volume of 125 mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>November 2004</p> <p>to</p> <p>July 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (9.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hispanic (6.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (2.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>McVary (2007a)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: sildenafil 50 to 100 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Men ≥ 45 years, with IPSS &gt; 12 and IIEF score &lt; 25</p> <p>All participants had ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>March 2004</p> <p>to</p> <p>May 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White (82%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Black American (11.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asian (2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>‐ denotes not reported; "‐" denotes missing information.</p> <p>BOO: bladder outflow obstruction; BOOI: Bladder Outflow Obstruction Index; C: comparator; I: intervention; IIEF: International Index of Erectile Function; PSA: prostate‐specific antigen; Qmax: maximum urinary flow rate; SD: standard deviation; SHIM: Sexual Health Inventory for Males. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010060-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Other treatment‐related harms ‐ PDEI versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of the subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number</p> <p>of RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary estimate</p> <p>RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (1.18 to 1.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to body pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.44 (1.98 to 5.98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to GI tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.19 (5.80 to 34.72)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs leading to treatment discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.20 (1.38 to 3.51)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>AE: adverse event; CI: confidence interval; GI: gastrointestinal; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Other treatment‐related harms ‐ PDEI versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010060-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Other treatment‐related harms ‐ PDEI versus alpha‐blockers</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of the subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number</p> <p>of RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary estimate</p> <p>RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42 (1.05 to 5.56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to body pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (0.38 to 8.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to GI tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.87 (0.58 to 41.22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs leading to retreatment discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26 (0.31 to 5.05)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>AE: adverse event; CI: confidence interval; GI: gastrointestinal; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Other treatment‐related harms ‐ PDEI versus alpha‐blockers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010060-tbl-0011"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Other treatment‐related harms: PDEI + alpha‐blockers versus alpha‐blockers alone</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of the subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number</p> <p>of RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary estimate</p> <p>RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.80 (1.93 to 11.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to GI tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.00 (0.75 to 48.30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs leading to retreatment discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.13 to 70.53)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>AE: adverse event; CI: confidence interval; GI: gastrointestinal; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Other treatment‐related harms: PDEI + alpha‐blockers versus alpha‐blockers alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010060-tbl-0012"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Other treatment‐related harms: PDEI + 5‐ARI versus 5‐ARI alone</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of the subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number</p> <p>of RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary estimate</p> <p>RR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.46 to 2.22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to body pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.70 (1.07 to 6.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to GI tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.05 (0.87 to 18.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs leading to retreatment discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (0.21 to 1.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs related to sexual function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.17 to 1.46)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>5‐ARI: 5‐alpha reductase inhibitor; AE: adverse event; CI: confidence interval; GI: gastrointestinal; PDEI: phosphodiesterase inhibitor; RCT: randomised controlled trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Other treatment‐related harms: PDEI + 5‐ARI versus 5‐ARI alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/full#CD010060-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010060-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PDEI versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 IPSS‐total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.89 [‐2.27, ‐1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 IPSS‐total: subgroup analysis (with or without ED) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.42 [‐3.04, ‐1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 IPSS‐total in participants with LUTS and ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.55 [‐3.33, ‐1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 IPSS‐total in participants with LUTS but without ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐3.39, ‐0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 IPSS‐total: subgroup analysis (different PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.89 [‐2.27, ‐1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐2.20, ‐1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.4 [‐6.96, ‐1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐3.57, ‐0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 IPSS‐total: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.96 [‐2.41, ‐1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.31 [‐2.19, ‐0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.88 [‐2.33, ‐1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Tadalafil 10 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.43 [‐4.79, ‐2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Tadalafil 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.29 [‐4.44, ‐2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 IPSS‐total: sensitivity analysis (RCT without run‐in period excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.71 [‐2.12, ‐1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 BPHII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.71, ‐0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 BPHII: subgroup analysis (with or without ED) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐0.99, ‐0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 IPSS‐BPHII score ‐ in participants with LUTS and ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐1.12, ‐0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 IPSS‐BPHII score ‐ in participants with LUTS but no ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.98, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 BPHII: subgroup analysis (different PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.71, ‐0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.70, ‐0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.1 [‐2.11, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 BPHII: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.61, ‐0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.61, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.69, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Tadalafil 10 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.15, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Tadalafil 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.20, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Any AE with short‐term use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.21, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Any AE with short‐term use: subgroup analysis (with or without ED) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.21, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Participants with ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.11, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Participants without ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.33, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Any AE with short‐term use: subgroup analysis (different PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.21, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.19, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.99, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.11, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Any AE with short‐term use: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.25, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.03, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.12, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Tadalafil 10 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.19, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Tadalafil 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.53, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Any AE with short‐term use: sensitivity analysis (RCT without run‐in period excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.13, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 IPSS‐QOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.35, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 IPSS‐QOL: subgroup analysis (with or without ED) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.60, ‐0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 IPSS‐QOL in participants with LUTS and ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.62, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 IPSS‐QOL in participants with LUTS but no ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.98, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 IPSS‐QOL: subgroup analysis (different PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.35, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.34, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.18, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 IPSS‐QOL: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.35, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Tadalafil 2.5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.34, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Tadalafil 5 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.38, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Tadalafil 10 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.71, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Tadalafil 20 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.69, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 IPSS‐QOL: sensitivity analysis (RCT without run‐in period excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.34, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Other treatment‐related harms: AE with short‐term use related to vasodilatation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.18, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Other treatment‐related harms: AE with short‐term use related to body pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.44 [1.98, 5.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Other treatment‐related harms: AE with short‐term use related to upper GI tract <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.19 [5.80, 34.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Other treatment‐related harms: AE with short‐term use leading to treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [1.38, 3.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PDEI versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010060-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PDEI versus AB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 IPSS‐total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐0.49, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 IPSS‐total: subgroup analysis (different PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.58, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.65, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐2.24, 5.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 IPSS‐total: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.28, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tadalafil 5 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.98, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tadalafil 5 mg/d vs tamsulosin 0.2 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [‐0.68, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Tadalafil 2.5 mg/d vs tamsulosin 0.2 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐0.41, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Sildenafil 25 mg administered 4 times a week vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐2.24, 5.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 IPSS‐total: sensitivity analysis (RCT without run‐in period excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.88, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 BPHII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐1.10, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 BPHII: subgroup analysis (different PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.23, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.23, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 BPHII: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.40, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Tadalafil 5 mg/d vs tamsulosin 0.2 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐1.13, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Tadalafil 2.5 mg/d vs tamsulosin 0.2 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐0.06, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 BPHII: sensitivity analysis (RCT without run‐in period excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐1.10, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Any AE with short‐term use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.80, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 IPSS‐QOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.48, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 IPSS‐QOL: subgroup analysis (different PDEIs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.19, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.16, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.8 [‐1.78, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 IPSS‐QOL: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.29, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Tadalafil 5 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.48, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Tadalafil 5 mg/d vs tamsulosin 0.2 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.37, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Tadalafil 2.5 mg/d vs tamsulosin 0.2 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.02, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Sildenafil 25 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.8 [‐1.78, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 IPSS‐QOL: sensitivity analysis (RCT without run‐in period excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.38, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Other treatment‐related harms: AE with short‐term use related to vasodilatation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.05, 5.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Other treatment‐related harms: AE with short‐term use related to body pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.38, 8.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Other treatment‐related harms: AE with short‐term use related to upper GI tract <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [0.58, 41.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Other treatment‐related harms: AE with short‐term use leading to treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.31, 5.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PDEI versus AB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010060-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PDEI + AB versus AB alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 IPSS‐total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.56 [‐3.92, ‐1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 IPSS‐total: subgroup analysis (different PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.56 [‐3.92, ‐1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.02 [‐4.83, ‐1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐5.56, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐4.53, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 IPSS‐total: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.56 [‐3.92, ‐1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tadalafil 5 mg + tamsulosin 0.4 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐6.44, ‐0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tadalafil 20 mg + tamsulosin 0.4 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐4.91, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Vardenafil 10 mg + tamsulosin 0.4 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐4.53, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Sildenafil 25 mg + tamsulosin 0.4 mg 4 times weekly vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐5.56, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 IPSS‐total: sensitivity analysis (RCTs without placebo run‐in period excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.34 [‐4.02, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Any AE in short‐term use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.53, 5.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Any AE in short‐term use: subgroup analysis (different PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.53, 5.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [1.30, 6.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.6 [1.06, 6.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Any AE with short‐term use: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.53, 5.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Tadalafil 5 mg + tamsulosin 0.4 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Tadalafil 20 mg + tamsulosin 0.4 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [1.27, 7.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Vardenafil 5 mg + tamsulosin 0.4 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.6 [1.06, 6.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Sildenafil 25 mg + tamsulosin 0.4 mg 4 times weekly vs tamsulosin 0.4 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Any AE with short‐term use: sensitivity analysis (RCT without run‐in period excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.8 [1.50, 5.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 IPSS‐QOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐1.92, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 IPSS‐QOL: subgroup analysis (different PDEIs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐1.92, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.7 [‐2.40, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.2 [‐2.18, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 IPSS‐QOL: subgroup analysis (different doses of PDEI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐1.92, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Sildenafil 25 mg + tamsulosin 0.4 mg 4 times weekly vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.2 [‐2.18, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Tadalafil 20 mg + tamsulosin 0.4 mg/d vs tamsulosin 0.4 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.7 [‐2.40, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 IPSS‐QOL: sensitivity analysis (RCT without placebo run‐in period excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.7 [‐2.40, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Other treatment‐related harms: AE with short‐term use related to vasodilatation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.8 [1.93, 11.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Other treatment‐related harms: AE with short‐term use related to upper GI tract <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.0 [0.75, 48.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Other treatment‐related harms: AE with short‐term use leading to treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PDEI + AB versus AB alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010060-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PDEI + AB versus PDEI alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 IPSS‐total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐6.47, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 IPSS‐QOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.80, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PDEI + AB versus PDEI alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010060-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">PDEI + 5‐ARI versus 5‐ARI alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 IPSS‐total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐2.84, ‐1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐2.24, ‐0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 at 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐1.83, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 IPSS‐QOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.3 [‐0.58, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.48, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 at 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.48, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any AE with long‐term use (26 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.84, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Other treatment‐related harms: AE with long‐term use (26 weeks) related to vasodilatation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.46, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Other treatment‐related harms: AE with long‐term use (26 weeks) related to body pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [1.07, 6.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Other treatment‐related harms: AE with long‐term use (26 weeks) related to upper GI tract <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.05 [0.87, 18.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Other treatment‐related harms: AE with long‐term use (26 weeks) leading to treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.21, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Other treatment‐related harms: AE with long‐term use (26 weeks) related to sexual function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.17, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">PDEI + 5‐ARI versus 5‐ARI alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010060.pub2/references#CD010060-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010060.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010060-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010060-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010060-note-0001">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010060-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010060-note-0019">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010060\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010060\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010060\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010060\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010060.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010060.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010060.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010060.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010060.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728569280"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010060.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728569284"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010060.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec7aa8ab6f431',t:'MTc0MDcyODU2OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 